Cutibacterium acnes recombinant phage, method for producing same and use
Patent Information
- Application Number
- JP2023527081
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-02-04
- Filing Date
- 2021-11-04
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2041-11-04
AI Technical Summary
Current methods for delivering genetic material to Cutibacterium acnes populations in situ are challenging due to the lack of robust replicative DNA vectors and efficient delivery systems, limiting the ability to genetically modify strains associated with conditions like acne vulgaris.
Development of Cutibacterium acnes phagemids and phage-derived particles that contain recombinant DNA vectors, equipped with phage packaging signals and origins of replication, enabling stable transduction and expression of genes of interest within Cutibacterium acnes cells.
Facilitates direct manipulation of Cutibacterium acnes populations on the skin, allowing for targeted genetic modifications to treat or prevent conditions such as acne by ensuring efficient delivery and expression of therapeutic genes.
Smart Images

Figure 00000112_0000 
Figure 00000112_0001 
Figure 00000112_0002
Abstract
Description
[Technical Field]
[0001] The present invention relates to a recombinant Cutibacterium acnes phage and a method for producing the same. [Background technology]
[0002] Skin is the largest organ of the human body and the largest interface between our body and the environment. Therefore, it also acts as a barrier to protect us from physical threats (e.g., UV, trauma), chemical threats (e.g., acids, bases), and microbial threats (viruses, bacteria, fungi). This defense is not only the result of the passive physical isolation of the skin, which consists of a continuous layer of dense, interconnected dead cells (stratum corneum) surrounded by a lipid matrix. It is also due to active mechanisms integrated by various types of skin and immune cells to secrete antimicrobial peptides (AMPs), produce cytokines and chemokines to recruit lymphocyte immune cells, sense skin damage, and trigger wound healing mechanisms, among other processes. 1 .
[0003] Because the skin is the first organ to come into contact with microorganisms after birth and because it contains a vast number of immune cells in close contact with a wide variety of microorganisms, the skin's immune system must develop the ability to distinguish beneficial from pathogenic microorganisms in order to avoid constant immune responses and inflammation. Part of this education occurs early in life when specific bacterial species colonize the skin, modulating the immune response so that these bacterial species can be tolerated. 2 In this case, this particular bacterial species is able to stably colonize the skin, establish a community, and become a commensal strain.
[0004] Skin is not physiologically and spatially homogeneous throughout the body: depending on the body region, there is oily skin (e.g., cheeks, back), moist skin (e.g., inguinal crease, interdigital web space, antecubital crease), and dry skin (e.g., volar forearm, hypothenar palm). 3 These different body sites have different physiological conditions and distinct microbiomes, with oily sites colonized primarily by Cutibacterium acnes (formerly known as Propionibacterium acnes) and moist sites with higher abundances of Staphylococcus species and Corynebacterium species. 4 In addition to these physiological characteristics, the skin is also spatially heterogeneous with different appendages, namely sweat glands, hair follicles, and sebaceous glands. The colonization of these appendages has only recently been studied and shows differences compared to the skin surface (stratum corneum). 4~6 .
[0005] These skin appendages are unique anatomical locations because they lack a stratum corneum. As a result, microorganisms within these appendages come into contact with living keratinocytes and, due to their proximity to the dermis, have access to a wider variety of immune cells. Hair follicles have specific immunological properties. They can recruit specific immune cells, such as monocyte-derived Langerhans cell precursors. 7 and can actively maintain resident memory T cells (TRM). 8 Therefore, hair follicles are potentially essential sites for antigen presentation. Hair follicles are also poor in effector T cells and have a strongly immunosuppressive environment, making them immune-privileged regions. 9 .
[0006] Examples in the published literature show that resident skin bacteria actively participate in host immunity through the intact skin barrier and activate specific immune cells in a species- and strain-dependent manner (Chen et al., Nature 2018;555(7697):543). For example, some, but not all, S. epidermidis express S. epidermidis-specific IL-17, which protects against skin infections. + CD8 + It induces the activation of T cells (Naik et al., Nature 2015, 520(7545):104-108 (Non-Patent Document 2)).
[0007] Due to the absence of a stratum corneum, skin appendages are also more permeable to chemicals because chemicals only need to cross the tight junction barrier, rather than the stratum corneum, which normally prevents water exchange, allowing all water-soluble substances to diffuse through.
[0008] The pilosebaceous subunit, which contains hair follicles and sebaceous glands, is primarily colonized by Propionibacterium acnes, which thrives in the sebum-rich, anaerobic environment. Cutibacterium acnes (formerly Propionibacterium acnes) is a Gram-positive, aerotolerant bacillus that was first isolated from skin in 1897. It belongs to the order Actinomycetales, part of the family Propionibacteriaceae, and the genus Cutibacterium. This genus is also home to other human skin species, such as Cutibacterium avidum, Cutibacterium granulosum, and Cutibacterium humerusii. 10Propionibacterium acnes is one of the most common and abundant bacteria on human skin and can be found both on the skin surface (stratum corneum) and in hair follicles. Inside hair follicles, Propionibacterium acnes is in direct contact with a considerable variety of living cells, such as keratinocytes, stem cells, sebocytes, and immune cells, unlike on the stratum corneum, where it is mainly in contact with dead corneocytes. Propionibacterium acnes is a commensal bacterium, but it also plays a role in the pathogenesis of several skin diseases, such as acne vulgaris. 11 or progressive patchy hypomelanosis 12~14 is associated with.
[0009] In particular, new discoveries about Propionibacterium acnes reveal that specific phylotypes may play a crucial role in acne development. 11 Specifically, the role of P. acnes phylotype IA1 has been widely emphasized. Fitz-Gibbon and colleagues demonstrated that chromosomal regions loci 1, 2, and 3, characteristic of ribotypes RT4 and RT5 (classified within phylotype IA1), are strongly associated with acne. 15 Because this chromosomal region is absent from ribotypes associated with healthy skin (i.e., RT6), it may be a potential target for eliminating acne-associated P. acnes strains.
[0010] Editing the Cutibacterium acnes population by eliminating specific proinflammatory strains to prevent or treat diseases such as acne vulgaris, or exploiting its privileged location in the pilosebaceous subunit to modulate the host immune response or improve wound healing, are intriguing therapeutic approaches. To implement such approaches, P. acnes strains can either be genetically modified in situ or genetically engineered in vitro. Because of the high intra- and inter-individual microbiome diversity at both the species and strain levels, it appears difficult to provide a single engineered P. acnes strain or a cocktail of engineered strains capable of colonizing the skin of most patients. [Prior art documents] [Patent documents]
[0011] [Patent Document 1] WO 04 / 92360 [Patent Document 2] International Publication No. 2007 / 120362 [Patent Document 3] International Publication No. 98 / 18931 [Patent Document 4] International Publication No. 98 / 18930 [Patent Document 5] U.S. Patent No. 6,699,703 [Patent Document 6] U.S. Patent No. 6,800,744 [Patent Document 7] International Publication No. 97 / 43303 [Patent Document 8] International Publication No. 97 / 37026 [Patent Document 9] International Publication No. 02 / 079241 [Patent Document 10] WO 02 / 34773 [Patent Document 11] International Publication No. 00 / 06737 [Patent Document 12] International Publication No. 00 / 06738 [Patent Document 13] International Publication No. 00 / 58475 [Patent Document 14] International Publication No. 2003 / 082183 [Patent Document 15] International Publication No. 00 / 37105 [Patent Document 16] International Publication No. 02 / 22167 [Patent Document 17] WO 02 / 22168 [Patent Document 18] International Publication No. 2003 / 104272 [Patent Document 19] International Publication No. 02 / 08426 [Patent Document 20] International Publication No. 01 / 12219 [Patent Document 21] WO 99 / 53940 [Patent Document 22] International Publication No. 01 / 81380 [Patent Document 23] International Publication No. 2004 / 092209 [Patent Document 24] International Publication No. 00 / 76540 [Patent Document 25] International Publication No. 2007 / 116322 [Patent Document 26] WO 02 / 34771 [Patent Document 27] International Publication No. 2005 / 032582 [Patent Document 28] International Publication No. 02 / 094851 [Patent Document 29] WO 02 / 18595 [Patent Document 30] International Publication No. 99 / 58562 [Patent Document 31] International Publication No. 02 / 094868 [Patent Document 32] International Publication No. 2008 / 019162 [Patent Document 33] International Publication No. 02 / 059148 [Patent Document 34] WO 02 / 102829 [Patent Document 35] International Publication No. 03 / 011899 [Patent Document 36] International Publication No. 2005 / 079315 [Patent Document 37] International Publication No. 02 / 077183 [Patent Document 38] International Publication No. 99 / 27109 [Patent Document 39] WO 01 / 70955 [Patent Document 40] International Publication No. 00 / 12689 [Patent Document 41] International Publication No. 00 / 12131 [Patent Document 42] International Publication No. 2006 / 032475 [Patent Document 43] International Publication No. 2006 / 032472 [Patent Document 44] International Publication No. 2006 / 032500 [Patent Document 45] International Publication No. 2007 / 113222 [Patent Document 46] International Publication No. 2007 / 113223 [Patent Document 47] International Publication No. 2007 / 113224 [Patent Document 48] International Publication No. 03 / 093306 [Patent Document 49] International Publication No. 04 / 041157 [Patent Document 50] International Publication No. 2005 / 002619 [Patent Document 51] International Publication No. 99 / 24578 [Patent Document 52] International Publication No. 99 / 36544 [Patent Document 53] International Publication No. 99 / 57280 [Patent Document 54] International Publication No. 02 / 079243 [Patent Document 55] International Publication No. 00 / 37494 [Patent Document 56] International Publication No. 03 / 049762 [Patent Document 57] International Publication No. 03 / 068811 [Patent Document 58] International Publication No. 05 / 002619 [Patent Document 59] International Publication No. 02 / 02606 [License 60] U.S. Patent and Trademark Publication No. 2016 / 0022788 [License 61] International Publication No. 2020181180 [Patent Document 62] International Publication No. 2020181193 [License 63] International Publication No. 2020181178 [Patent Document 64] International Publication No. 2020181195 [Patent Document 65] International Publication No. 2020181202 [Non-licensed literature]
[0012] [Non-licensed Document 1] Chen et al., Nature 2018;555(7697):543 [Non-licensed Document 2] Naik et al., Nature 2015, 520(7545): 104-108 [Non-licensed Document 3] Fitz-Gibbon, S. et al. (2013) J Invest Dermatol 133, 2152-2160 [Non-licensed Document 4] Dreno, B. et al. (2018). Journal of the European Academy of Dermatology and Venereology 32, pages 5~14 [Non-licensed Document 5] Barnard, E. et al. (2016) Scientific Reports 6, srep39491 [Non-licensed Document 6] Yu et al. (2016) Journal of Investigative Dermatology 136:2221-2228 [Non-licensed Document 7] Chen et al. (2019) "Decoding commensal-host communication through genetic engineering of Staphylococcus epidermidis" bioRxiv https: / / doi.org / 10.1101 / 664656 [Non-licensed Document 8] Girolamo, SD et al., Biochem J 476, 665-682 (2019) [Non-licensed Document 9] Webb, Edwin C. Enzyme nomenclature 1992: recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes. San Diego: Academic Press. ISBN 0-12-227164-5(1992) [Non-licensed Document 10] Reap et al., Vaccine (2007) 25: 7441-7449 [Non-licensed Document 11] LeMieux et al., Infect. Imm. (2006) 74: 2453-2456. [Non-licensed Document 12] Hoskins et al., J. Bacteriol. (2001) 183: 5709-5717 [Non-licensed Document 13] Adamou et al., Infect. Immun. (2001) 69(2): 949-958. [Non-licensed Document 14] Briles et al., J. Infect. Dis. (2000) 182: 1694-1701. [Non-licensed Document 15] Talkington et al., Microb. Pathog. (1996) 21(1): 17-22 [Non-licensed Document 16] Bethe et al., FEMS Microbiol. Lett. (2001) 205(1): 99~104 pages [Non-licensed Document 17] Brown et al., Infect. Immun. (2001) 69: 6702-6706. [Non-licensed Document 18] Whalen et al., FEMS Immunol. Med. Microbiol. (2005) 43:73~80 pages [Non-licensed Document 19] Jomaa et al., Vaccine (2006) 24(24): 5133-5139 [Non-licensed Document 20] Dale, Vaccine (1999) 17: 193-200 pages [Non-licensed Document 21] Dale, Vaccine 14(10): 944-948 pages [Non-licensed Document 22] Zhu et al., Vaccine (2004) 22: 660-669 [Non-licensed Document 23] Price et al., Infection and Immunity (2004) 71(1): 277-283 [Non-licensed Document 24] Plante et al., J Infectious Disease (2000) 182: 848-855 [Non-licensed Document 25] Clin. Exp. Allergy, No. 26, pp. 494-516 (1996) [Non-licensed Document 26] Mol. Biol. of Allergy and Immunology, edited by R. Bush, Immunology and Allergy Clinics of North American Series (August 1996) [Non-licensed Document 27] Smillie et al., Microbiology and Molecular Biology Rev, 2010, pages 434~452 [Non-licensed Document 28] Chemical Reviews 2016, 116(20)12655~12687 pages [Non-licensed Document 29] E. Meyers and W. Miller (Comput. Appl. Biosci., pages 4:11~17 (1988)) [Non-licensed Document 30] Needleman and Wunsch (J. Mol. Biol. 48:444~453 pages (1970)) [Non-licensed Document 31] Henkel et al. (Toxins from Bacteria in EXS. 2010;100:1-29) [Non-licensed Document 32] Komor, A et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533:420~4 pages (2016) [Non-licensed Document 33] Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. Nature 551(7681) pages 464~471 (2017) [Non-licensed Document 34] Chen, L et al., Precise and programmable C:G to G:C base editing in genomic DNA. Biorxiv(2020) [Non-licensed Document 35] Kurt, I et al., CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nature Biotechnology (2020) [Non-licensed Document 36] Zhao, D et al., New base editors change C to A in bacteria and C to G in mammalian cells. Nature Biotechnology(2020) [Non-Patent Document 37] Grunewald, J et al., A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing, Nature Biotechnology(2020) [Non-Patent Document 38] Li, C et al., Targeted, random mutagenesis of plant genes with dual cytosine and adenine base editors, Nature Biotechnology(2020) [Non-Patent Document 39] Anzalone, AV et al., Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, pp. 149-157 (2019) [Non-Patent Document 40] Sharon, E. et al., Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing. Cell 175, pp. 544-557.e16 (2018) [Non-Patent Document 41] Wannier, TM et al., Improved bacterial recombineering by parallelized protein discovery. Biorxiv 2020.01.14.906594(2020)doi:10.1101 / 2020.01.14.906594. [Non-Patent Document 42] Karberg, M. et al., Group II introns as controllable gene targeting vectors for genetic manipulation of bacteria. Nat Biotechnol 19, pp. 1162-7 (2001) [Non-Patent Document 43] Simon, AJ, Ellington, AD & Finkelstein, IJ, Retrons and their applications in genome engineering. Nucleic Acids Res 47, pp. 11007-11019 (2019) [Non-Patent Document 44] Armenteros, J. et al., SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat Biotechnol 37, pp. 420-423 (2019) Summary of the Invention [Problem to be solved by the invention]
[0013] In situ DNA delivery to P. acnes populations offers a way around such difficulties by allowing the utilization of pre-established strains, potentially without disturbing the local microbiome. However, in situ delivery of genetic material to P. acnes is challenging for several reasons. First, to date, there are no genetic elements, e.g., plasmids, that can replicate robustly and autonomously within P. acnes. The few genetic modifications described consist of genomic insertion of synthetic DNA by homologous recombination. 16~18This in vitro process has been shown to be very inefficient and relies on the use of antibiotic selection markers to select for such events. Furthermore, this genetic modification is limited to a few specific strains (KPA17202, RT6 P. acnes) and may not be generalizable to all P. acnes strains. Second, in situ genetic modification of P. acnes requires the delivery of DNA into P. acnes. The only described method for introducing DNA into P. acnes is the use of electroporation. 19、20 , a method that can only be performed in vitro. [Means for solving the problem]
[0014] The present invention overcomes both the lack of replicative and stable DNA vectors and their delivery into P. acnes using phage-derived particles, and further provides a unique and robust tool for engineering P. acnes phages.
[0015] The present invention includes Cutibacterium acnes phagemids, bacterial cells containing the phagemids, Cutibacterium acnes recombinant phages, methods for making phage-derived particles containing the phagemids, phage-derived particles containing the phagemids, and methods of using the phagemids, particles, and cells, particularly in the treatment of Cutibacterium acnes-associated disorders and / or diseases.
[0016] The present invention includes recombinant DNA phagemid vectors, phage-derived particles containing the vectors, and Cutibacterium acnes carrying the vectors, wherein the vectors are - a phage packaging signal that allows packaging of the DNA vector into a Cutibacterium acnes phage capsid; and - Gene of interest Includes:
[0017] In one embodiment, the DNA vector comprises: - a phage packaging signal that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 76, which allows packaging of the DNA vector into a Cutibacterium acnes phage capsid; and - Gene of interest Includes:
[0018] In one embodiment, the DNA vector comprises: - a phage packaging signal that allows packaging of the DNA vector into the Cutibacterium acnes phage capsid; - the gene of interest; and - A selection marker that allows selection of the DNA vector in Cutibacterium acnes Includes:
[0019] In one embodiment, the DNA vector comprises: - a phage packaging signal that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 76, allowing packaging of the DNA vector into a Cutibacterium acnes phage capsid; - the gene of interest; and - A selection marker that allows selection of the DNA vector in Cutibacterium acnes Includes:
[0020] In one embodiment, the DNA vector comprises: - a phage packaging signal that allows packaging of the DNA vector into the Cutibacterium acnes phage capsid; - gene of interest; - an origin of replication that allows replication within Cutibacterium acnes; and - Optionally, a selection marker that allows selection of the DNA vector in Cutibacterium acnes Includes:
[0021] In one embodiment, the DNA vector comprises: - a phage packaging signal that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 76, allowing packaging of the DNA vector into a Cutibacterium acnes phage capsid; - gene of interest; - an origin of replication that allows replication within Cutibacterium acnes; and - Optionally, a selection marker that allows selection of the DNA vector in Cutibacterium acnes Includes:
[0022] In one embodiment, the phage packaging signal sequence is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to a phage packaging signal sequence selected from the group consisting of SEQ ID NO:76, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, and SEQ ID NO:90.
[0023] In one embodiment, the DNA vector further comprises an origin of replication for the P. acnes phage.
[0024] In one embodiment, the DNA vector further comprises an origin of replication of a Propionibacterium acnes phage, the sequence of which is at least 75%, 77%, 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO:67.
[0025] In one embodiment, the gene of interest is DNA encoding an antigen.
[0026] The present invention includes Cutibacterium acnes producing cells carrying a recombinant DNA vector for the production of Cutibacterium acnes phage-derived particles containing the recombinant DNA vector.
[0027] The DNA vector is typically packaged within the Cutibacterium acnes phage genome or proteins produced by a helper phage. The P. acnes phage genome can be introduced into P. acnes producing cells, for example, by transformation or transduction with the P. acnes phage, and the helper phage can be introduced into P. acnes producing cells, for example, by transformation or conjugation, before or after introduction of the DNA vector into the P. acnes producing cells (Figure 1).
[0028] Cutibacterium acnes producing cells carrying the recombinant DNA vector typically contain the Cutibacterium acnes phage genome, resulting in the production of phage-derived particles carrying the DNA vector.
[0029] In one embodiment, the Cutibacterium acnes phage genome is a non-engineered / wild-type genome.
[0030] In another embodiment, the Cutibacterium acnes phage genome is engineered.
[0031] In one embodiment, the DNA vector comprises an origin of replication that allows it to replicate only in Cutibacterium acnes producer cells and not in Cutibacterium acnes receiver cells.
[0032] In one embodiment, the DNA vector comprises: - a phage packaging signal that allows packaging of the DNA vector into the Cutibacterium acnes phage capsid; - at least one gene of interest; - an origin of replication that allows replication only within Cutibacterium acnes-producing cells; and - Optionally, a selection marker that allows selection of the DNA vector in Cutibacterium acnes Includes:
[0033] In one embodiment, the selectable marker is an auxotrophic marker, and growth of the Cutibacterium acnes producing cells is dependent on the auxotrophic marker.
[0034] In one embodiment, the selectable marker is an antibiotic resistance marker.
[0035] In one embodiment, the DNA vector further comprises a CRISPR-Cas system.
[0036] In one embodiment, the CRISPR-Cas system targets a P. acnes chromosomal locus. Preferably, the target locus is not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the chromosomal locus.
[0037] In one embodiment, the CRISPR-Cas system targets multiple P. acnes chromosomal loci. Preferably, the target loci are not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the chromosomal loci.
[0038] In one embodiment, the CRISPR-Cas system targets a P. acnes plasmid locus. Preferably, the target locus is not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the plasmid locus.
[0039] In one embodiment, the CRISPR-Cas system targets multiple P. acnes plasmid loci. Preferably, the target loci are not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the plasmid loci.
[0040] In one embodiment, the CRISPR-Cas system is not expressed in P. acnes-producing cells. Preferably, the CRISPR-Cas system is repressed in P. acnes-producing cells.
[0041] In one embodiment, the CRISPR-Cas system targets pro-inflammatory sequences associated with host disease.
[0042] In one embodiment, the CRISPR-Cas system targets pro-inflammatory sequences associated with acne vulgaris.
[0043] In one embodiment, the DNA vector comprises a CRISPR-Cas system that targets the DNA vector itself.
[0044] In one embodiment, the DNA vector comprises a template suitable for homologous recombination within the P. acnes phage.
[0045] In one embodiment, the DNA vector comprises a template suitable for homologous recombination within the P. acnes chromosome.
[0046] In one embodiment, the DNA vector contains a template suitable for homologous recombination within a P. acnes endogenous plasmid.
[0047] In one embodiment, the DNA vector comprises a template suitable for homologous recombination and a CRISPR-Cas system that targets the DNA vector itself outside of the template region.
[0048] In one embodiment, a DNA vector comprises a template suitable for homologous recombination and a CRISPR-Cas system that targets the DNA vector itself outside the template region, with the proviso that the RNA guide (crRNA or sgRNA) derived from the CRISPR-Cas system does not perfectly match the DNA target.
[0049] In one embodiment, the DNA vector comprises an integrase gene expression cassette and a site-specific recombination site, allowing integration of the DNA vector within a chromosome.
[0050] In one embodiment, a DNA vector comprises a prime editor gene expression cassette and one or more pegRNAs.
[0051] In one embodiment, a DNA vector comprises a base editor gene expression cassette and one or more crRNAs or sgRNAs.
[0052] In one embodiment, the selectable marker is catA.
[0053] In one embodiment, the selectable marker is ermE.
[0054] In one embodiment, the selectable marker is hygB.
[0055] The present invention includes a P. acnes phage-derived particle comprising any of the DNA vectors of the present invention.
[0056] The present invention includes Propionibacterium acnes, particularly engineered Propionibacterium acnes, comprising any of the DNA vectors of the present invention.
[0057] In a particular embodiment, the engineered Propionibacterium acnes comprises at least one, two, three or more DNA vectors, particularly the DNA vectors of the present invention.
[0058] In one particular embodiment, the engineered Propionibacterium acnes comprises a DNA vector of the present invention comprising DNA encoding an antigen.
[0059] The present invention includes P. acnes engineered following transduction by phage-derived particles of any of the vectors of the present invention.
[0060] The present invention includes engineered Propionibacterium acnes whose genome has been altered following transduction with a phage-derived particle containing any of the vectors of the present invention.
[0061] The present invention includes engineered P. acnes produced by transducing P. acnes with any of the vectors of the present invention, modifying the P. acnes with a gene of interest carried by the vector, and selecting for the modification.
[0062] The present invention includes engineered P. acnes produced by transducing P. acnes with any of the vectors of the present invention, modifying the P. acnes with a gene of interest carried by the vector, selecting for the modification, and curing the vector from the engineered P. acnes.
[0063] In one embodiment, the engineered Propionibacterium acnes is modified with a vector-borne CRISPR-Cas system and transduced by a phage-derived particle containing any of the vectors of the invention.
[0064] In one embodiment, the engineered P. acnes is modified by the insertion of an exogenous gene into the P. acnes chromosome.
[0065] In one embodiment, the engineered P. acnes is modified by insertion of a foreign gene into an P. acnes plasmid.
[0066] In one embodiment, the engineered P. acnes is modified by deletion or mutation of an endogenous gene sequence in the P. acnes chromosome.
[0067] In one embodiment, the engineered P. acnes is modified by the deletion, insertion, or substitution of one or more nucleotides into the P. acnes chromosome.
[0068] In one embodiment, the engineered P. acnes plasmid is modified by the deletion, insertion, or substitution of one or more nucleotides.
[0069] The present invention includes a method for producing a P. acnes phage-derived particle containing any of the vectors of the present invention, the method comprising the steps of introducing any of the DNA vectors of the present invention into a P. acnes producing cell and contacting the producing cell with a P. acnes phage genome.
[0070] The present invention includes a method for manipulating P. acnes comprising introducing any of the DNA vectors of the present invention into P. acnes. The method may further include selecting for modified P. acnes. The method may further include selecting for modified P. acnes having an insertion of a foreign gene into the P. acnes chromosome or endogenous plasmid. The method may further include selecting for modified P. acnes having one or more deletions, insertions, or substitutions of one or more nucleotides in the P. acnes chromosome or endogenous plasmid.
[0071] The present invention includes phage-derived particles produced by any of the methods of the present invention.
[0072] The present invention includes a method for treating a P. acnes-associated disorder or disease. In one embodiment, the method comprises administering a phage-derived particle of the present invention, or a bacterium producing such a phage-derived particle, to a subject. The present invention further relates to a phage-derived particle of the present invention, or a bacterium producing such a phage-derived particle, for use in a method for treating a P. acnes-associated disorder or disease.
[0073] The present invention includes a method of modifying Propionibacterium acnes to treat a disorder, disease, or skin condition, or for cosmetic use. In one embodiment, the method comprises administering a phage-derived particle of the present invention, or a bacterium producing such a phage-derived particle, to a subject. The present invention further relates to a phage-derived particle of the present invention, or a bacterium producing such a phage-derived particle, for use in a method of treating a disorder, disease, or skin condition.
[0074] In one embodiment, the method is performed ex-situ.
[0075] In one embodiment, the method is performed in situ.
[0076] In one embodiment, the method is performed ex-situ using a P. acnes strain isolated from a subject.
[0077] For a better understanding of the subject matter disclosed herein, and to illustrate how it may be carried out in practice, embodiments will now be described, by way of non-limiting example, in connection with the accompanying drawings, in which it is emphasized that, with particular reference to the drawings, the details shown are exemplary and explanatory of embodiments of the invention. [Brief explanation of the drawings]
[0078] [Figure 1] The figure shows P. acnes producer cells infected with P. acnes phage carrying a DNA vector with a packaging signal and a transgene; phage-derived particles carrying the DNA vector are then produced, which upon binding to P. acnes receiver cells transduce the DNA vector, leading to replication and expression of the transgene. Instead, the P. acnes producer cells are not infected by the phage but instead carry helper phage that is induced to induce the production of phage-derived particles. [Figure 2] Figure 1 shows the host range determination of isolated P. acnes bacteriophages. 1 indicates strain infection with full spot lysis; 0.5 indicates lower efficiency in strain infection, where a single plaque was observed instead of full spot lysis. [Figure 3] A gel is shown. Individual colonies from a titration of phage-derived particles were streaked, and PCR was performed on individual colonies using primers IC208 (SEQ ID NO: 99) / IC310 (SEQ ID NO: 100) to confirm the presence of the phagemid. 1 and 2 relate to transductants derived from independent production and titration of phage-derived particles carrying the same phagemid. B and W are PCRs on phagemid extracts (positive control) and strain ATCC11828 (negative control), respectively. The presence of the plasmid after restreaking confirms that the transductants carry the replicating phagemid. [Figure 4]This figure shows a method for engineering the P. acnes genome using a non-replicating vector carrying a recombination template. Figure 4A shows a vector (pEB_HR01) conjugated into P. acnes, containing a single homology arm (HA) to the P. acnes chromosome. Because the vector is non-replicative in P. acnes, only P. acnes cells that undergo a single recombination event stably maintain the antibiotic marker and can grow on antibiotic plates. Cells that do not undergo the first recombination event or cells that undergo both the first and second recombination events cannot grow on antibiotic plates (erythromycin). Figure 4B shows a vector (pEB_HR02) conjugated into P. acnes, containing two homology arms to the P. acnes chromosome. Selection of final recombinants is performed using antibiotic selection (ErmE) and counterselection (SacB). [Figure 5] This paper demonstrates a method for manipulating the P. acnes genome using a replicating CRISPR-Cas system selection vector carrying a recombination template. A replicating CRISPR-Cas system selection vector containing a template suitable for homologous DNA recombination with the chromosome is ligated into P. acnes. The template contains two homology arms (LHA and RHA), leading to homologous recombination within the P. acnes chromosome and removal of the CRISPR-Cas system target sequence. Therefore, when the presence of a vector expressing the CRISPR-Cas system is selected, only recombinant P. acnes can grow in the presence of erythromycin. [Figure 6]
[0049] Figure 6A shows a method for manipulating the P. acnes genome using a self-targeting replicating vector carrying a CRISPR-Cas system and a recombination template. Figure 6A shows a vector conjugated into P. acnes containing an antibiotic selection marker flanked by two homology arms and a CRISPR-Cas system targeting the vector outside the homology region. The CRISPR-Cas system cleaves the vector, resulting in template linearization and plasmid loss. Thus, only recombinant cells can grow in the presence of antibiotics. Figure 6B shows a vector conjugated into P. acnes containing a mutant allele flanked by two homology arms and a CRISPR-Cas system targeting the vector and a non-mutated allele of the P. acnes chromosome outside the homology region. The CRISPR-Cas system cleaves the vector, resulting in template linearization and plasmid loss, as well as cleaving the P. acnes chromosome. Thus, only recombinant cells can grow in the presence of erythromycin. [Figure 7] A two-step method for engineering and selecting Propionibacterium acnes phages using the CRISPR-Cas system is shown. Figure 7A shows the first step of the method. The first step consists of generating a mutant phage (mtPAC7) by infecting a strain (Propionibacterium acnes pEB-PRECOMB) containing a plasmid with a recombination template with a first phage (wtPAC7). The recombination template contains a left homology arm (LHA) and a right homology arm (RHA) flanking the mutant allele. The two homology arms allow in vivo recombination between the plasmid (pEB-PRECOMB) and the phage genome. The suspension resulting from the infection contains a mixture of the initial phage (wtPAC7) and the new mutant phage (mtPAC7). Figure 7B shows the second step of the method. To select between the two phage particles, the suspension was contacted with a P. acnes strain (P. acnes pEB-PSCREEN) containing a plasmid expressing a CRISPR-Cas system that targets only the wt PAC7 phage but not mt PAC7. Thus, infection with P. acnes pEB-PSCREEN results in the selective replication of mt PAC7. [Figure 8] Figure 1 shows P. acnes transductants with phage-derived particles carrying DNA vectors containing different sizes of phage packaging signals (cos). Each suspension of phage-derived particles, also containing phage, was mixed with P. acnes ATCC11828 pseudolysogens, and the mixtures were incubated for 1 hour at room temperature, diluted, and 4 μL of each dilution was plated on Brucella plates in the presence of erythromycin (5 μg / mL). For each phage-derived particle containing the same DNA vector, two suspensions from independent productions were used (e.g., pIC400.1 and pIC400.2). [Figure 9] Figure 1 shows titration of the supernatant, designated Sup-253, obtained after infection of P. acnes (Ca0s18206) containing the editing / targeting vector pIC253 with P. acnes ATCC11828 wt, P. acnes ATCC11828 (Ca0s18233) containing pIC238, and P. acnes ATCC11828 (Ca0s18234) containing pIC240. The P. acnes ATCC11828 strain is sensitive to both wild-type phage PAC7 and any mutant phage obtained by homologous recombination. The Ca0s18233 strain is resistant to wild-type phage PAC7 and to mutant phage obtained by homologous recombination with the pIC253 template. The Ca0s18234 strain is resistant to wild-type phage PAC7 and to mutant phage obtained by homologous recombination with pIC253. [Figure 10]The figure shows the titration of the supernatant, designated Sup-257, obtained after infection of P. acnes (Ca0s18208) containing the editing / targeting vector pIC257 with P. acnes ATCC11828 wt, P. acnes ATCC11828 (Ca0s18234) containing pIC240, and P. acnes ATCC11828 (Ca0s18233) containing pIC238. The P. acnes ATCC11828 strain is sensitive to both the wild-type phage PAC7 and any mutant phage obtained by homologous recombination. The Ca0s18234 strain is resistant to the wild-type phage PAC7 and sensitive to any mutant phage obtained by homologous recombination with pIC257. The Ca0s18233 strain is resistant to the wild-type phage PAC7 and to any mutant phage obtained by homologous recombination with pIC257. [Figure 11] Figure 1 shows titration of the supernatant, designated Sup-350, obtained after infection with P. acnes ATCC11828 wt and P. acnes ATCC11828 (Ca0s18233) containing pIC238. The P. acnes ATCC11828 strain is sensitive to both the wild-type phage PAC7 and the mutant phage obtained by homologous recombination with pIC350. The Ca0s18233 strain is resistant to the wild-type phage PAC7 and sensitive to the mutant phage obtained by homologous recombination with pIC350. [Figure 12] Figure 1 shows titration of the supernatant, designated Sup-351, obtained after infection with P. acnes ATCC11828 wt and P. acnes ATCC11828 (Ca0s18233) containing pIC238. The P. acnes ATCC11828 strain is sensitive to both the wild-type phage PAC7 and the mutant phage obtained by homologous recombination with pIC351. The Ca0s18233 strain is resistant to both the wild-type phage PAC7 and the mutant phage obtained by homologous recombination with pIC351. [Figure 13]The P. acnes phage genome organization is shown. Five distinct regions encode different proteins involved in various functions, namely packaging, head assembly, tail assembly, lysis, and DNA replication (Brown et al. 28). [Figure 14] (A and B) Absorbance values from ELISA for the presence of chicken ovalbumin (OVA) protein in different P. acnes culture supernatants diluted 1 / 10. Figures 14A and 14B represent two independent replicates. Bar graphs represent the average of three technical replicates of the same supernatant culture. P. acnes strain ATCC11828 (WT) was used as a negative control. [Figure 15] Ovalbumin-specific Western blots using culture supernatants from different P. acnes strains engineered to secrete ovalbumin are shown. From left to right: (1) Pageruler ladder, (2) supernatant from strain Ca0s22120, (3) supernatant from strain Ca0s22122, (4) supernatant from strain Ca0s22126, (5) supernatant from strain Ca0s22128, (6) supernatant from strain Ca0s22130, (7) supernatant from strain Ca0s22132, (8) supernatant from strain Ca0s16973, and (9) ovalbumin. [Figure 16] The gel is shown. The first well on the left (1) corresponds to a 1 kb DNA ladder from GeneRuler. The other wells correspond to PCR performed on plaques using primers IC443 / IC290. From left to right: (2) plaque number 5 from the lawn of strain CaOs20472 plus infected CaOs20855 suspension; (3) plaque number 7 from the lawn of strain CaOs20472 plus infected CaOs20855 suspension; (4) plaque number 1 from the lawn of strain CaOs20472 plus PAC7 suspension; (5) plaque number 2 from the lawn of strain CaOs20472 plus PAC7 suspension; (6) plaque number 3 from the lawn of strain CaOs20472 plus infected CaOs20857 suspension; (7) plaque number 3 from the lawn of strain CaOs20472 plus PAC7 suspension. [Figure 17]The gel is shown. The first well on the left (1) corresponds to a 1 kb DNA ladder from GeneRuler. The other wells correspond to PCR using primers IC619 / AL219. From left to right: (wells 2-8) seven plaques isolated from plaque number 28, (wells 9-15) seven plaques isolated from plaque number 28, (well 16) PCR on wt PAC7 (positive control), (well 17) negative control on a lawn of Ca0s22235. [Figure 18] 1 shows DNA alignment between the PAC7 wt genome (SEQ ID NO: 113) and sequencing of three different plaques isolated from PAC7-m28-gp45 using IC619 (SEQ ID NO: 78; SEQ ID NO: 85; SEQ ID NO: 114). Alignment performed using Clustal Omega (Sievers, F. et al., Mol Syst Biol 7, 539-539 (2011)). DETAILED DESCRIPTION OF THE INVENTION
[0079] The present inventors are the first to demonstrate the introduction of recombinant replicative DNA in P. acnes by transduction with phage-derived particles.
[0080] Furthermore, the present inventors have demonstrated for the first time the production of P. acnes phage-derived particles carrying recombinant self-replicating DNA vectors from P. acnes strains.
[0081] The present invention relates to P. acnes strains carrying a DNA vector comprising a phage packaging signal and a gene of interest, the production of phage-derived particles containing said DNA vector, and the use of said phage-derived particles for transducing P. acnes in vitro or in situ, and the expression of said gene of interest in said transduced P. acnes cells. The present invention further relates to modified P. acnes, with or without the DNA vector, obtained by transduction of the DNA vector with phage-derived particles.
[0082] Propionibacterium acnes phages naturally occur on human skin and have been isolated many times since their first isolation in 1964. More recently, sequencing of Propionibacterium acnes phages has revealed an exceptionally high level of nucleotide conservation, with approximately 85% identity. All Propionibacterium acnes phages described to date are members of the Siphoviridae family, with a genome size constraint of approximately 30 kb and similar genome structure. Despite their limited genetic diversity, most Propionibacterium acnes phages are considered broad-host-range because they have the ability to infect multiple Propionibacterium acnes phylotypes. Due to their in situ infectivity and broad host range, Propionibacterium acnes phages are suitable platforms to engineer for transgene delivery into Propionibacterium acnes populations.
[0083] The present inventors demonstrate for the first time that the simultaneous presence of a wild-type or engineered P. acnes phage genome and a recombinant DNA vector carrying a packaging signal in P. acnes cells ("producer cells") can produce phage-derived particles. The phage-derived particles can transduce the DNA vector into "receiver" P. acnes cells to express a transgene, e.g., an antibiotic resistance gene, allowing for the selection of transductants. This greatly expands the possibilities for directly manipulating P. acnes populations on the skin, facilitating many applications (industrial, therapeutic, cosmetic, environmental). The present invention includes P. acnes "producer" cells carrying DNA vectors, particularly phagemids, and methods for generating phage-derived particles, as well as the use of phage-derived particles to modify or kill P. acnes.
[0084] DNA vectors The present invention includes a recombinant DNA vector for use in Cutibacterium acnes. Preferably, the DNA vector is a recombinant DNA vector that does not integrate into the P. acnes chromosome. The vector allows transmission to progeny cells. The vector is preferably a phagemid. The DNA vector preferably contains an origin of replication that allows replication in P. acnes and a phage packaging signal.
[0085] In various embodiments, the DNA vector comprises any combination of a phage packaging signal, an origin of replication that allows replication in P. acnes, a selection marker that allows selection of the DNA vector in P. acnes, a gene of interest, and an origin of replication that allows replication in P. acnes producer cells but not in P. acnes receiver cells.
[0086] In one embodiment, the DNA vector comprises a phage packaging signal, an origin of replication that allows replication in P. acnes, a first selection marker that allows selection of the DNA vector in P. acnes, and a gene of interest.
[0087] In one embodiment, the DNA vector comprises a phage packaging signal, an origin of replication that allows replication in P. acnes but not in P. acnes receiver cells, a first selection marker that allows selection of the DNA vector in P. acnes, and a gene of interest.
[0088] Preferably, the gene of interest is foreign to P. acnes, ie, a gene not naturally found in P. acnes.
[0089] In one embodiment, the DNA vector comprises a phage packaging signal that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 76; an origin of replication that allows replication in P. acnes; a selection marker that allows selection of the DNA vector in P. acnes; and a gene of interest.
[0090] In one embodiment, the DNA vector comprises a phage packaging signal that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 76; an origin of replication that allows replication in P. acnes or a related species; a selection marker that allows selection of the DNA vector in P. acnes; and a gene of interest.
[0091] In one embodiment, the DNA vector comprises a phage packaging signal that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 76; an origin of replication that allows replication in P. acnes or a closely related species; a selection marker that allows selection of the DNA vector in P. acnes; a selection marker that allows selection in a first bacterium that is E. coli; an origin of replication that allows replication in a first bacterium that is E. coli; and a gene of interest.
[0092] In one embodiment, DNA vectors can be efficiently introduced into P. acnes-producing cells and stably replicated using electroporation, protoplast electroporation, chemical transformation, conjugation, natural competency, or transduction.
[0093] In one embodiment, physical methods, such as electroporation of P. acnes cells or electroporation of P. acnes protoplasts, can be used to efficiently transform and stably replicate DNA vectors into P. acnes producing cells.
[0094] In one embodiment, P. acnes protoplasts are generated using mutanolysin or lysozyme treatment, mutanolysin-lysozyme treatment, or mutanolysin-lysozyme bead-beating treatment followed by resuspension in hypotonic media.
[0095] In one embodiment, the P. acnes protoplast mixture can be used together with a DNA vector, or with a DNA vector plus glass beads, to efficiently transform and stably replicate the DNA vector into P. acnes producing cells.
[0096] In one embodiment, delivery of the DNA vector into P. acnes is by transduction. In one embodiment, the DNA vector comprises a packaging signal selected from the group consisting of packaging signals of the following P. acnes phages: PAC7 (typically the sequence of SEQ ID NO: 68); PAC1 (typically the sequence of SEQ ID NO: 69); PAC9 (typically the sequence of SEQ ID NO: 70); PAC2 (typically the sequence of SEQ ID NO: 71); PAC10 (typically the sequence of SEQ ID NO: 72); PAC22 (typically the sequence of SEQ ID NO: 73); PAC13 (typically the sequence of SEQ ID NO: 74), and PAC263 (typically the sequence of SEQ ID NO: 75), and is a packaging signal selected from the group consisting of packaging signals of the phage P. acnes. PAC7 (typically the sequence of SEQ ID NO: 68); PAC1 (typically the sequence of SEQ ID NO: 69); PAC9 (typically the sequence of SEQ ID NO: 70); PAC2 (typically the sequence of SEQ ID NO: 71); PAC10 (typically the sequence of SEQ ID NO: 72); PAC22 (typically the sequence of SEQ ID NO: 73); PAC13 (typically the sequence of SEQ ID NO: 74), and PAC263 (typically the sequence of SEQ ID NO: 75), and enables the DNA vector to be transduced into P. acnes.
[0097] In one embodiment, the DNA vector comprises a packaging signal whose sequence is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of any of the above packaging signals.
[0098] In one embodiment, the phage packaging signal has a sequence that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to a phage packaging signal sequence selected from the group consisting of SEQ ID NO:76, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, and SEQ ID NO:90.
[0099] In one embodiment, delivery of the DNA vector into P. acnes is by conjugation.
[0100] In one embodiment, the DNA vector is selected from the group consisting of oriT_pMRC01 (typically the sequence of SEQ ID NO: 1); oriT_RSF1010 (typically the sequence of SEQ ID NO: 2); oriT_pRS01 (typically the sequence of SEQ ID NO: 3); oriT_pMV158 (typically the sequence of SEQ ID NO: 4); oriT_pTF1 (typically the sequence of SEQ ID NO: 5); oriT_pSC101 (typically the sequence of SEQ ID NO: 6); oriT_pBTK445 (typically the sequence of SEQ ID NO: 7); oriT_pBBR1 (typically the sequence of SEQ ID NO: 8); oriT_R721 (typically the sequence of SEQ ID NO: oriT_pRmeGR4a (typically the sequence of SEQ ID NO: 10); oriT_ColE1 (typically the sequence of SEQ ID NO: 11); oriT_pTiC58 (typically the sequence of SEQ ID NO: 12); oriT_pMdT1 (typically the sequence of SEQ ID NO: 13); oriT_R1 (typically the sequence of SEQ ID NO: 14); oriT_Tn5520 (typically the sequence of SEQ ID NO: 15); oriT_QKH54 (typically the sequence of SEQ ID NO: 16); oriT_R64 (typically the sequence of SEQ ID NO: 17); oriT_R751 (typically the sequence of SEQ ID NO: 18); or oriT_RP4 (typically the sequence of SEQ ID NO: 19); oriT_pKL1 (typically the sequence of SEQ ID NO: 20); oriT_RK2 (typically the sequence of SEQ ID NO: 21); oriT_R1162 (typically the sequence of SEQ ID NO: 22); oriT_Tn4555 (typically the sequence of SEQ ID NO: 23); oriT_pHT (typically the sequence of SEQ ID NO: 24); oriT_Tn4399 (typically the sequence of SEQ ID NO: 25); oriT_Tn916 (typically the sequence of SEQ ID NO: 26); oriT_pST12 (typically the sequence of SEQ ID NO: 27); oriT_pCU1 (typically is the sequence of SEQ ID NO: 28); oriT_pSU233 (typically the sequence of SEQ ID NO: 29); oriT_F (typically the sequence of SEQ ID NO: 30); oriT_pMAB01 (typically the sequence of SEQ ID NO: 31); oriT_R388 (typically the sequence of SEQ ID NO: 32); oriT_pS7a (typically the sequence of SEQ ID NO: 33); oriT_pS7b (typically the sequence of SEQ ID NO: 34); oriT_R702 (typically the sequence of SEQ ID NO: 35); oriT_pMUR274 (typically the sequence of SEQ ID NO: 36); oriT_R100 (typically the sequence of SEQ ID NO: 37);The origin of transfer is selected from the group consisting of oriT_pVCR94deltaX (typically the sequence of SEQ ID NO: 38); oriT_R46 (typically the sequence of SEQ ID NO: 39); oriT_pGO1 (typically the sequence of SEQ ID NO: 40); and oriT_pIP501 (typically the sequence of SEQ ID NO: 41).
[0101] In one embodiment, the DNA vector comprises the origin of transfer oriT_pMRC01 (typically the sequence of SEQ ID NO: 1). In one embodiment, the DNA vector comprises the origin of transfer oriT_RSF1010 (typically the sequence of SEQ ID NO: 2). In one embodiment, the DNA vector comprises the origin of transfer oriT_pRS01 (typically the sequence of SEQ ID NO: 3). In one embodiment, the DNA vector comprises the origin of transfer oriT_pMV158 (typically the sequence of SEQ ID NO: 4). In one embodiment, the DNA vector comprises the origin of transfer oriT_pTF1 (typically the sequence of SEQ ID NO: 5). In one embodiment, the DNA vector comprises the origin of transfer oriT_pSC101 (typically the sequence of SEQ ID NO: 6). In one embodiment, the DNA vector comprises the origin of transfer oriT_pBTK445 (typically the sequence of SEQ ID NO: 7). In one embodiment, the DNA vector comprises the origin of transfer oriT_pBBR1 (typically the sequence of SEQ ID NO: 8). In one embodiment, the DNA vector comprises the origin of transfer oriT_R721 (typically the sequence of SEQ ID NO: 9). In one embodiment, the DNA vector comprises the origin of transfer oriT_pRmeGR4a (typically the sequence of SEQ ID NO: 10). In one embodiment, the DNA vector comprises the origin of transfer oriT_ColE1 (typically the sequence of SEQ ID NO: 11). In one embodiment, the DNA vector comprises the origin of transfer oriT_pTiC58 (typically the sequence of SEQ ID NO: 12). In one embodiment, the DNA vector comprises the origin of transfer oriT_pMdT1 (typically the sequence of SEQ ID NO: 13). In one embodiment, the DNA vector comprises the origin of transfer oriT_R1 (typically the sequence of SEQ ID NO: 14). In one embodiment, the DNA vector comprises the origin of transfer oriT_Tn5520 (typically the sequence of SEQ ID NO: 15). In one embodiment, the DNA vector comprises the origin of transfer oriT_QKH54 (typically the sequence of SEQ ID NO: 16). In one embodiment, the DNA vector comprises the origin of transfer oriT_R64 (typically the sequence of SEQ ID NO: 17). In one embodiment, the DNA vector comprises the origin of transfer oriT_R751 (typically the sequence of SEQ ID NO: 18). In one embodiment, the DNA vector comprises the origin of transfer oriT_RP4 (typically the sequence of SEQ ID NO: 19).In one embodiment, the DNA vector comprises the origin of transfer oriT_pKL1 (typically the sequence of SEQ ID NO: 20). In one embodiment, the DNA vector comprises the origin of transfer oriT_RK2 (typically the sequence of SEQ ID NO: 21). In one embodiment, the DNA vector comprises the origin of transfer oriT_R1162 (typically the sequence of SEQ ID NO: 22). In one embodiment, the DNA vector comprises the origin of transfer oriT_Tn4555 (typically the sequence of SEQ ID NO: 23). In one embodiment, the DNA vector comprises the origin of transfer oriT_pHT (typically the sequence of SEQ ID NO: 24). In one embodiment, the DNA vector comprises the origin of transfer oriT_Tn4399 (typically the sequence of SEQ ID NO: 25). In one embodiment, the DNA vector comprises the origin of transfer oriT_Tn916 (typically the sequence of SEQ ID NO: 26). In one embodiment, the DNA vector comprises the origin of transfer oriT_pST12 (typically the sequence of SEQ ID NO: 27). In one embodiment, the DNA vector comprises the origin of transfer oriT_pCU1 (typically the sequence of SEQ ID NO: 28). In one embodiment, the DNA vector comprises the origin of transfer oriT_pSU233 (typically the sequence of SEQ ID NO: 29). In one embodiment, the DNA vector comprises the origin of transfer oriT_F (typically the sequence of SEQ ID NO: 30). In one embodiment, the DNA vector comprises the origin of transfer oriT_pMAB01 (typically the sequence of SEQ ID NO: 31). In one embodiment, the DNA vector comprises the origin of transfer oriT_R388 (typically the sequence of SEQ ID NO: 32). In one embodiment, the DNA vector comprises the origin of transfer oriT_pS7a (typically the sequence of SEQ ID NO: 33). In one embodiment, the DNA vector comprises the origin of transfer oriT_pS7b (typically the sequence of SEQ ID NO: 34). In one embodiment, the DNA vector comprises the origin of transfer oriT_R702 (typically the sequence of SEQ ID NO: 35). In one embodiment, the DNA vector comprises the origin of transfer oriT_pMUR274 (typically the sequence of SEQ ID NO: 36). In one embodiment, the DNA vector comprises the origin of transfer oriT_R100 (typically the sequence of SEQ ID NO: 37). In one embodiment, the DNA vector comprises the origin of transfer oriT_pVCR94deltaX (typically the sequence of SEQ ID NO: 38).In one embodiment, the DNA vector comprises the origin of transfer oriT_R46 (typically the sequence of SEQ ID NO: 39). In one embodiment, the DNA vector comprises the origin of transfer oriT_pGO1 (typically the sequence of SEQ ID NO: 40). In one embodiment, the DNA vector comprises the origin of transfer oriT_pIP501 (typically the sequence of SEQ ID NO: 41).
[0102] In one embodiment, the DNA vector comprises an oriT whose sequence is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of any of the above-mentioned origins of transfer (oriT).
[0103] In one embodiment, the donor bacterium, e.g., E. coli, is selected from the group consisting of pMRCO1, RSF1010, pRS01, pMV158, pTF1, pSC101, pBTK445, pBBR1, R721, pRmeGR4a, ColE1, pTiC58, pMdT1, R1, Tn5520, QKH54, R64, R751, RP4, pKL1, RK2, R1162, Tn4555, pH The plasmid carries a conjugative plasmid, conjugative transposon, or integrative and conjugative element (ICE) selected from the group consisting of T, Tn4399, Tn916, pST12, pCU1, pSU233, F, pMAB01, R388, pS7a, pS7b, R702, pMUR274, R100, pVCR94deltaX, R46, pGO1, and pIP501, and is used to efficiently transfer the DNA vector into P. acnes recipient cells. In one embodiment, the DNA vector is pMRCO1;RSF1010;pRS01;pMV158;pTF1;pSC101;pBTK445;pBBR1;R721;pRmeGR4a;ColE1;pTiC58;pMdT1;R1;Tn5520;QKH54;R64;R751;RP4;pKL1;RK2;R1162;Tn4555;pHT;Tn4399;Tn9 16; pST12; pCU1; pSU233; F; pMAB01; R388; pS7a; pS7b; R702; pMUR274; R100; pVCR94deltaX; R46; pGO1, and pIP501, containing a conjugative plasmid, a conjugative transposon, and an origin of transfer of integrative and conjugative elements (ICEs) and associated relaxases.
[0104] In a preferred embodiment, the DNA vector is one of the following: pMRC01; RSF1010; pRS01; pMV158; pTF1; pSC101; pBTK445; pBBR1; R721; pRmeGR4a; ColE1; pTiC58; pMdT1; R1; Tn5520; QKH54; R64; R751; RP4; pKL1; RK2; R1162; Tn4555; pHT; Tn The conjugative plasmid, conjugative transposon, and integrative and conjugative element (ICE) origin of transfer and relaxase are selected from the group consisting of 4399; Tn916; pST12; pCU1; pSU233; F; pMAB01; R388; pS7a; pS7b; R702; pMUR274; R100; pVCR94deltaX; R46; pGO1, and pIP501.
[0105] In a preferred embodiment, the DNA vector is selected from the group consisting of oriT_pMRC01 (SEQ ID NO: 1); oriT_RSF1010 (SEQ ID NO: 2); oriT_pRS01 (SEQ ID NO: 3); oriT_pMV158 (SEQ ID NO: 4); oriT_pTF1 (SEQ ID NO: 5); oriT_pSC101 (SEQ ID NO: 6); oriT_pBTK445 (SEQ ID NO: 7); oriT_pBBR1 (SEQ ID NO: 8); oriT_R721 (SEQ ID NO: 9); oriT_pRmeGR4a ( SEQ ID NO: 10); oriT_ColE1 (SEQ ID NO: 11); oriT_pTiC58 (SEQ ID NO: 12); oriT_pMdT1 (SEQ ID NO: 13); oriT_R1 (SEQ ID NO: 14); oriT_Tn5520 (SEQ ID NO: 15); oriT_QKH54 (SEQ ID NO: 16); oriT_R64 (SEQ ID NO: 17); oriT_R751 (SEQ ID NO: 18); oriT_RP4 (SEQ ID NO: 19); oriT_pKL1 (SEQ ID NO: 20); oriT_RK2 (SEQ ID NO: No. 21); oriT_R1162 (SEQ ID NO: 22); oriT_Tn4555 (SEQ ID NO: 23); oriT_pHT (SEQ ID NO: 24); oriT_Tn4399 (SEQ ID NO: 25); oriT_Tn916 (SEQ ID NO: 26); oriT_pST12 (SEQ ID NO: 27); oriT_pCU1 (SEQ ID NO: 28); oriT_pSU233 (SEQ ID NO: 29); oriT_F (SEQ ID NO: 30); oriT_pMAB01 (SEQ ID NO: 31); oriT_R388( The origin of transfer is selected from the group consisting of: oriT_pS7a (SEQ ID NO: 33); oriT_pS7b (SEQ ID NO: 34); oriT_R702 (SEQ ID NO: 35); oriT_pMUR274 (SEQ ID NO: 36); oriT_R100 (SEQ ID NO: 37); oriT_pVCR94deltaX (SEQ ID NO: 38); oriT_R46 (SEQ ID NO: 39); oriT_pGO1 (SEQ ID NO: 40), and oriT_pIP501 (SEQ ID NO: 41).
[0106] In one embodiment, the DNA vector comprises an origin of transfer (oriT) that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to any of these ICEs.
[0107] In one embodiment, the invention includes a DNA vector comprising an origin of replication allowing replication in P. acnes, an oriT allowing conjugation into P. acnes, a selectable marker allowing selection in transconjugant P. acnes, and a selectable marker allowing selection in donor bacteria. In another embodiment, the invention includes a DNA vector comprising an origin of replication allowing replication in P. acnes and an oriT allowing conjugation into P. acnes, as defined above.
[0108] In one embodiment, the origin of replication allowing replication in P. acnes is selected from the group consisting of R6K (typically the sequence of SEQ ID NO: 42); RK2 (typically the sequence of SEQ ID NO: 43); pBBR1 (typically the sequence of SEQ ID NO: 44); pRO1600 (typically the sequence of SEQ ID NO: 45); RSF1010 (typically the sequence of SEQ ID NO: 46); pAMβ1 (typically the sequence of SEQ ID NO: 47); pLME106 (typically the sequence of SEQ ID NO: 48); pTZC1 (typically the sequence of SEQ ID NO: 49); pBC1 (typically the sequence of SEQ ID NO: 50); pEP2 (typically the sequence of SEQ ID NO: 51); pWVO1 (typically the sequence of SEQ ID NO: 52); pAP1 (typically the sequence of SEQ ID NO: 53) pWKS1 (typically the sequence of SEQ ID NO: 54); pLME108 (typically the sequence of SEQ ID NO: 55); pLS1 (typically the sequence of SEQ ID NO: 56); pUB6060 (typically the sequence of SEQ ID NO: 57); p545 (typically the sequence of SEQ ID NO: 58); pJD4 (typically the sequence of SEQ ID NO: 59); pIJ101 (typically the sequence of SEQ ID NO: 60); pSN22 (typically the sequence of SEQ ID NO: 61); pGP01 (typically the sequence of SEQ ID NO: 62); pIP501 (typically the sequence of SEQ ID NO: 63); pCU1 (typically the sequence of SEQ ID NO: 64); and pBAV1K-T5 (typically the sequence of SEQ ID NO: 65). In one embodiment, the origin of replication enabling replication in Propionibacterium acnes is R6K (typically the sequence of SEQ ID NO: 42). In one embodiment, the origin of replication enabling replication in Propionibacterium acnes is RK2 (typically the sequence of SEQ ID NO: 43). In one embodiment, the origin of replication enabling replication in Propionibacterium acnes is pBBR1 (typically the sequence of SEQ ID NO: 44). In one embodiment, the origin of replication that allows replication in P. acnes is pRO1600 (typically the sequence of SEQ ID NO: 45). In one embodiment, the origin of replication that allows replication in P. acnes is RSF1010 (typically the sequence of SEQ ID NO: 46). In one embodiment, the origin of replication that allows replication in P. acnes is pAMβ1 (typically the sequence of SEQ ID NO: 47). In one embodiment, the origin of replication that allows replication in P. acnes is pLME106 (typically the sequence of SEQ ID NO: 48).In one embodiment, the origin of replication that allows replication in P. acnes is pTZC1 (typically the sequence of SEQ ID NO: 49). In one embodiment, the origin of replication that allows replication in P. acnes is pBC1 (typically the sequence of SEQ ID NO: 50). In one embodiment, the origin of replication that allows replication in P. acnes is pEP2 (typically the sequence of SEQ ID NO: 51). In one embodiment, the origin of replication that allows replication in P. acnes is pWVO1 (typically the sequence of SEQ ID NO: 52). In one embodiment, the origin of replication that allows replication in P. acnes is pAP1 (typically the sequence of SEQ ID NO: 53). In one embodiment, the origin of replication that allows replication in P. acnes is pWKS1 (typically the sequence of SEQ ID NO: 54). In one embodiment, the origin of replication that allows replication in P. acnes is pLME108 (typically the sequence of SEQ ID NO: 55). In one embodiment, the origin of replication that allows replication in P. acnes is pLS1 (typically the sequence of SEQ ID NO: 56). In one embodiment, the origin of replication that allows replication in P. acnes is pUB6060 (typically the sequence of SEQ ID NO: 57). In one embodiment, the origin of replication that allows replication in P. acnes is p545 (typically the sequence of SEQ ID NO: 58). In one embodiment, the origin of replication that allows replication in P. acnes is pJD4 (typically the sequence of SEQ ID NO: 59). In one embodiment, the origin of replication that allows replication in P. acnes is pIJ101 (typically the sequence of SEQ ID NO: 60). In one embodiment, the origin of replication that allows replication in P. acnes is pSN22 (typically the sequence of SEQ ID NO: 61). In one embodiment, the origin of replication that allows replication in P. acnes is pGP01 (typically the sequence of SEQ ID NO: 62). In one embodiment, the origin of replication that allows replication in P. acnes is pIP501 (typically the sequence of SEQ ID NO: 63). In one embodiment, the origin of replication that allows replication in P. acnes is pCU1 (typically the sequence of SEQ ID NO: 64). In one embodiment, the origin of replication that allows replication in P. acnes is pBAV1K-T5 (typically the sequence of SEQ ID NO: 65).
[0109] In one embodiment, the DNA vector comprises an origin of replication that allows it to replicate in P. acnes. In one embodiment, the DNA vector comprises an origin of replication selected from the group consisting of R6K (SEQ ID NO:42); RK2 (SEQ ID NO:43); pBBR1 (SEQ ID NO:44); pRO1600 (SEQ ID NO:45); RSF1010 (SEQ ID NO:46); pAMβ1 (SEQ ID NO:47); pLME106 (SEQ ID NO:48); pTZC1 (SEQ ID NO:49); pBC1 (SEQ ID NO:50); pEP2 (SEQ ID NO:51); pWVO1 (SEQ ID NO:52); pAP1 (SEQ ID NO:53); pWKS1 (SEQ ID NO:54); pLME108 (SEQ ID NO:55); pLS1 (SEQ ID NO:56); pUB6060 (SEQ ID NO:57); p545 (SEQ ID NO:58); pJD4 (SEQ ID NO:59); pIJ101 (SEQ ID NO:60); pSN22 (SEQ ID NO:61); pGP01 (SEQ ID NO:62); pIP501 (SEQ ID NO:63); pCU1 (SEQ ID NO:64); and pBAV1K-T5 (SEQ ID NO:65).
[0110] Preferably, the origin of replication has a sequence that is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 98%, 99%, or 100% identical to the sequence of any of the origins of replication described above.
[0111] In various embodiments, the selectable marker is selected from ermE, catA, hygB, ermX, tetW, erm(50), and other GC-rich antibiotic resistance genes. In one embodiment, the selectable marker is not ermE. In one embodiment, the selectable marker is catA. In one embodiment, the selectable marker is hygB.
[0112] In one embodiment, the DNA vector further comprises a CRISPR-Cas system. Typically, the CRISPR-Cas system comprises a CRISPR array. Typically, the CRISPR-Cas system comprises an RNA guide (crRNA or sgRNA).
[0113] In one embodiment, the CRISPR-Cas system targets a P. acnes chromosomal locus. Preferably, the target locus is not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the chromosomal locus.
[0114] In one embodiment, the CRISPR-Cas system targets multiple P. acnes chromosomal loci. Preferably, the target loci are not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the chromosomal loci.
[0115] In one embodiment, the CRISPR-Cas system targets a P. acnes plasmid locus. Preferably, the target locus is not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the plasmid locus.
[0116] In one embodiment, the CRISPR-Cas system targets multiple P. acnes plasmid loci. Preferably, the target loci are not present in P. acnes-producing cells. Preferably, the CRISPR array derived from the CRISPR-Cas system expresses one or more crRNAs that target the plasmid loci.
[0117] In one embodiment, the CRISPR-Cas system is not expressed in P. acnes-producing cells. Preferably, the CRISPR-Cas system is repressed in P. acnes-producing cells.
[0118] In one embodiment, the CRISPR-Cas system targets pro-inflammatory sequences associated with host disease.
[0119] In one embodiment, the CRISPR-Cas system targets pro-inflammatory sequences associated with acne vulgaris.
[0120] In one embodiment, the DNA vector contains a suitable template for homologous recombination, and the CRISPR-Cas system targets the DNA vector itself.
[0121] In one embodiment, the DNA vector comprises a template suitable for homologous recombination within the P. acnes phage.
[0122] In one embodiment, the DNA vector comprises a template suitable for homologous recombination within the P. acnes chromosome.
[0123] In one embodiment, the DNA vector contains a template suitable for homologous recombination within a P. acnes endogenous plasmid.
[0124] In one embodiment, the DNA vector comprises a template suitable for homologous recombination and a CRISPR-Cas system that targets the DNA vector itself outside of the template region.
[0125] In one embodiment, a DNA vector comprises a template suitable for homologous recombination and a CRISPR-Cas system that targets the DNA vector itself outside the template region, with the proviso that the RNA guide (crRNA or sgRNA) derived from the CRISPR-Cas system does not perfectly match the DNA target.
[0126] In one embodiment, the DNA vector comprises an integrase gene expression cassette and a site-specific recombination site, allowing integration of the DNA vector within a chromosome.
[0127] In one embodiment, a DNA vector comprises a base editor gene expression cassette and one or more crRNAs or sgRNAs.
[0128] In one embodiment, a base editor is used to inactivate expression of a gene by editing one or more nucleotides involved in the transcription or translation of the gene, particularly targeting one or more nucleotides in the promoter, RBS, or start codon.
[0129] In one embodiment, a base editor is used to introduce a premature stop codon.
[0130] In one embodiment, a base editor is used to introduce one or more rare codons.
[0131] In other embodiments, base editors are used to regulate expression of a gene by editing one or more nucleotides involved in the transcription or translation of the gene, particularly targeting one or more nucleotides in the promoter, RBS, or start codon, resulting in an increase or decrease in gene expression.
[0132] In other embodiments, base editors are used to reverse mutations that result in the inactivation, decreased activity, or increased activity of a gene or pathway.
[0133] In other embodiments, base editors are used to reverse mutations that result in increased pathogenicity.
[0134] In one embodiment, a base editor is used to alter the regulation of a gene by editing one or more nucleotides involved in the regulation of that gene, such as nucleotides of an operator sequence, a transcription factor binding site, a riboswitch, an RNAse recognition site, a protease cleavage site, a methylation site, or a post-translational modification site (phosphorylation, glycosylation, acetylation, pupylation...).
[0135] In one embodiment, a DNA vector comprises a prime editor gene expression cassette and one or more pegRNAs.
[0136] In one embodiment, a prime editor is used to introduce one or more premature stop codons.
[0137] In one embodiment, a prime editor is used to introduce one or more rare codons.
[0138] In one embodiment, a prime editor is used to introduce or delete nucleotides to induce a frameshift in the reading frame.
[0139] In other embodiments, a prime editor is used to regulate expression of a gene by replacing, deleting, or inserting one or more nucleotides involved in the transcription or translation of the gene. In particular, a prime editor replaces, deletes, or inserts one or more nucleotides in the promoter, RBS, or start codon, resulting in an increase or decrease in gene expression.
[0140] In other embodiments, a prime editor is used to revert mutations that result in the inactivation or reduced activity of a gene or pathway.
[0141] In other embodiments, a prime editor is used to revert mutations that result in increased pathogenicity.
[0142] In one embodiment, the vector is a plasmid that contains an E. coli replicon and an E. coli resistance marker, allowing for extraction of the plasmid from P. acnes and transformation and replication in E. coli.
[0143] In one embodiment, the vector is a plasmid that contains an E. coli replicon and an E. coli resistance marker, allowing for extraction of the plasmid from E. coli and transformation and replication in P. acnes.
[0144] In one embodiment, the vector contains two origins of replication, one that allows replication only in P. acnes or P. acnes-producing cells, and a second that allows replication in other bacteria.
[0145] In one embodiment, a vector containing a template DNA suitable for homologous recombination allows for the expression of a gene that enhances the rate of recombination.
[0146] In one embodiment, a template suitable for homologous recombination contains homology arms upstream and downstream of the recombination point, which may be at least 50 bp, 100 bp, 500 bp, or at least 1000 bp in size.
[0147] In one embodiment, the gene of interest contained in the DNA vector can be a transgene that is foreign to P. acnes. - DNA encoding a fluorescent protein (e.g., UnaG) that results in fluorescent P. acnes cells once a specific substrate is added; - DNA encoding an enzyme reporter (e.g., LacZ) that leads to the production of a chromogenic compound by P. acnes colonies; - DNA encoding human proteins (e.g., interleukins); - DNA encoding an antigen (e.g., a tumor antigen, a viral antigen, a bacterial antigen, a fungal antigen, an autoantigen, an allergen, or a graft-specific antigen); - CRISPR-Cas system; - Prime Editing System; or - Base Editor System Including but not limited to:
[0148] In a particular embodiment, the gene of interest encoded by the DNA vector is DNA encoding an antigen, in particular DNA encoding an antigen selected from the group consisting of tumor antigens, viral antigens, bacterial antigens, fungal antigens, autoantigens, allergens and graft-specific antigens, as defined below.
[0149] Propionibacterium acnes strains containing DNA vectors, engineered Propionibacterium acnes strains The present invention includes P. acnes comprising any of the DNA vectors of the present invention. The present invention further includes P. acnes produced by any of the methods of the present invention. Thus, the present invention includes P. acnes modified following transduction with any of the DNA vectors of the present invention by a phage-derived particle, whether the DNA vector is maintained or subsequently removed (i.e., cured) from the P. acnes.
[0150] Thus, the present invention includes P. acnes produced by a method comprising the steps of producing phage-derived particles from P. acnes producer cells containing a DNA vector of the present invention; contacting the phage-derived particles with P. acnes receiver cells, resulting in transduction of the DNA vector into the P. acnes receiver cells and modification of the P. acnes receiver cells with a gene of interest (e.g., a CRISPR-Cas system) carried by the vector and / or an exogenous gene inserted into the P. acnes chromosome; selecting for the modification; and curing the vector from P. acnes.
[0151] The present invention includes engineered Propionibacterium acnes modified with the CRISPR-Cas system transduced by phage-derived particles carrying the vectors of the present invention.
[0152] The present invention includes engineered P. acnes that have been modified by transduction of a DNA vector and subsequent insertion of a foreign gene into the P. acnes chromosome.
[0153] The present invention includes engineered P. acnes that have been modified by the transduction of a DNA vector and subsequent deletion or mutation of an endogenous gene into the P. acnes chromosome or into an endogenous P. acnes plasmid.
[0154] The present invention includes Propionibacterium acnes produced by transduction with a DNA vector of the present invention.
[0155] The present invention includes engineered P. acnes that have been modified by delivery of a plasmid, particularly by conjugation. In a particular embodiment, the plasmid comprises a CRISPR-Cas system. In another particular embodiment, the plasmid comprises an exogenous gene. In another particular embodiment, the plasmid allows for insertion of an exogenous gene into the P. acnes chromosome. In another particular embodiment, the plasmid allows for deletion or mutation of an endogenous gene into the P. acnes chromosome or into an endogenous P. acnes plasmid. In a particular embodiment, the plasmid comprises an origin of replication, as defined above, that allows replication in P. acnes, and / or an origin of transfer, as defined above.
[0156] Cutibacterium acnes, formerly known as Propionibacterium acnes, was historically classified into three major phylotypes: IA, IB, II, and III, based on recA and tly sequences. These phylotypes were further subdivided into IA1, IA2, IB, II, and III using different multilocus sequence typing (MLST) schemes. More recently, Fitz-Gibbon et al. (Fitz-Gibbon, S. et al. (2013) J Invest Dermatol 133, 2152-2160) introduced a new classification based on 16S rRNA gene sequence variation (ribotyping) and a refined classification of the phylotypes: IA-1, IA-2, IB-1, IB-2, IB-3, IC, II, and III. While the present disclosure relates to this classification, the correspondence between this classification and other classifications is known to those skilled in the art and can be obtained from the following review (Dreno, B. et al. (2018). Journal of the European Academy of Dermatology and Venereology 32, pp. 5-14). Thus, in a particular embodiment, the Propionibacterium acnes may be derived from a phylotype selected from the group consisting of phylotypes IA-1, IA-2, IB-1, IB-2, IB-3, IC, II, and III.
[0157] By comparing the whole genome sequences of strains isolated from acne and healthy subjects, Fitz-Gibbon and colleagues were able to identify acne-associated strains (IA-2 and IB-1) and healthy-associated strains (II), consistent with previous studies. Interestingly, specific loci (locus 1, locus 2, and locus 3) were found to be present in acne-associated strains but absent in neutral and healthy strains. Similar loci were found in subsequent metagenomic analysis, confirming the association between the presence of these loci and acne vulgaris (Barnard, E. et al. (2016) Scientific Reports 6, srep39491 (Non-Patent Document 5)).
[0158] The ability of specific strain phylotypes to induce immune responses has recently been investigated (Yu et al. (2016) Journal of Investigative Dermatology 136:2221-2228 (Non-Patent Document 6)). Yu et al. demonstrated that different Propionibacterium acnes phylotypes induce distinct cytokine profiles when incubated with peripheral blood mononuclear cells (PBMCs). In particular, Yu et al. showed that the acne-associated phylotypes IA-2 p+ (i.e., containing a large acne-associated plasmid), IB-1, and IC induce high levels of inflammatory IFN-γ and IL-17, but low levels of IL-10, suggesting that these specific phylotypes can induce both Th1 and Th17 responses. Furthermore, phylotypes IB-3, II, and III were shown to induce lower levels of IL-17 (and IFN-γ in phylotype III), but higher levels of IL-10, suggesting the induction of a Treg response. Furthermore, phylotypes IA-1, IA-2 p- (i.e., not containing the large acne-associated plasmid), and IB-2 induced lower levels of IFN-γ and IL-10, and higher levels of IL-17, suggesting the induction of a primarily Th17 response.
[0159] Therefore, depending on the particular immune response desired when using the engineered P. acnes of the present invention for a particular indication, the use of a particular P. acnes phylotype or strain may be advantageous. Thus, in one particular embodiment, the P. acnes is derived from a phylotype selected from the group consisting of phylotypes IA-2 p+, IB-1, and IC. In another embodiment, the P. acnes is derived from a phylotype selected from the group consisting of phylotypes IA-1, IA-2 p-, and IB-2. In yet another embodiment, the P. acnes is derived from a phylotype selected from the group consisting of phylotypes IB-3, II, and III.
[0160] Furthermore, previous studies have shown that it is possible to induce different T cell responses in S. epidermidis using different strains of the same species by manipulating the strains (Chen et al. (2019) "Decoding commensal-host communication through genetic engineering of Staphylococcus epidermidis" bioRxiv https: / / doi.org / 10.1101 / 664656 (Non-Patent Document 7)).
[0161] Thus, in a particular embodiment, the Propionibacterium acnes is a strain that induces, or has been engineered to induce, a predetermined T cell response. In a particular embodiment, particularly when the Propionibacterium acnes cells are intended to be used in the prevention and / or treatment of cancer, the Propionibacterium acnes is a strain that induces, or has been engineered to induce, elevated levels of IFN-γ and / or IL-17. In a particular embodiment, particularly when the Propionibacterium acnes cells are intended to be used in the prevention and / or treatment of infection, the Propionibacterium acnes is a strain that induces, or has been engineered to induce, elevated levels of IFN-γ and / or IL-17. In a particular embodiment, particularly when the Propionibacterium acnes cells are intended to be used in the prevention and / or treatment of autoimmune diseases, the Propionibacterium acnes is a strain that induces, or has been engineered to induce, elevated levels of IL-10. In a particular embodiment, particularly when the Propionibacterium acnes cells are intended for use in the prevention and / or treatment of allergies, such as asthma, the Propionibacterium acnes is a strain that induces, or has been engineered to induce, elevated levels of IFN-g and / or IL-10. In a particular embodiment, particularly when the Propionibacterium acnes cells are intended for use in the prevention and / or treatment of transplant rejection, the Propionibacterium acnes is a strain that induces, or has been engineered to induce, elevated levels of IL-10.
[0162] For expression of a molecule of interest and modulation of P. acnes host interactions, P. acnes can be generated that contains a recombinant self-replicating DNA vector of the present invention (or a plasmid, particularly a conjugative plasmid as defined above). The molecule of interest can be carried on a self-replicating DNA vector (or a plasmid, particularly a conjugative plasmid as defined above) in P. acnes, or can be inserted into the P. acnes chromosome through the action of a self-replicating DNA vector (or a plasmid, particularly a conjugative plasmid as defined above).
[0163] In one embodiment, a DNA vector is used for P. acnes chromosomal engineering.
[0164] In one embodiment, a DNA vector is used for P. acnes plasmid engineering.
[0165] In one embodiment, a DNA vector is used to engineer the P. acnes phage.
[0166] In one embodiment, a DNA vector (or plasmid, particularly a conjugative plasmid as defined above) is used for expression of a molecule of interest and modulation of P. acnes host interaction. In one embodiment, a DNA vector (or plasmid, particularly a conjugative plasmid as defined above) is used for expression of a transgene in P. acnes. The transgene can be cloned into a recombinant autonomously replicating DNA vector (or plasmid, particularly a conjugative plasmid) under the control of a predefined promoter (constitutive or inducible) followed by a predefined terminator. Transfer of this vector into P. acnes allows expression of the transgene. The transgene can, for example, be a CRISPR-Cas system or can encode a human protein, such as an interleukin. In one embodiment, a DNA vector (or plasmid, particularly a conjugative plasmid) encodes multiple transgenes under the control of a single promoter or under the control of different promoters. The promoter can be endogenous or exogenous, inducible or constitutive.
[0167] In one embodiment, a DNA vector (or plasmid, particularly a conjugative plasmid) is used to modify the P. acnes genome. In one embodiment, transfer of the vector (or plasmid, particularly a conjugative plasmid) into P. acnes allows expression of a CRISPR / Cas system that cleaves the P. acnes genome (plasmid or chromosome) at a specific site, resulting in modification of the P. acnes genome. In one embodiment, the vector (or plasmid, particularly a conjugative plasmid) further contains a gene of interest and homology to the cleavage site, facilitating integration of the gene of interest into the P. acnes genome.
[0168] Delivery of DNA vectors to P. acnes strains In one embodiment, any of the DNA vectors of the present invention is delivered into P. acnes-producing cells by contacting any of the DNA vectors of the present invention with P. acnes.
[0169] In one embodiment, any DNA vector of the present invention is delivered into P. acnes-producing cells by transfection (e.g., electroporation) into the P. acnes cells, where the DNA vector is stably replicated. In one embodiment, the transfected DNA vector is purified from dam(-) E. coli cells, e.g., ET12567, and electroporated into P. acnes cells made competent at 24°C.
[0170] In one embodiment, any DNA vector of the present invention is delivered into P. acnes-producing cells by transfection (e.g., electroporation) into P. acnes protoplasts. In one embodiment, P. acnes protoplasts are generated using mutanolysin or lysozyme treatment, mutanolysin-lysozyme treatment, or mutanolysin-lysozyme-bead beating treatment, followed by resuspension in a hypotonic medium.
[0171] In one embodiment, any DNA vector of the present invention is delivered into P. acnes-producing cells by mixing the DNA vector with P. acnes protoplasts. In one embodiment, glass beads are added together with the DNA vector, and bead crushing is performed to introduce the DNA into the P. acnes protoplasts.
[0172] In one embodiment, the DNA vector of the present invention is delivered into P. acnes by transduction. In one embodiment, the DNA vector comprises a packaging signal of a P. acnes phage selected from the group consisting of phage PAC7 (typically the sequence of SEQ ID NO: 68); PAC1 (typically the sequence of SEQ ID NO: 69); PAC9 (typically the sequence of SEQ ID NO: 70); PAC2 (typically the sequence of SEQ ID NO: 71); PAC10 (typically the sequence of SEQ ID NO: 72); PAC22 (typically the sequence of SEQ ID NO: 73); PAC13 (typically the sequence of SEQ ID NO: 74), and PAC263 (typically the sequence of SEQ ID NO: 75); phage PAC7 (typically the sequence of SEQ ID NO: 69); PAC9 (typically the sequence of SEQ ID NO: 70); PAC2 (typically the sequence of SEQ ID NO: 71); PAC10 (typically the sequence of SEQ ID NO: 72); PAC22 (typically the sequence of SEQ ID NO: 73); PAC13 (typically the sequence of SEQ ID NO: 74), and PAC263 (typically the sequence of SEQ ID NO: 75); PAC1 (typically the sequence of SEQ ID NO: 68); PAC1 (typically the sequence of SEQ ID NO: 69); PAC9 (typically the sequence of SEQ ID NO: 70); PAC2 (typically the sequence of SEQ ID NO: 71); PAC10 (typically the sequence of SEQ ID NO: 72); PAC22 (typically the sequence of SEQ ID NO: 73); PAC13 (typically the sequence of SEQ ID NO: 74), and PAC263 (typically the sequence of SEQ ID NO: 75), and enables the DNA vector to be transduced into P. acnes.
[0173] In one embodiment, any DNA vector of the present invention is delivered into P. acnes-producing cells by conjugation. In one embodiment, the DNA vector comprises an origin of transfer. In one embodiment, a donor bacterium, such as E. coli, is used to efficiently transfer the DNA vector into P. acnes-producing cells, where the DNA vector stably replicates. In one embodiment, the DNA vector is selected from the group consisting of oriT_pMRCO1 (typically the sequence of SEQ ID NO: 1); oriT_RSF1010 (typically the sequence of SEQ ID NO: 2); oriT_pRS01 (typically the sequence of SEQ ID NO: 3); oriT_pMV158 (typically the sequence of SEQ ID NO: 4); oriT_pTF1 (typically the sequence of SEQ ID NO: 5); oriT_pSC101 (typically the sequence of SEQ ID NO: 6); oriT_pBTK445 (typically the sequence of SEQ ID NO: 7); oriT_pBBR1 (typically the sequence of SEQ ID NO: 8); oriT_R721 (typically the sequence of SEQ ID NO: 9); oriT_pRmeGR4a (typically the sequence of SEQ ID NO: 10); oriT_ColE1 (typically the sequence of SEQ ID NO: 11); oriT_pTiC58 (typically the sequence of SEQ ID NO: 12); oriT_pMdT1 (typically the sequence of SEQ ID NO: 13); oriT_R1 (typically the sequence of SEQ ID NO: 14); oriT_Tn5520 (typically the sequence of SEQ ID NO: 15); riT_QKH54 (typically the sequence of SEQ ID NO: 16); oriT_R64 (typically the sequence of SEQ ID NO: 17); oriT_R751 (typically the sequence of SEQ ID NO: 18); oriT_RP4 (typically the sequence of SEQ ID NO: 19); oriT_pKL1 (typically the sequence of SEQ ID NO: 20); oriT_RK2 (typically the sequence of SEQ ID NO: 21); oriT_R1162 (typically the sequence of SEQ ID NO: 22); oriT_Tn4555 (typically the sequence of SEQ ID NO: 23); oriT_pHT (typically the sequence of SEQ ID NO: 24); oriT_Tn4399 (typically the sequence of SEQ ID NO: 25); oriT_Tn916 (typically the sequence of SEQ ID NO: 26); oriT_pST12 (typically the sequence of SEQ ID NO: 27); oriT_pCU1 (typically the sequence of SEQ ID NO: 28); oriT_pSU233 (typically the sequence of SEQ ID NO: 29); oriT_F (typically the sequence of SEQ ID NO: 30); oriT_pMAB01 (typically the sequence of SEQ ID NO: 31);The origin of transfer is selected from the group consisting of oriT_R388 (typically the sequence of SEQ ID NO: 32); oriT_pS7a (typically the sequence of SEQ ID NO: 33); oriT_pS7b (typically the sequence of SEQ ID NO: 34); oriT_R702 (typically the sequence of SEQ ID NO: 35); oriT_pMUR274 (typically the sequence of SEQ ID NO: 36); oriT_R100 (typically the sequence of SEQ ID NO: 37); oriT_pVCR94deltaX (typically the sequence of SEQ ID NO: 38); oriT_R46 (typically the sequence of SEQ ID NO: 39); oriT_pGO1 (typically the sequence of SEQ ID NO: 40), and oriT_pIP501 (typically the sequence of SEQ ID NO: 41). In one embodiment, the donor bacterium, e.g., E. coli, is selected from the group consisting of pMRC01;RSF1010;pRS01;pMV158;pTF1;pSC101;pBTK445;pBBR1;R721;pRmeGR4a;ColE1;pTiC58;pMdT1;R1;Tn5520;QKH54;R64;R751;RP4;pKL1;RK2;R1162;Tn4555;pHT;Tn4399;Tn916;pST 12; pCU1; pSU233; F; pMAB01; R388; pS7a; pS7b; R702; pMUR274; R100; pVCR94deltaX; R46; pGO1, and pIP501, and having a conjugative plasmid, conjugative transposon, or integrative and conjugative element (ICE) selected from the group consisting of pCU1; pSU233; F; pMAB01; R388; pS7a; pS7b; R702; pMUR274; R100; pVCR94deltaX; R46; pGO1, and pIP501, and used to efficiently transfer the DNA vector into P. acnes recipient cells. In one embodiment, the DNA vector is pMRC01;RSF1010;pRS01;pMV158;pTF1;pSC101;pBTK445;pBBR1;R721;pRmeGR4a;ColE1;pTiC58;pMdT1;R1;Tn5520;QKH54;R64;R751;RP4;pKL1;RK2;R1162;Tn4555;pHT;Tn4399; Containing a conjugative plasmid, conjugative transposon, or integrative and conjugative element (ICE) origin of transfer and associated relaxase, selected from the group consisting of Tn916; pST12; pCU1; pSU233; F; pMAB01; R388; pS7a; pS7b; R702; pMUR274; R100; pVCR94deltaX; R46; pGO1, and pIP501;
[0174] In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pMRC01 (typically the sequence of SEQ ID NO: 1). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_RSF1010 (typically the sequence of SEQ ID NO: 2). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pRS01 (typically the sequence of SEQ ID NO: 3). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pMV158 (typically the sequence of SEQ ID NO: 4). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pTF1 (typically the sequence of SEQ ID NO: 5). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pSC101 (typically the sequence of SEQ ID NO: 6). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pBTK445 (typically the sequence of SEQ ID NO: 7). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pBBR1 (typically the sequence of SEQ ID NO: 8). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_R721 (typically the sequence of SEQ ID NO: 9). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pRmeGR4a (typically the sequence of SEQ ID NO: 10). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_ColE1 (typically the sequence of SEQ ID NO: 11). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pTiC58 (typically the sequence of SEQ ID NO: 12). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pMdT1 (typically the sequence of SEQ ID NO: 13). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_R1 (typically the sequence of SEQ ID NO: 14). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_Tn5520 (typically the sequence of SEQ ID NO: 15). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_QKH54 (typically the sequence of SEQ ID NO: 16). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_R64 (typically the sequence of SEQ ID NO: 17). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_R751 (typically the sequence of SEQ ID NO: 18).In a preferred embodiment, the DNA vector comprises the transfer origin oriT_RP4 (typically the sequence of SEQ ID NO: 19). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pKL1 (typically the sequence of SEQ ID NO: 20). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_RK2 (typically the sequence of SEQ ID NO: 21). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_R1162 (typically the sequence of SEQ ID NO: 22). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_Tn4555 (typically the sequence of SEQ ID NO: 23). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pHT (typically the sequence of SEQ ID NO: 24). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_Tn4399 (typically the sequence of SEQ ID NO: 25). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_Tn916 (typically the sequence of SEQ ID NO: 26). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pST12 (typically the sequence of SEQ ID NO: 27). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pCU1 (typically the sequence of SEQ ID NO: 28). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pSU233 (typically the sequence of SEQ ID NO: 29). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_F (typically the sequence of SEQ ID NO: 30). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pMAB01 (typically the sequence of SEQ ID NO: 31). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_R388 (typically the sequence of SEQ ID NO: 32). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pS7a (typically the sequence of SEQ ID NO: 33). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pS7b (typically the sequence of SEQ ID NO: 34). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_R702 (typically the sequence of SEQ ID NO: 35). In a preferred embodiment, the DNA vector comprises the origin of transfer oriT_pMUR274 (typically the sequence of SEQ ID NO: 36).In a preferred embodiment, the DNA vector comprises the transfer origin oriT_R100 (typically the sequence of SEQ ID NO: 37). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pVCR94deltaX (typically the sequence of SEQ ID NO: 38). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_R46 (typically the sequence of SEQ ID NO: 39). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pGO1 (typically the sequence of SEQ ID NO: 40). In a preferred embodiment, the DNA vector comprises the transfer origin oriT_pIP501 (typically the sequence of SEQ ID NO: 41).
[0175] In one embodiment, the donor bacterium is selected from the group consisting of Escherichia coli, Pseudomonas aeruginosa, Lactococcus lactis, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus rhamnosus, Propionibacterium freudenreichii, Lactobacillus brevis, and the like, carrying a conjugative plasmid, a conjugative transposon, or an integrative and conjugative element (ICE). brevis, Staphylococcus epidermidis, Staphylococcus aureus, Cutibacterium granulosum, Cutibacterium fumerci, Enterococcus faecalis, and Bacillus subtilis.
[0176] In one embodiment, donor bacteria, e.g., E. coli, containing the mobilizable DNA vector and conjugation machinery (ICE, plasmid, conjugative transposon) are grown to high density and conjugation is performed. The donor cells are pelleted by centrifugation and washed to remove antibiotics added during growth to maintain the mobilizable and conjugated DNA vectors. The donor cells are then mixed in the presence of P. acnes cells. The donor cell-P. acnes mixture is spotted on a Brucella agar plate and allowed to conjugate under anaerobic conditions at 37°C. After conjugation, cells are harvested from the conjugation plate and resuspended in BHI broth. - a compound that kills donor cells but not acne bacteria, or - Antibiotics that select for mobilizable DNA vectors The strains are plated on Brucella agar supplemented with .
[0177] After several days of incubation, P. acnes colonies are streaked onto Brucella agar plates supplemented with the appropriate selection, and the presence of the conjugated plasmid is confirmed by specific PCR. The identity of P. acnes, as well as the absence of donor cells, is also confirmed by PCR analysis.
[0178] In one embodiment, conjugation is performed according to the following protocol: 2 mL of an overnight culture of E. coli donor cells containing the mobilizable DNA vector and conjugation machinery (ICE, plasmid, conjugative transposon) is grown in LB broth and pelleted at 6,000 × g for 1 minute. The supernatant is discarded, and the pellet is washed with 500 μL of pre-sterilized LB medium and centrifuged again under the same conditions. The pellet is then resuspended in 200 μL of exponentially growing (OD600 = 0.5) 10× concentrated C. acnes receptor BHI culture. The E. coli-P. acnes mixture is spotted (50 μL / spot) onto a Brucella agar plate and allowed to conjugate for 24 hours under anaerobic conditions at 37°C. Cells from the conjugation plates are then harvested, resuspended in 300 μL of BHI broth, and plated onto Brucella agar supplemented with 50 μg / mL polymyxin B and 5 μg / mL erythromycin or 3.5 μg / mL chloramphenicol, depending on the selection marker present in the mobilizable DNA vector. After 7 days, P. acnes cells grown in the presence of selection are streaked onto Brucella agar plates supplemented with the appropriate selection, and the presence of the conjugated plasmid is confirmed by specific PCR. The identity of P. acnes and the absence of the E. coli donor strain are also confirmed by PCR analysis.
[0179] Method for modifying endogenous Propionibacterium acnes plasmids Naturally occurring P. acnes plasmids have been described. 21、22 Some of these can be transferred from one P. acnes strain to another by conjugation. 20 The ability to modify such plasmids would be of interest for studying their effects in acne vulgaris, particularly their pro-inflammatory role, or for using them for further genetic manipulation of P. acnes. The present inventors have developed a method for modifying P. acnes plasmids.
[0180] In one embodiment, the method comprises, in a first step: - a selection marker for Propionibacterium acnes as defined above, - an origin of replication for Propionibacterium acnes as defined above, - a phage packaging signal as defined above, and - A suitable template for homologous recombination with P. acnes endogenous plasmid The method includes a step of introducing a replicative vector containing the above into Propionibacterium acnes.
[0181] In one embodiment, the method comprises, in a first step: - a selection marker for Propionibacterium acnes as defined above, - an origin of replication for Propionibacterium acnes as defined above, - a phage packaging signal as defined above, - CRISPR-Cas systems, and - A suitable template for homologous recombination within P. acnes endogenous plasmids The method includes a step of introducing a replicative vector containing the above into Propionibacterium acnes.
[0182] Introduction can be achieved by electroporation, electroporation of protoplasts, conjugation, chemical transformation, or transduction. The P. acnes recombinant is then grown, preferably in the presence of an antibiotic.
[0183] The recombinant is then typically infected with P. acnes phage to produce phage-derived particles that carry the DNA vector.
[0184] The phage-derived particles are then typically mixed with P. acnes receiver cells containing an endogenous plasmid, such as pIMPLE-HL096PA1. P. acnes transductants are then typically selected on an appropriate antibiotic.
[0185] In a second step, P. acnes transductants are grown to high density in the presence of antibiotic A to increase the likelihood of a homologous recombination event occurring. Homologous recombination typically results in the introduction of a selectable marker, conferring resistance to antibiotic B. The dense culture typically contains P. acnes strains carrying both the wild-type endogenous plasmid and a recombinant endogenous plasmid carrying the resistance marker. The dense culture is then preferably washed and placed in the presence of a receiver P. acnes strain that is typically resistant to a third antibiotic, C. Selection for exconjugants with antibiotics C and B typically results in selection of receiver cells carrying the recombinant plasmid.
[0186] Other modifications that the methods of the present invention allow include the insertion of an E. coli replicon and E. coli resistance marker on the plasmid, allowing for extraction of the plasmid from P. acnes and transformation and replication in E. coli.
[0187] Furthermore, the plasmid carrying the template DNA suitable for homologous recombination preferably allows expression of a gene that enhances the recombination rate.
[0188] Templates suitable for homologous recombination typically contain homology arms upstream and downstream of the recombination point, which are preferably 50 bp, 100 bp, 500 bp, 1000 bp or more in length.
[0189] Genome manipulation of P. acnes and engineered P. acnes strains The present invention includes methods for engineering the P. acnes genome, and engineered P. acnes strains engineered by any of the methods of the present invention. An "engineered strain" is a strain containing an alteration, either found in nature or not, obtained by any of the methods of the present invention. For example, an engineered P. acnes strain may comprise any of the vectors or DNA of the present invention.
[0190] The present invention includes methods for delivering DNA of interest into P. acnes strains by conjugation. The present invention further includes methods for delivering DNA of interest into P. acnes strains via phage-derived particles. The present invention includes methods for manipulating the P. acnes chromosome using replicating and non-replicating vector methods.
[0191] In one embodiment, delivery of the DNA vector into P. acnes is by transduction. In one embodiment, the DNA vector comprises a phage packaging signal (cos) derived from a P. acnes phage. In one embodiment, phage-derived particles containing the DNA vector can be generated, allowing the DNA vector to be transduced into P. acnes cells.
[0192] In one embodiment, the invention includes replicating and non-replicating vector methods using vectors containing at least one recombination template with one or two homology arms.
[0193] To manipulate the P. acnes genome, the present inventors developed a method using replicating and non-replicating vectors.
[0194] Non-replicating vector method In one embodiment, the non-replicating vector method comprises at least - a phage packaging signal as defined above; - a selection marker for Propionibacterium acnes, as defined above; - a recombination template with one or two homology arms; - an origin of replication that allows replication only within Cutibacterium acnes-producing cells; and - optionally a counterselectable marker, e.g. SacB A vector containing
[0195] The non-replicating vector method uses a vector carrying a P. acnes replicon that replicates only in P. acnes-producing cells but not in other P. acnes cells. Thus, such a vector can replicate in P. acnes-producing cells, and upon contact with a phage genome, can be packaged into a phage capsid, resulting in a phage-derived particle, which can then be transduced by the phage-derived particle into an P. acnes receiver cell, where it does not replicate.
[0196] The method involves introducing into P. acnes-producing cells a plasmid containing a template suitable for homologous DNA recombination within the genome, which template may contain one (FIG. 4A) or two homologous regions (FIG. 4B) that result in homologous recombination.
[0197] In one embodiment, the method involves a P. acnes producer cell carrying a plasmid containing a template suitable for intrachromosomal homologous DNA recombination, the homologous DNA of which is not present within the chromosome of the P. acnes producer cell, a phage packaging signal (cos) from a P. acnes phage, a selectable marker for P. acnes as defined above, and an origin of replication for the P. acnes producer cell that does not replicate in the P. acnes receiver cell. The template may contain one (FIG. 4A) or two homologous regions (FIG. 4B) that result in homologous recombination. The producer cell is typically infected with the P. acnes phage, resulting in the production of phage-derived particles containing a DNA vector with homologous arms. The phage-derived particles are preferably mixed with P. acnes receiver cells (e.g., ATCC11828). Transductants can be selected on antibiotic plates, streaked on antibiotic plates, and screened for plasmid integration by PCR. Because the plasmid is non-replicative in P. acnes, only recombinant cells that stably maintain the antibiotic marker can grow on the antibiotic plate.
[0198] If two homology arms are present on the template DNA, a first recombination event (also called a crossover) typically results in full integration of the plasmid, typically followed by a second recombination event, which removes the plasmid backbone and results in chromosomal modification or reconstitution of the wild-type locus.
[0199] In one embodiment, P. acnes producer cells carry a vector containing a left homology arm (LHA) and a right homology arm (RHA) flanking a P. acnes selection marker, e.g., ermE (pEB_HR02). The two homology arms typically do not correspond to the P. acnes producer cell chromosome. In one embodiment, the vector further contains a phage packaging signal (cos) from a P. acnes phage, a selection marker for P. acnes, and an origin of replication for P. acnes producer cells that do not replicate in P. acnes receiver cells. In one embodiment, the DNA vector further contains an P. acnes counterselection marker, e.g., sacB, on the plasmid backbone, allowing for selection of a second recombination event. P. acnes producer cells carrying pEB_HR02 are typically infected with phage, resulting in the production of phage-derived particles containing pEB_HR02. The phage-derived particles are typically placed in the presence of P. acnes receiver cells (e.g., ATCC11828). Transductants are typically selected on plates supplemented with an antibiotic (e.g., erythromycin) and streaked onto plates supplemented with an antibiotic (e.g., erythromycin), and integration of the plasmid is confirmed by PCR. Because the plasmid is non-replicative in P. acnes recipient cells, P. acnes clones that can grow in the presence of an antibiotic (e.g., erythromycin) have undergone a single homologous recombination event, resulting in integration of the complete plasmid. Selection of the final recombinant locus typically involves exposing cells to a counterselection (e.g., sucrose) and an antibiotic (e.g., erythromycin), which results in cell death due to sacB activity (the complete plasmid remains integrated into the chromosome). Surviving bacteria are typically screened for the presence of a successful final recombinant locus by PCR. In one embodiment, the DNA vector contains only one homology arm (pEB_HR01). In one embodiment, both pEB_HR01 and pEB_HR02 phage-derived particles are applied to the skin, without antibiotic selection.
[0200] In one embodiment, P. acnes producer cells carry a plasmid (vector) containing a left homology arm (LHA) and a right homology arm (RHA) flanking the P. acnes selectable marker ErmE (pEB_HR02). The vector further preferably contains an E. coli origin of replication, an E. coli selectable marker, oriT and relaxase from the conjugative plasmid, and a P. acnes counterselectable marker, e.g., sacB. pEB_HR02 can be transformed into an E. coli donor strain (e.g., Ec0s2862). Transformants are typically selected, grown, and mixed with P. acnes receiver cells (e.g., ATCC11828). Exconjugants are typically selected on plates supplemented with an antibiotic (e.g., erythromycin), streaked on plates supplemented with an antibiotic (e.g., erythromycin), and integration of the plasmid is confirmed by PCR. Because the plasmid is non-replicative in P. acnes recipient cells, P. acnes clones that are able to grow in the presence of an antibiotic (e.g., erythromycin) have undergone a single homologous recombination event that results in integration of the complete plasmid. Selection for the final recombinant locus typically involves exposing cells to a counterselection (e.g., sucrose) and an antibiotic (e.g., erythromycin), which results in cell death due to sacB activity (the complete plasmid remains integrated into the chromosome). Surviving bacteria are typically screened for the presence of a successful final recombinant locus by PCR.
[0201] Replication CRISPR-Cas system selection vector method The present invention includes replicating vectors that contain an origin of replication for Propionibacterium acnes.
[0202] In one embodiment, the replicating CRISPR-Cas selection vector method comprises at least - a phage packaging signal (cos) derived from the Propionibacterium acnes phage, as defined above; - a selection marker for Propionibacterium acnes, as defined above; - origin of replication for Propionibacterium acnes; - a recombination template having two homology arms; and - CRISPR-Cas system for expression in P. acnes A vector containing
[0203] In one embodiment, the replicating CRISPR-Cas selection vector method comprises at least - a selection marker for E. coli as defined above; - origin of replication for E. coli; - a selection marker for Propionibacterium acnes, as defined above; - a recombination template with two homology arms; - an origin of replication for Propionibacterium acnes; and - CRISPR-Cas system expressed in acne bacteria A vector containing
[0204] Such vectors are therefore replicable in E. coli and in P. acnes, and further carry a CRISPR-Cas system capable of inducing a double-strand break at the wild-type locus where recombination is desired, resulting in the death of the P. acnes receiver cell.
[0205] In one embodiment, the method involves the use of P. acnes producer cells, e.g., strain ATCC6919, carrying a replicating CRISPR-Cas system selection vector containing a template suitable for intrachromosomal homologous DNA recombination and a phage packaging signal (cos) derived from P. acnes phage. In one embodiment, the template contains two homologous regions (Figure 5), resulting in homologous recombination. The producer cells preferably do not contain the wild-type locus targeted by the CRISPR-Cas system. The P. acnes producer cells are typically infected with P. acnes phage, resulting in the production of phage-derived particles carrying the DNA vector. The phage-derived particles are typically contacted with P. acnes receiver cells. After transduction into the P. acnes receiver cells, cells that have recombined with the DNA template vector are not targeted by the CRISPR-Cas system, e.g., because they no longer have the associated PAM sequence. Plating onto antibiotic-containing media, e.g., erythromycin plates, typically ensures that surviving cells have been transduced and still carry the DNA vector (e.g., a plasmid) expressing the CRISPR-Cas system. Single colonies are typically streaked onto antibiotic-containing media, e.g., erythromycin plates, and recombinant loci are typically confirmed by PCR and sequencing.
[0206] In one embodiment, a process of plasmid curing is performed to remove the plasmid.
[0207] In one embodiment, the P. acnes producing cells contain a DNA target for the CRISPR-Cas system, but the CRISPR-Cas system is not expressed in the P. acnes producing cells but is expressed in the P. acnes receiver cells. More preferably, the CRISPR-Cas system is repressed in the P. acnes producing cells but not in the P. acnes receiver cells.
[0208] Such methods can be used for scarless editing, e.g., substitutions, deletions, or insertions, because there is no need to introduce a selectable marker to select for recombinants, which are selected for by CRISPR-Cas killing.
[0209] Self-targeted replication vector method In one embodiment, the present invention comprises a self-targeted replicating vector method, which results in linearization of the recombination template, which has been shown to increase recombination efficiency. 9 This involves the use of a CRISPR-Cas system to plan the cleavage of a DNA vector (e.g., a plasmid) at one or more target sequences. To make the self-targeting vector cloning-enabled, an inducible CRISPR-Cas system can be used, for example, using an inducible promoter upstream of a gene encoding a Cas nuclease. By combining this inducible promoter with a riboswitch, even tighter inhibition of CRISPR-Cas system expression can be ensured. Another strategy for generating a self-targeting CRISPR-Cas system relies on a promoter that is repressed in P. acnes producer cells but not in P. acnes receiver cells. In this way, the CRISPR-Cas system is only active once it is introduced into the P. acnes receiver cells.
[0210] For example, such strategies can be used to perform gene replacement using antibiotic markers flanked by homology arms (Figure 6A) or by scarless recombination using the CRISPR-Cas system, which, when targeted to the P. acnes chromosome, has the ability to kill bacteria (Figure 6B).
[0211] After introduction and selection of the DNA vector (e.g., a plasmid), a homology event typically occurs, resulting in the removal of the PAM sequence.
[0212] Furthermore, DNA vectors (eg, plasmids) carrying suitable template DNA for homologous recombination typically allow expression of genes that enhance the rate of recombination.
[0213] In one embodiment, a DNA vector comprises a template suitable for homologous recombination and a CRISPR-Cas system that targets the DNA vector itself outside the template region, with the proviso that the RNA guide (crRNA or sgRNA) derived from the CRISPR-Cas system does not perfectly match the DNA target.
[0214] In one embodiment, the present invention provides at least - a phage packaging signal (cos) derived from the Propionibacterium acnes phage, as defined above; - a selection marker for Propionibacterium acnes, as defined above; - an origin of replication for Propionibacterium acnes, as defined above; and - CRISPR-Cas system for expression in P. acnes The present invention also includes a replicative vector method using a vector comprising:
[0215] In one embodiment, the vector carries a CRISPR-Cas system that can induce a double-stranded break that results in the death of most P. acnes receiver cells, except those that, due to spontaneous mutation or recombination, no longer carry the CRISPR-Cas system target sequence.
[0216] Propionibacterium acnes phage genome manipulation The present invention includes methods for engineering the P. acnes phage genome, and engineered P. acnes phage engineered by any of the methods of the invention. An "engineered or recombinant phage" is a phage obtained by any of the methods of the invention that contains changes either found in nature or not. For example, an engineered P. acnes phage genome carries one or more nucleotide substitutions, deletions, or insertions. In other examples, the P. acnes phage genome carries one or more transgenes that are expressed upon phage infection.
[0217] In one embodiment, the P. acnes phage contains one or more genetic modifications into the P. acnes phage genome.
[0218] In one embodiment, the P. acnes phage genome modification is an insertion, deletion, or substitution of one or more nucleotides in the P. acnes phage genome.
[0219] In one embodiment, the P. acnes phage genome modification is silent.
[0220] In one embodiment, the P. acnes phage genome modification is not silent.
[0221] In one embodiment, the P. acnes phage genome modification does not impair P. acnes phage production.
[0222] In one embodiment, the P. acnes phage genome modification alters the phage host range.
[0223] In one embodiment, the P. acnes phage genome modification results in the inhibition of its packaging into a phage capsid without interfering with the production of the capsid itself. More preferably, the genome modification is a modification of the phage packaging sequence. Even more preferably, the modification is a deletion of the phage packaging sequence.
[0224] In one embodiment, the deleted phage packaging sequence is a cos site from Propionibacterium acnes phage, the sequence of which is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO:66.
[0225] In one embodiment, the deleted phage packaging sequence is a cos site from Propionibacterium acnes phage, the sequence of which is at least 80%, 83%, 85%, 87%, 90%, 93%, 95%, 96%, 97%, 98%, 99 or 100% identical to one or more sequences selected from the group consisting of SEQ ID NO:76, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, and SEQ ID NO:90.
[0226] In one embodiment, the P. acnes phage modification is internal to the coding sequence.
[0227] In one embodiment, the P. acnes phage modification is within a regulatory element, such as a promoter, transcription terminator, origin of replication, RBS, or riboswitch.
[0228] In one embodiment, the P. acnes phage modification is within the non-coding and non-regulatory sequences.
[0229] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome.
[0230] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, which insertion does not remove any nucleotides naturally present in the phage genome.
[0231] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome within an intergenic region.
[0232] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, which insertion replaces one or more nucleotides.
[0233] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, which transgene replaces one or more genes within a transcription unit containing the one or more genes without perturbing the genes upstream and downstream.
[0234] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, wherein the transgenes replace the holin gene.
[0235] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, wherein the transgenes replace the endolysin gene.
[0236] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, wherein the transgenes replace the holin and endolysin genes.
[0237] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, wherein the holin and endolysin genes have been previously modified to be inactive.
[0238] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, the transgene being a selectable marker in P. acnes, as defined above.
[0239] In one embodiment, the P. acnes phage modification is the insertion of an origin of replication that allows replication in P. acnes.
[0240] In one embodiment, the P. acnes phage modification comprises: below: - an origin of replication allowing replication in P. acnes, as defined above; and - a selectable marker in P. acnes, as defined above is the insertion of
[0241] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, each transgene containing a promoter, one or more coding sequences, and a transcription terminator.
[0242] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, each transgene containing an inducible promoter, one or more coding sequences and their ribosome binding sites, and a transcription terminator.
[0243] In one embodiment, the P. acnes phage modification is the insertion of one or more transgenes into the P. acnes phage genome, each transgene containing a promoter, one or more coding sequences and their ribosomal binding sites, and a transcription terminator, the promoter being active in a particular P. acnes strain and inactive or less active in other P. acnes strains.
[0244] To engineer the P. acnes phage genome, we: - using in vitro or in vivo DNA assembly of the recombinant phage genome and introduction of the recombinant phage genome into rebooting bacteria, such as, but not limited to, Propionibacterium acnes, which allows for the production of recombinant phage; and / or - Recombination and replication in P. acnes using a CRISPR-Cas system selection vector to select recombinant phages A method for generating recombinant Propionibacterium acnes phages was developed.
[0245] Genome assembly and rebooting of recombinant Propionibacterium acnes phages The present invention includes a method for producing engineered phage using DNA assembly to generate a modified phage genome, followed by generation of phage containing the assembled modified phage genome.
[0246] In one embodiment, to produce a recombinant P. acnes phage, DNA fragments are assembled into a recombinant P. acnes phage genome and introduced into the rebooting bacterium.
[0247] In one embodiment, to produce a recombinant P. acnes phage, DNA fragments are assembled into a recombinant P. acnes phage genome and transformed into a rebooting bacterium.
[0248] In one embodiment, the rebooting bacterium is from the family Propionibacteriaceae. Preferably, the rebooting bacterium is P. freudenreichii, and more preferably, the rebooting bacterium is P. acnes.
[0249] In one embodiment, to produce a recombinant P. acnes phage, DNA fragments are assembled into a recombinant P. acnes phage genome within a vector and introduced into the rebooting bacterium.
[0250] In one embodiment, the DNA fragments are assembled into a recombinant P. acnes phage genome within a vector, and the vector carrying the recombinant P. acnes phage genome is introduced into bacteria, such as E. coli, where it conjugates into P. acnes producing recombinant phage, which are then amplified on P. acnes.
[0251] In one embodiment, the DNA fragments are assembled into a recombinant P. acnes phage genome within a vector, and the vector carrying the recombinant P. acnes phage genome is transformed into bacteria, such as E. coli, which conjugates into P. acnes producing recombinant phage, which are then amplified on P. acnes.
[0252] In one embodiment, below: - an origin of replication allowing replication in E. coli, as defined above; - a selection marker for E. coli as defined above; - oriT from a conjugative plasmid, as defined above, optionally, a relaxase from a conjugative plasmid; and - optionally an origin of replication allowing replication in P. acnes, as defined above; The DNA fragments are assembled into a recombinant P. acnes phage genome within a vector containing the vector and transformed into E. coli carrying the conjugation vector. The vector containing the recombinant P. acnes phage genome is then typically conjugated into P. acnes.
[0253] In one embodiment, the vector in which the DNA fragments are assembled into the recombinant P. acnes phage genome is a bacterial artificial chromosome (BAC).
[0254] In one embodiment, the following techniques: - Gibson Assembly, - PCR assembly, - Golden Gate assemblies and derivatives (MOCLO, GoldenBraid...), - GeneArt® Seamless Assemblies, - SLIC assembly, - CPEC Assembly, - SLiCE assembly One or a combination of the above is used to assemble the DNA fragments in vitro into a recombinant P. acnes phage genome.
[0255] In one embodiment, the method comprises: - PCR using the P. acnes phage genome, - Digestion of P. acnes phage genome, - DNA synthesis (chemical or enzymatic), - Oligo Assembly The DNA fragments are generated by one or a combination of the following:
[0256] In one embodiment, transformation-associated recombination (TAR) in yeast is used to assemble DNA fragments in vivo into a recombinant P. acnes phage genome.
[0257] In one embodiment, DNA fragments are assembled in vitro or in vivo into a recombinant phage genome within a cloning vector, such as a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a P1 phage-derived artificial chromosome, a plasmid, or any combination. The recombinant phage genome is then typically extracted from the cloning vector, optionally circularized, and introduced into a rebooting bacterial strain.
[0258] In one embodiment, the recombinant P. acnes phage genome is introduced into P. acnes by transformation. More preferably, the recombinant P. acnes phage genome is introduced into P. acnes by electroporation.
[0259] In one embodiment, the recombinant P. acnes phage genome is introduced into P. acnes L-form or P. acnes protoplasts.
[0260] Engineering Propionibacterium acnes phages by recombinant methods The present invention includes a method for producing engineered phage, comprising introducing modifications into the P. acnes phage genome using recombination between a DNA template and the P. acnes phage genome, and producing phage containing the modified phage genome.
[0261] In one embodiment, the P. acnes phage genome is introduced into a P. acnes strain containing a DNA template, and a recombination event between the phage genome and the DNA template results in the modification of a portion of the phage genome, which is then packaged into an P. acnes phage.
[0262] In one embodiment, below: - a selection marker for Propionibacterium acnes, as defined above; - an origin of replication for Propionibacterium acnes as defined above, - a recombination template having one or two homology arms, and - possibly recombination mechanisms After introduction of the P. acnes phage genome into P. acnes cells containing a replication vector containing the gene, an engineered P. acnes phage is produced.
[0263] In one embodiment, below: - a selection marker for the donor bacterium, for example E. coli, as defined above, - an origin of replication for a donor bacterium, for example E. coli, as defined above, - a selection marker for Propionibacterium acnes as defined above, - oriT from the conjugative plasmid, as defined above; - possibly a relaxase from a conjugative plasmid, - an origin of replication for Propionibacterium acnes as defined above, - a recombination template having one or two homology arms, - possibly recombination mechanisms After introduction of the P. acnes phage genome into P. acnes carrying a replication vector containing the gene, an engineered P. acnes phage is produced.
[0264] In one embodiment, the P. acnes phage genome is introduced into P. acnes by electroporation.
[0265] In one embodiment, the P. acnes phage genome is introduced into P. acnes via infection with the phage.
[0266] In one embodiment, the DNA template suitable for homologous recombination is linear double-stranded DNA (dsDNA) or single-stranded DNA (ssDNA) introduced by electroporation.
[0267] In one embodiment, the DNA template suitable for homologous recombination is an oligonucleotide.
[0268] In one embodiment, both the phage genome and the DNA template are transformed into P. acnes. Preferably, the transformation method is electroporation.
[0269] CRISPR-Cas system selection method for recombinant phages The present invention includes a method for selecting a recombinant phage CRISPR-Cas system. The present invention includes a Propionibacterium acnes cell carrying a CRISPR-Cas system that is expressed in Propionibacterium acnes and engineered to target a wild-type phage genome or a previously modified phage genome, but not a newly generated recombinant Propionibacterium acnes phage.
[0270] In one embodiment, the engineered CRISPR system is an endogenous CRISPR-Cas system.
[0271] In other embodiments, the CRISPR-Cas system is an exogenous CRISPR-Cas system.
[0272] In one embodiment, the CRISPR-Cas system is an exogenous CRISPR-Cas system integrated onto the P. acnes chromosome.
[0273] In one embodiment, the CRISPR-Cas system is an exogenous CRISPR-Cas system on a replicating vector.
[0274] In one embodiment, the present invention provides a method for producing a medicament for the treatment of a pulmonary arthritis, comprising at least the following: - a selection marker for Propionibacterium acnes as defined above, - an origin of replication for Propionibacterium acnes, as defined above; and - An exogenous CRISPR-Cas system that is expressed in P. acnes and targets the wild-type or previously modified phage genome, but not the newly generated recombinant P. acnes phage genome. Contains a replicating CRISPR-Cas system selection vector containing:
[0275] In one embodiment, the present invention provides a method for producing a medicament for the treatment of a pulmonary arthritis, comprising at least the following: - a selection marker for the donor bacterium, for example E. coli, as defined above, - an origin of replication for a donor bacterium, for example E. coli, as defined above, - a selection marker for Propionibacterium acnes as defined above, - oriT from the conjugative plasmid, as defined above; - possibly a relaxase from a conjugative plasmid, - an origin of replication for Propionibacterium acnes, as defined above; and - An exogenous CRISPR-Cas system that is expressed in P. acnes and targets the wild-type or previously modified phage genome, but not the newly generated recombinant P. acnes phage genome. Contains a replicating CRISPR-Cas system selection vector containing:
[0276] In one embodiment, the method comprises: - a selection marker for the donor bacterium, for example E. coli, as defined above, - an origin of replication for a donor bacterium, for example E. coli, as defined above, - a selection marker for Propionibacterium acnes as defined above, - oriT from a conjugative plasmid, as defined above, - possibly a relaxase from a conjugative plasmid, - an origin of replication for Propionibacterium acnes, as defined above; and - An exogenous CRISPR-Cas system that is expressed in P. acnes and targets the wild-type or previously modified phage genome, but not the newly generated recombinant P. acnes phage genome. The method includes the step of conjugating a replicating CRISPR-Cas system selection vector containing the vector into Propionibacterium acnes, for example, the ATCC 6919 strain.
[0277] After conjugation into P. acnes, exconjugants are typically selected on an appropriate antibiotic. After confirming the presence of the replicating CRISPR-Cas system selection vector in P. acnes, optionally by PCR, a single colony is typically grown in dense culture in the presence of an appropriate antibiotic, mixed with an P. acnes phage suspension, preferably containing a mixture of wild-type phage or previously produced recombinant phage and newly produced recombinant phage, and typically poured as a top agar lawn. Optionally, a first amplification of the recombinant P. acnes phage may be performed on P. acnes carrying the replicating CRISPR-Cas system selection vector, and a phage suspension is typically obtained and mixed with a new culture of P. acnes carrying the replicating CRISPR-Cas system selection vector for top agar.
[0278] Newly generated recombinant phage typically bind, inject their recombinant phage genome, replicate, generate new recombinant particles, and form plaques, whereas wild-type or previously generated recombinant phage inject a phage genome that is recognized and cleaved by the CRISPR-Cas system, resulting in a failure of the phage replication cycle and therefore no plaques being produced. Typically, single plaques are picked and isolated to confirm that they are recombinant and carry the expected genetic modification. Finally, isolated plaques are typically reamplified in an P. acnes indicator strain or in P. acnes carrying a replicating CRISPR-Cas system selection vector, and the pure phage suspension is preferably stored.
[0279] In one embodiment, the recombinant DNA phage is not targeted by the CRISPR-Cas system, for example, because it does not have an associated PAM sequence.
[0280] Method for producing recombinant phages in Propionibacterium acnes The present invention includes a method for producing phage-derived particles in P. acnes. All P. acnes phages described so far are genetically highly conserved and are unable to stably replicate in a plasmid state or integrate into the chromosome of their host.1 As a result, P. acnes phages are difficult to engineer because they cause the death of the cells they infect. To address this problem, we developed a two-step method for engineering P. acnes phages.
[0281] In the first step, the E. coli donor strain carrying the conjugative vector is below: - a selection marker for E. coli as defined above; - an origin of replication for E. coli as defined above, - a selection marker for Propionibacterium acnes as defined above, - relaxase and oriT from the conjugative plasmid, and - a recombination template with one or two homology arms The vector is transformed with a mobilizable replicating vector (e.g., pEB-PRECOMB) containing
[0282] Conjugation occurs between E. coli donor cells (E. coli pEB-PRECOMB) and P. acnes receiver cells (e.g., P. acnes ATCC 6919). P. acnes transconjugants (P. acnes pEB-PRECOMB) are typically selected on an appropriate antibiotic, grown, and infected with P. acnes phage (e.g., PAC7). After phage infection, a recombination event occurs, resulting in a phage lysate containing wild-type P. acnes phage (e.g., wt PAC7) or parent P. acnes phage (i.e., the phage from which the desired recombinant phage was derived) and the recombinant phage (e.g., mt PAC7) (Figure 7A).
[0283] In a second step, - a selection marker for E. coli as defined above; - an origin of replication for E. coli as defined above, - a selectable marker for P. acnes, as defined above, and - the relaxase and oriT from the conjugative vector as defined above, and - CRISPR-Cas system expressed in P. acnes and targeting wild-type phages (e.g., PAC7) Use a replicative plasmid (e.g., pEB-PSCREEN) containing
[0284] In one embodiment, the replicative plasmid is transformed into an E. coli donor strain carrying the conjugative plasmid (e.g., resulting in the production of E. coli donor strain pEB-PSCREEN). Conjugation occurs between the E. coli donor strain pEB-PSCREEN and P. acnes recipient cells (e.g., ATCC6919). Transconjugant P. acnes pEB-PSCREEN cells are typically selected on antibiotic plates, grown to high-density culture, and mixed with a phage lysate containing both wild-type phage (e.g., wt PAC7) and mutant phage (e.g., mt PAC7) (Figure 7B). The wild-type phage genome is typically cleaved by the CRISPR-Cas nuclease and therefore cannot replicate to form plaques, whereas the recombinant mt phage genome is not recognized by the CRISPR-Cas system and does not replicate successfully, resulting in the formation of plaques. Single plaques are typically isolated and screened by PCR to verify the sequence. Once confirmed by sequencing, the recombinant phage is typically amplified on wild-type P. acnes or on a P. acnes strain harboring a CRISPR-Cas system vector targeting the wild-type phage.
[0285] Recombination events can result in substitutions, deletions, or insertions that result in the removal of any part of the PAM sequence or of sequences essential for CRISPR-Cas targeting. Insertions can result in the introduction of fluorescent or enzymatic reporters that aid in the isolation of recombinant plaques.
[0286] Templates suitable for homologous recombination typically contain homology arms upstream and downstream of the recombination point, which are typically at least 50 bp, 100 bp, 500 bp, 1000 bp or at least 5000 bp in size.
[0287] Examples of applications of engineered P. acnes phages include the following: - expression of therapeutic proteins produced during phage infection and released upon cell lysis, - expression of therapeutic proteins that are produced, secreted or transported to the surface during phage infection; - display of specific proteins, e.g., antigens, on the capsid of the phage; - modifying the host range of the phage, and - Obtaining strictly lytic phage variants Including but not limited to:
[0288] Furthermore, vectors (eg, plasmids) carrying suitable template DNA for homologous recombination typically allow expression of genes that enhance the rate of recombination.
[0289] Furthermore, vectors (e.g., plasmids) carrying template DNA suitable for homologous recombination typically carry an inducible endonuclease, such as, but not limited to, CRISPR-Cas, which results in linearization of the vector during phage infection. This linearization of the template vector typically increases the rate of recombination.
[0290] Protein expression by engineered Propionibacterium acnes phages The present invention involves the expression of proteins by engineered P. acnes phage. By incorporating an expression cassette into the phage, the protein can be expressed by infected P. acnes. The promoter within the expression cassette can be inducible or constitutive, allowing for inducible or constitutive expression of the protein by the engineered P. acnes phage.
[0291] In one embodiment, phages are used to express a molecule of interest and / or modulate P. acnes host interactions. In one embodiment, a phage genome is used to express a transgene in P. acnes. The transgene can be cloned into a recombinant autonomously replicating phage vector under the control of a predefined promoter (constitutive or inducible) followed by a predefined terminator. Injection of this phage genome into P. acnes allows for expression of the transgene. The transgene can be, for example, an expression cassette for a CRISPR / Cas system, base editing, or prime editing, or can encode a human protein, such as an interleukin, or can encode an antigen as defined below, such as a tumor antigen, a viral antigen, a bacterial antigen, a fungal antigen, an autoantigen, an allergen, or a graft-specific antigen.
[0292] Protein expression by engineered P. acnes strains The present invention encompasses the expression of proteins by engineered P. acnes strains. Proteins can be expressed by the transduced P. acnes strains by incorporating an expression cassette into a DNA vector. The promoter in the expression cassette can be inducible or constitutive, allowing for inducible or constitutive expression of the protein by the engineered P. acnes strain. Expression of multiple proteins can be carried out as a single transcription unit (operon) or as separate transcription units. In a particular embodiment, the protein is an antigen, as defined below, for example, a tumor antigen, a viral antigen, a bacterial antigen, a fungal antigen, an autoantigen, an allergen, or a graft-specific antigen.
[0293] acnes phage The present invention includes P. acnes phages and related engineered phages, methods for producing these phages, and methods for using these phages to transduce P. acnes.
[0294] In one particular embodiment, the engineered P. acnes phage of the present invention is incapable of self-replicating.
[0295] In the context of the present invention, the terms "self-propagation" and "self-replication" are used indifferently and refer to the ability to have progeny, in particular the ability to produce new phages.
[0296] As used herein, a "phage incapable of self-propagation" means that at least one, multiple, or all functional genes (also referred to herein as "essential genes") required to produce the phage are absent from the engineered phage (and the phage genome contained within the engineered phage).
[0297] In a preferred embodiment, at least one, more, or all of the functional genes necessary to produce the engineered phage are present in a producer cell, preferably in a plasmid, phagemid, chromosome, or helper phage present in the producer cell, allowing production of the engineered phage within the producer cell. In one such embodiment, the engineered P. acnes phage that is incapable of autonomous replication is further referred to as a conditionally replicating P. acnes phage.
[0298] In the context of the present invention, said functional genes necessary to produce an engineered phage may be absent due to (i) the absence of the corresponding gene, or (ii) the presence of a non-functional form of the corresponding gene.
[0299] In one embodiment, the sequence of the gene required to produce the engineered phage is absent from the engineered phage, hi a preferred embodiment, the sequence of the gene required to produce the engineered phage is replaced by a nucleic acid sequence of interest.
[0300] Instead, the genes necessary to produce the engineered phage are present in the engineered phage in a non-functional form, e.g., a mutated non-functional or non-expressible form, e.g., with a deleted or mutated non-functional regulator. In a preferred embodiment, the genes necessary to produce the engineered phage are present in the engineered phage in a mutated form that makes them non-functional in receiver cells but remains functional in producer cells.
[0301] In the context of the present invention, the genes necessary to produce said engineered phage include any coding or non-coding nucleic acid required for the production of said engineered phage.
[0302] Examples of genes required to produce the engineered phage include genes encoding phage structural proteins; phage genes involved in the control of gene expression; phage genes involved in transcriptional and / or translational regulation; phage genes involved in phage DNA replication; phage genes involved in phage protein production; phage genes involved in phage protein folding; phage genes involved in phage DNA packaging; and phage genes encoding proteins involved in bacterial cell lysis.
[0303] In one embodiment, the engineered P. acnes phage comprises an essential gene as defined above, the expression of which is controlled by a P. acnes phage promoter. The essential gene can be expressed constitutively or under an inducible system, such as an inducible promoter or a riboswitch. When the essential gene is under an inducible system, the engineered P. acnes phage is also considered a conditionally replicating phage.
[0304] In one embodiment, the conditionally replicating phage does not or cannot kill a non-engineered P. acnes producing strain, particularly a non-engineered P. acnes producing strain that does not contain the essential gene that is not present in the conditionally replicating phage.
[0305] In one embodiment, the conditionally replicating phage carries a CRISPR-Cas system.
[0306] In one embodiment, the conditionally replicative phage comprises a transgene.
[0307] Phage-derived particles in Propionibacterium acnes The present invention includes phage-derived particles comprising any of the DNA vectors of the present invention, and methods for producing those phage-derived particles.
[0308] In one embodiment, a P. acnes strain carrying any of the DNA vectors of the present invention is contacted with a P. acnes phage, resulting in the introduction of the phage genome into the P. acnes strain and the expression of phage proteins required for assembly of the phage capsid and packaging of the DNA vector inside the phage capsid.
[0309] In one embodiment, a P. acnes strain carrying any DNA vector comprising a selectable marker for P. acnes, as defined above, a P. acnes phage packaging signal (cos site), as defined above, and an origin of replication for P. acnes, as defined above, is contacted with an P. acnes phage, resulting in the introduction of the phage genome into the P. acnes strain and the expression of phage proteins required for assembly of the phage capsid, and packaging of the DNA vector within the phage capsid.
[0310] In one embodiment, the phage genome is a wild-type phage genome.
[0311] In one embodiment, the P. acnes phage is PAC7 (typically the sequence of SEQ ID NO: 68).
[0312] In one embodiment, the phage genome is an engineered phage genome.
[0313] Phage-derived particles can be purified by methods known in the art. The present invention includes purified phage-derived particles comprising the DNA vectors of the present invention. In one embodiment, the purified phage-derived particles are in an isolated composition or pharmaceutical composition. The composition comprises at least 10 4 pieces, 10 5 pieces, 10 6 pieces, 10 7 pieces, 10 8 pieces, 10 9 pieces, 10 10 pieces, 10 11 pieces, 10 12pieces, 10 13 pieces, 10 14 The purified phage-derived particles may comprise one or more.
[0314] Sequence-specific killing of Propionibacterium acnes by phage-derived particles In one embodiment, the invention involves the specific killing of Propionibacterium acnes by phage-derived particles carrying a CRISPR-Cas system.
[0315] Phage-derived particles carrying vectors (e.g., plasmids) encoding CRISPR-Cas systems have recently been used to perform sequence-specific killing of bacteria in situ. 10、11 The present inventors have developed methods for producing such phage-derived particles that target P. acnes, which methods are included in the present invention.
[0316] In the method, a P. acnes producer strain containing a DNA vector of the invention is contacted with a P. acnes phage, such as PAC7 (typically the sequence of SEQ ID NO: 68), to produce a high titer phage suspension.
[0317] In one embodiment, the Propionibacterium acnes is - a selection marker for Propionibacterium acnes as defined above, - the Propionibacterium acnes phage packaging signal (cos site) as defined above, - an origin of replication for Propionibacterium acnes, as defined above, and - CRISPR-Cas system targeting specific P. acnes receiver cell chromosomal loci (p targeting) The present invention relates to a DNA vector comprising:
[0318] A high-titer P. acnes phage suspension is typically added to P. acnes. The suspension typically contains a mixture of wild-type phage and phage-derived particles carrying a plasmid. P. acnes cells carrying the locus targeted by the pTarget CRISPR-Cas system are typically contacted with phage-derived particles containing pTarget. This can be done in vivo or in vitro. Sequence-specific killing is typically observed in a lysate containing phage-derived particles containing pTarget.
[0319] In one embodiment, phage-derived particles containing p-targeting vectors (e.g., plasmids) are not mixed with the phage, allowing the CRISPR-Cas system to perform sequence-specific killing of cells carrying the targeted DNA.
[0320] acnes plasmid curing Naturally occurring P. acnes plasmids have been described, some of which confer a pro-inflammatory phenotype. 15、23 and acne vulgaris 16~18 The ability to cure such plasmids is of interest for studying their effects on acne vulgaris, particularly their pro-inflammatory role. The present inventors have developed a method for curing Propionibacterium acnes plasmids.
[0321] In the first step, - a Propionibacterium acnes phage packaging signal as defined above, - optionally a selection marker for P. acnes, as defined above, - an origin of replication that allows replication only in P. acnes-producing cells, as defined above; and - a transgene, e.g., a CRISPR-Cas system targeting a gene sequence, preferably within a conserved region, e.g., the origin of replication or a locus associated with acne vulgaris, of an endogenous plasmid to be cured in target P. acnes receiver cells; P. acnes-producing cells carrying a DNA vector containing the vector are infected with P. acnes phages, resulting in the production of phage-derived particles carrying the DNA vector.
[0322] The P. acnes phage-derived particles are contacted with P. acnes receiver cells carrying the endogenous plasmid to be cured, e.g., pIMPLE-HL096PA1, which can be done in vivo or in vitro.
[0323] In some embodiments, P. acnes transductants can be selected on an appropriate antibiotic. Single colonies are typically streaked onto antibiotic-containing media, and the presence of the plasmid is typically screened by PCR. Single colonies without positive PCR of the plasmid pIMPLE-HL096PA1 are obtained, and then the vector (e.g., plasmid) containing the CRISPR-Cas system is cured and typically stored as a cryostock.
[0324] Treatment method The present invention includes a method of treating a Propionibacterium acnes-associated disorder or disease.
[0325] The present invention includes the use of engineered Propionibacterium acnes strains as defined above, phage-derived particles as defined above, and engineered phages as defined above, and / or bacteria producing them, for the treatment and / or prevention of a wide range of skin diseases and disorders.
[0326] The present invention includes methods of treating reduced sebum production, follicular hyperkeratinization, skin bacterial colonization, and inflammation using engineered Propionibacterium acnes as defined above, phage-derived particles as defined above, and engineered phages as defined above, and / or bacteria that produce them.
[0327] The present invention includes the use of engineered Propionibacterium acnes strains as defined above in cosmetic and other compositions.
[0328] In one embodiment, the present invention involves the expression of therapeutic molecules by engineered P. acnes.
[0329] In one embodiment, the present invention involves the expression of non-therapeutic molecules by engineered P. acnes.
[0330] Cutibacterium acnes is one of the most common and abundant bacteria on human skin and can be found both on the skin surface (stratum corneum) and in hair follicles. 12 Inside the hair follicle, P. acnes is in direct contact with a large variety of living cells, including keratinocytes, stem cells, sebocytes, and immune cells, but not on the stratum corneum, where it is primarily in contact with dead corneocytes. 13 Therefore, it seems interesting to use P. acnes as a bacterial chassis for the production and delivery of therapeutic molecules in situ inside and outside the hair follicle.
[0331] The phage-derived particles as defined above, and the engineered phages as defined above, and / or the bacteria that produce them, may be delivered to the skin of a subject by transdermal administration or other suitable administration method.
[0332] The subject according to the present invention is an animal, preferably a mammal, more preferably a human. However, the term "subject" may also refer to non-human animals in need of treatment, particularly mammals, such as dogs, cats, horses, cows, pigs, sheep, donkeys, rabbits, ferrets, gerbils, hamsters, chinchillas, rats, mice, guinea pigs, and non-human primates, among others, or non-mammals, such as poultry.
[0333] A human subject according to the present invention may be a human in the fetal stage, a newborn, a child, an infant, an adolescent, or an adult of any age.
[0334] Preferably, treatment is administered periodically, preferably daily to monthly, more preferably daily to every two weeks, more preferably daily to weekly, and more preferably daily. In one particular embodiment, treatment is administered multiple times per day, preferably two or three times per day, and more preferably three times per day.
[0335] The treatment period according to the present invention with the engineered Propionibacterium acnes as defined above, the phage-derived particles as defined above, the engineered phages as defined above, and / or the bacteria producing them (e.g., E. coli or Propionibacterium acnes) is preferably comprised between 1 day and 20 weeks, more preferably between 1 day and 10 weeks, more preferably between 1 day and 4 weeks, and even more preferably between 1 day and 2 weeks. In a particular embodiment, the treatment period is about 1 week. Alternatively, the treatment may be continued for as long as the infection, injury, and / or disease persists.
[0336] The form, route of administration and dosage of the pharmaceutical or veterinary composition according to the invention of the engineered Propionibacterium acnes as defined above, the phage-derived particles as defined above, the engineered phages as defined above and / or the bacteria producing them (e.g., E. coli or Propionibacterium acnes) can be adjusted by the skilled artisan according to the type and severity of the disease, disorder and / or infection (e.g., depending on the bacterial species involved in the disease, disorder and / or infection and the localization of the bacterial species within the body of the patient or subject), as well as according to the age, weight, sex and general health of the patient or subject, in particular their age, weight, sex and general health.
[0337] In particular, the dosages of the engineered Propionibacterium acnes as defined above, the phage-derived particles as defined above, the engineered phages as defined above, and / or the bacteria producing them (e.g., E. coli or Propionibacterium acnes) according to the present invention should be determined by standard procedures well known to those skilled in the art. To determine the appropriate dose, so that a therapeutically effective amount is administered to a patient or subject, the physiological data of the patient or subject (e.g., age, size, and weight) and the route of administration should be taken into account.
[0338] For example, the total amount according to the present invention for each administration of phage-derived particles as defined above and / or engineered phages as defined above may be 10 4 particles to 10 15 It is contained between particles.
[0339] Preferably, the total amount according to the present invention for each administration of engineered bacteria (e.g., E. coli or P. acnes) producing the phage-derived particles as defined above and / or engineered phages as defined above, or engineered P. acnes strains as defined above, is 10 4 10 to 10 bacteria 15 Contained between individual bacteria.
[0340] The present invention includes plasmids for the expression of toxins, such as nucleases, and more preferably CRISPR-Cas systems that kill transduced populations of P. acnes.
[0341] The present invention includes a plasmid for expression of a CRISPR-Cas system that targets sequences present only in certain strains and not in others, allowing for strain-specific killing among populations of Propionibacterium acnes.
[0342] The present invention encompasses modifications of the P. acnes chromosome or endogenous P. acnes plasmids, for example, modifications that result in a change in the P. acnes-host relationship, such as deletions, substitutions, and / or insertions.
[0343] The present invention includes vectors, eg, plasmids, for the expression of therapeutic molecules, which contain one or more genes involved in the production of the therapeutic molecule.
[0344] If the therapeutic molecule does not freely diffuse out of the P. acnes cell, e.g., a therapeutic protein, it is preferably encoded on a vector, e.g., a plasmid, as a fusion with a signal peptide that enables secretion or transport onto the cell membrane or cell wall of the P. acnes cell. Examples of secretion systems or signal peptides include the TAT, SEC, and type VII / WXG100 secretion systems. In particular, the signal peptide is expressed in proteins PPA0532 (typically referenced as Q6AAD1 in the UniprotKB database as of November 4, 2020); PPA0533 (typically referenced as Q6AAD0 in the UniprotKB database as of November 4, 2020); PPA0534 (typically referenced as Q6AAC9 in the UniprotKB database as of November 4, 2020); PPA0598 (typically referenced as Q6AA63 in the UniprotKB database as of November 4, 2020); PPA0644 (typically referenced as Q6AA16 in the UniprotKB database as of November 4, 2020); PPA0687 (typically referenced as Q6A9X2 in the UniprotKB database as of November 4, 2020); PPA0721 (typically referenced as Q6A9 in the UniprotKB database as of November 4, 2020). T8); PPA0816 (typically referred to as Q6A9J4 in the UniprotKB database as of November 4, 2020); PPA1310 (typically referred to as Q6A856 in the UniprotKB database as of November 4, 2020); PPA1498 (typically referred to as Q6A7M0 in the UniprotKB database as of November 4, 2020); PPA1662 (typically referred to as Q6A771 in the UniprotKB database as of November 4, 2020); PPA1715 (typically referred to as Q6A720 in the UniprotKB database as of November 4, 2020); PPA1939 (typically referred to as Q6A6F6 in the UniprotKB database as of November 4, 2020); PPA2097 (typically referred to as Q6A608 in the UniprotKB database as of November 4, 2020);PPA2105 (typically referenced as Q6A601 in the UniprotKB database as of November 4, 2020); PPA2106 (typically referenced as Q6A600 in the UniprotKB database as of November 4, 2020); PPA2142 (typically referenced as Q6A5W4 in the UniprotKB database as of November 4, 2020); PPA2164 (typically referenced as Q6A5U3 in the UniprotKB database as of November 4, 2020); PPA2175 (typically referenced as Q6A5W4 in the UniprotKB database as of November 4, 2020); PPA2152 (typically referenced as Q6A5V4 in the UniprotKB database as of November 4, 2020); PPA1340 (typically referenced as Q6A826 in the UniprotKB database as of November 4, 2020), and PPA2239 (typically referenced as Q6A5M0 in the UniprotKB database as of November 4, 2020).
[0345] If secretion is undesirable or not functional, a lysis module may be added to the vector, e.g., a plasmid, to lyse the cell and release the therapeutic molecule.
[0346] In a specific embodiment, the therapeutic molecule may be displayed on the cell membrane or cell wall of Propionibacterium acnes cells. To be displayed, the protein of interest typically requires an N-terminal secretory signal peptide, such as those described above, and a C-terminal LPXTG motif that enables the class F sortase from Propionibacterium acnes (Girolamo, SD et al., Biochem J 476, pp. 665-682 (2019) (Non-Patent Document 8)) to covalently attach the protein of interest to the cell wall. Furthermore, a PT-rich region may be incorporated upstream of the LPXTG motif. Alternatively, a more classical cell wall sorting sequence (CWSS) may be used, combining an LPXTG motif followed by hydrophobic amino acids and a positively charged C-terminus.
[0347] To control the expression of therapeutic molecules, one or more of the genes can be placed under the control of an inducible system, such as an inducible promoter, a riboswitch, an RNA-based inducible system, or a combination thereof, either as an operon or as a single isolated gene. To optimize in situ production of therapeutic molecules, multiple promoters with multiple transcription strengths can be tested and combined with different RBS strengths. An RBS library approach can be used to select the best RBS variant for in vitro or in situ expression.
[0348] Examples of therapeutic molecules include, but are not limited to, antibodies, antibody-based drugs, Fc fusion proteins, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytic agents. Other examples include those that bind non-covalently to a target (e.g., monoclonal antibodies), those that affect covalent binding (e.g., enzymes), and those that exert activity without specific interaction (e.g., serum albumin).
[0349] For example, therapeutic molecules (e.g., therapeutic recombinant proteins) for use in treating cancer, immune disorders, infections, and / or other diseases are also contemplated herein. Engineered proteins, including bispecific mAbs, and multispecific fusion proteins, and proteins with optimized pharmacokinetics, are also contemplated by the present disclosure.
[0350] In some embodiments, the therapeutic protein is etanercept, bevacizumab, rituximab, adalimumab, infliximab, trastuzumab, insulin glargine, epoetin alfa, pegfilgrastim, ranibizumab, darbepoetin alfa, interferon beta-1a, interferon beta-1a, insulin aspart, Rhu insulin, octocog alfa, insulin lispro, cetuximab, peginterferon alfa-2a, interferon beta-1b, eptacog alfa, insulin aspart, onabotulinumtoxinA, epoetin beta, Rec antihemophilic factor, filgrastim, insulin detemir, natalizumab, insulin (humulin), or palivizumab.
[0351] Examples of antibodies, antibody fragments, and / or Fc fusion proteins that may be expressed in the context of the present disclosure include, but are not limited to, Abagovomab, Abciximab, Actoxumab, Adalimumab, Adecatumumab, Afelimomab, Afutuzumab, Alacizumab pegol, ALD, Alemtuzumab, Alirocumab, Altumomab pentetate, Amatuximab, Anatumomab mafenatoxin, Mafenatox, Anifrolumab, Anrukinzumab, Apolizumab, Arcitumomab, Aselizumab, Atinumab, Atolizumab (or Tocilizumab), Atorolimumab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Belimumab, Benralizumab, Bertilimumab, Besilesomab, Bevacizumab, Bezlotoxumab, Biciromab, Bimagrumab, Bivatuzumab-Mertansine mertansine, blinatumomab, brosozumab, brentuximab vedotin, briakinumab, brodalumab, canakinumab, cantuzumab mertansine, cantuzumab ravtansine, caplacizumab, capromab pendetide, carlumab, catumaxomab, cedelizumab, certolizumab pegol, cetuximab, sitatuzumab bogatox, cixutumumab, clazakizumab, clenoliximab, clivatuzumab tetraxetantetraxetan, conatumumab, concizumab, crenezumab, dacetuzumab, daclizumab, dalotuzumab, daratumumab, demcizumab, denosumab, detumomab, dorlimomab Aritox, Drozitumab, Durigotumab, Dupilumab, Dusigitumab, Ecromeximab, Eculizumab, Edobacomab, Edrecolomab, Efalizumab, Efungumab, Eldelumab, Elotuzumab, Elsilimomab, Enavatuzumab, Enlimomab pegol, Enokizumab, Enoticumab, Ensituximab, Epitumomab Cituxetan, Epratuzumab, Erlizumab, Ertumaxomab, Etaracizumab, Etrolizumab, Evolocumab, Exbivirumab, Fanolesomab, Faralimomab, Farletuzumab, Fasinumab, FBTA, Felvizumab, Fezakinumab, Ficlatuzumab atuzumab, figitumumab, flanvotumab, fontolizumab, foralumab, foravirumab, fresolimumab, furanumab, futuximab, galiximab, ganitumab, gantenerumab, gavilimomab, gemtuzumab ozogamicin, gevokizumab, girentuximab, glembatumumab vedotinvedotin, golimumab, gomiliximab, guselkumab, ibalizumab, ibritumomab tiuxetan, icrucumab, igovomab, imciromab, imgatuzumab, inclacumab, indatuximab ravtansine ravtansine, infliximab, intetumumab, inolimomab, inotuzumab ozogamicin, ipilimumab, iratumumab, itolizumab, ixekizumab, keliximab, labetuzumab, lambrolizumab, lampalizumab, lebrikizumab rikizumab, lemaresomab, lerdelimumab, lexatumumab, ribivirumab, ligelizumab, lintuzumab, lirilumab, rodelcizumab, lorvotuzumab Mertansine, Lucatumumab, Rumiliximab, Mapatumumab, Margetuximab, Maslimomab, Mavrilimumab, Matuzumab, Mepolizumab, Metelimumab, Milatuzumab, Minretumomab, Mitumomab, Mogamulizumab, Morolimumab, Motavizumab, Moxetumomab pasudotox, Muromonab-CD3, Nacolomab butafenatox tafenatox, namilumab, naptumomab estafenatox, narnatumab, natalizumab, nebacumab, necitumumab, nerelimomab, nesvacumab, nimotuzumab, nivolumab, nofetumomab merpentanemerpentan, ocaratuzumab, ocrelizumab, odulimomab, ofatumumab, olaratumab, olokizumab, omalizumab, onartuzumab, oportuzumab monatox, oregovomab, orticumab, otelixizumab, oxelumab, ozanezumab, ozoralizumab, pagibaximab, palivizumab, panitumumab, panobacumab, parsatuzumab, pascolizumab, pateclizumab, patritumab, pemtumomab, perakizumab, pertuzumab, pexelizumab, pidilizumab, pinatuzumab vedotin Polatuzumab vedotin, Pintumomab, Placulumab, Polatuzumab vedotin, Ponezumab, Priliximab, Pritoxaximab, Pritumumab, PRO, Quilizumab, Racotumomab, Radretumab, Rafivirumab, Ramucirumab, Ranibizumab, Raxibacumab , Regavirumab, Reslizumab, Rilotumumab, Rituximab, Robatumumab, Roledumab, Romosozumab, Rontalizumab, Rovelizumab, Ruplizumab, Samalizumab, Sarilumab, Satumomab PendetidePendetide, Secukinumab, Seribantumab, Setoxaximab, Sevirumab, Sibrotuzumab, Sifalimumab, Siltuximab, Simtuzumab, Siplizumab, Sirukumab, Solanezumab, Solitomab, Sonepcizumab, Sontuzumab, Stamulumab, Sulesomab, Suvizumab, Tabalumab, Tacatuzumab tetraxetan, tadocizumab, talizumab, tanezumab, taplitumomab paptox, tefibazumab, telimomab alitox aritox, tenatumomab, teneliximab, teplizumab, teprotumumab, TGN, ticilimumab (or tremelimumab), tildrakizumab, tigatuzumab, TNX-, tocilizumab (or atlizumab), toralizumab, tositumomab, tovetumab, tralokinumab, trastuzumab, TRBS, tregalizumab, tremelimumab, tucotuzumab Celmoleukin, Tuvirumab, Ublituximab, Urelumab, Urutoxazumab, Ustekinumab, Vantictumab, Vapaliximab, Vatelizumab, Vedolizumab, Veltuzumab, Bepalimomab, Vesencumab, Visilizumab, Volociximab, Borsetuzumabmafodotin, votumumab, zalutumumab, zanolimumab, zatuximab, ziralimumab, and zolimomab aritox.
[0352] Other examples of Fc fusion proteins that may be expressed in the context of the present disclosure include, but are not limited to, etanercept, alefacept, abatacept, rilonacept, romiplostim, belatacept, and aflibercept.
[0353] Examples of anticoagulants and / or blood factors that may be expressed in the context of the present disclosure include, but are not limited to, protein C, protein S, and antithrombin, factors I through VIII, prothrombinase, prothrombin, thrombin, von Willebrand factor (vWF), fibrinogen, fibrin, and fibrinopeptides.
[0354] Examples of bone morphogenetic proteins (BMPs) that may be expressed in the context of the present disclosure include, but are not limited to, BMP1 through BMP7, BMP8a, BMP8b, BMP10, and BMP15.
[0355] Examples of enzymes that may be expressed in the context of the present disclosure include, but are not limited to, any of the enzymes assigned an Enzyme Code (EC number) (e.g., EC1-EC6) by the International Union of Biochemistry and Molecular Biology (IUBMB) (Webb, Edwin C. Enzyme nomenclature 1992: recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes. San Diego: Academic Press, published for the International Union of Biochemistry and Molecular Biology. ISBN 0-12-227164-5 (1992) (Non-Patent Document 9), incorporated herein by reference). Other examples include styrene monooxygenase (StyAB), toluene dioxygenase (TODC1C2AB), luciferase, and lactase. In some embodiments, the enzyme is toluene dioxygenase. In some embodiments, the enzyme is styrene monooxygenase.
[0356] Examples of growth factors that may be expressed in the context of the present disclosure include, but are not limited to, adrenomedullin (AM), angiopoietin (Ang), autocrine motility factor, bone morphogenetic protein (BMP), brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), erythropoietin (EPO), fibroblast growth factor (FGF), glial cell line-derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), growth differentiation factor 9 (GDF9), hepatocyte growth factor (HGF), hepatocyte differentiation factor (HRF), hepatocyte growth factor (HGF), hepatocyte differentiation factor (HRF), hepatocyte differentiation factor (HGF), hepatocyte growth factor (HRF), hepatocyte differentiation factor (HGF), hepatocyte differentiation ...HRF), hepatocyte differentiation factor (HGF), hepatocyte differentiation factor (HRF), hepatocyte differentiation factor (HGF), hepatocyte differentiation factor (HRF), hepatocyte differentiation factor (HRF), hepatocyte differentiation factor (HGF), hepatocyte differentiation factor (HRF), hepatocyte differentiation factor (HR These include hematopoietic growth factors (HDGF), insulin-like growth factor (IGF), migration-stimulating factor, myostatin (GDF-8), nerve growth factor (NGF), and other neurotrophins, platelet-derived growth factor (PDGF), thrombopoietin (TPO), transforming growth factor alpha (TGF-a), transforming growth factor beta (TGF-P), tumor necrosis factor alpha (TNF-), vascular endothelial growth factor (VEGF), placental growth factor (P1GF), fetal bovine somatotropin (FBS), and IL-1 through IL-7.
[0357] Examples of peptide hormones that may be expressed in the context of the present disclosure include, but are not limited to, amylin (or islet amyloid polypeptide), anti-Mullerian hormone (or Mullerian inhibitory factor or hormone), adiponectin, adrenocorticotropic hormone (or corticotropin), angiotensinogen and angiotensin, antidiuretic hormone (or vasopressin, arginine vasopressin), atrial natriuretic peptide (or atriopeptin), brain natriuretic peptide, calcitonin, cholecystokinin, corticotropin-releasing hormone, enkephalin, endothelin, erythropoietin, follicle-stimulating hormone, and the like. These include hormones such as steroid hormones, ...
[0358] Examples of interferons (IFNs) that may be expressed in the context of the present disclosure include, but are not limited to, IFN-α, IFN-β, IFN-ω, and IFN-γ.
[0359] Examples of interleukins that may be expressed in the context of the present disclosure include, but are not limited to, interleukins 1 to 17. In some embodiments, the interleukin is interleukin-4, interleukin-6, interleukin-10, interleukin-11, or interleukin-13.
[0360] Other examples of therapeutic proteins that may be expressed in the context of the present disclosure include, but are not limited to, insulin (blood glucose control factor), pramlintide acetate (glucose control), growth hormone GH (growth inhibition), pegvisomant (growth hormone receptor antagonist), mecasermin (IGF1, growth inhibition), factor VIII (clotting factor), factor IX (clotting factor, protein C concentrate (anticoagulant)), al-proteinase inhibitor (antitrypsin inhibitor), erythropoietin (stimulates erythropoiesis), filgrastim (granulocyte colony-stimulating factor, G-CSF; stimulates neutrophil proliferation), sargramostim 36、37(granulocyte-macrophage colony-stimulating factor, GM-CSF), oprelvekin (interleukin II, IL11), human follicle-stimulating hormone (FSH), human chorionic gonadotropin (HCG), lutropin-a (human luteinizing hormone), interleukin-2 (IL2), interleukin-1 receptor agonist, denileukin diftitox (IL2 fusion with diphtheria toxin), interferon alfacon-1 (consensus interferon), interferon-2a (IFNa2a), interferon-2b (IFNa2b), interferon-n3 (IFNan3), interferon-pia (rIFN-β), interferon-β lb (rIFN-β), interferon-ylb (IFNy, salmon calcitonin (a 32-amino acid linear polypeptide hormone)), teriparatide (a portion of human parathyroid hormone, residues 1-34), exenatide (an incretin mimetic with actions similar to glucagon-like peptide 1), octreotide (an octapeptide that mimics natural somatostatin), divotermin-α (recombinant human bone morphogenetic protein 2), recombinant human bone morphogenetic protein 7, histrelin acetate (gonadotropin-releasing hormone, GnRH), palifermin (keratinocyte growth factor, KGF), becaplermin (platelet-derived growth factor, PDGF), nesiritide (recombinant human B-type natriuretic peptide), lepirudin (recombinant variant of hirudin; another variant is bivalirudin), anakinra (interleukin-1 (IL-1) receptor antagonist), enfuvirtide (HIV-1 gp41-derived peptides), β-glucocerebrosidase (hydrolyzes to glucose and ceramide), alglucosidase-a (degrades glycogen), laronidase (digests glycosaminoglycans in lysosomes), idursulfase (cleaves O-sulfates and prevents GAG accumulation), galsulfase (cleaves terminal sulfates from GAGs), agalsidase-β (human α-galactosidase A, hydrolyzes glycosphingolipids), lactase (digests lactose), pancreatic enzymes (lipase, amylase, protease;digests food), adenosine deaminase (metabolizes adenosine), tissue plasminogen activator (tPA, a serine protease involved in the breakdown of blood clots), factor Vila (serine protease, causes blood clotting), drotrecogin-a (serine protease, human activated protein C), trypsin (serine protease, hydrolyzes proteins), botulinum toxin type A (protease, inactivates SNAP-25 involved in synaptic vesicle fusion), botulinum toxin type B (protease that inactivates SNAP-25 involved in synaptic vesicle fusion), collagenase (endopeptidase, digests natural collagen), human deoxyribonuclease I (endonuclease, DNase I, cleaves DNA), hyaluronidase (hydrolyzes hyaluronan), papain (cysteine protease, hydrolyzes proteins), L-asparaginase (catalyzes the conversion of L-asparagine to aspartic acid and ammonia), rasburicase (urate oxidase, catalyzes the conversion of uric acid to allantoin), streptokinase (anistreplase catalyzes the anisoylated plasminogen streptokinase activator complex (APS AC)), and antithrombin III (a serine protease inhibitor);
[0361] Other examples of therapeutic proteins that may be expressed in the context of the present disclosure include antigens, as defined below.
[0362] The present invention further includes engineered Propionibacterium acnes containing vectors (eg, plasmids) for expression of antigens, such as tumor antigens, viral antigens, bacterial antigens, fungal antigens, autoantigens, allergens, or graft-specific antigens.
[0363] As used herein, "antigen" refers to a molecule containing one or more epitopes (e.g., linear, structural, or both) that elicit an immunological response. The antigen can be of any type. In particular, an antigen can be a protein, polypeptide, or peptide, carbohydrate, lipid, nucleic acid, e.g., DNA or RNA. In a particular embodiment, the antigen is a protein, polypeptide, or peptide. "Protein" as intended herein is understood to include proteins, polypeptides, and peptides. Furthermore, for the purposes of the present invention, "antigen" includes proteins containing modifications to the native sequence, such as deletions, additions, and substitutions (generally conservative in nature), so long as the protein maintains its ability to elicit an immunological response. Such modifications can be deliberate, such as by site-directed mutagenesis, or can be accidental, for example, due to mutations of hosts that produce the antigen.
[0364] In a particular embodiment, the antigen induces activation or enhancement of an immune response, particularly an immune response specific to the antigen, hi an alternative embodiment, the antigen causes tolerization or suppression of an immune response, particularly an immune response specific to the antigen.
[0365] In one particular embodiment, the antigen reduces an inflammatory response in a subject.
[0366] In one particular embodiment, the antigen is a tumor antigen.
[0367] As used herein, "tumor antigen" refers to an antigenic substance produced in tumor cells. A tumor antigen can be, for example, a peptide-containing tumor antigen, such as a polypeptide tumor antigen or a glycoprotein tumor antigen. A tumor antigen can also be, for example, a carbohydrate-containing tumor antigen, such as a glycolipid tumor antigen or a ganglioside tumor antigen.
[0368] Tumor antigens include, but are not limited to, (a) polypeptide-containing tumor antigens, including polypeptides (e.g., ranging from about 8 to about 20 amino acids in length, although lengths outside this range are common), lipopolypeptides, and glycoproteins, and (b) carbohydrate-containing tumor antigens, including polysaccharides, mucins, gangliosides, glycolipids, and glycoproteins. Furthermore, tumor antigens can be (a) full-length molecules associated with cancer cells, (b) homologs and modified forms of the same molecules (including molecules with deletions, additions, and / or substitutions), and (c) fragments of the same molecules. Tumor antigens include, for example, class I-restricted antigens, which are recognized by CD8+ lymphocytes, or class II-restricted antigens, which are recognized by CD4+ lymphocytes.
[0369] Numerous tumor antigens are known in the art, including (a) cancer-testis antigens, such as NY-ESO-1, SSX2, SCP1, and polypeptides of the RAGE, BAGE, GAGE, MAGE families, such as GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used to address, for example, melanoma, lung tumors, head and neck tumors, NSCLC, breast tumors, gastrointestinal tumors, and bladder tumors); (b) mutant antigens, such as p53 (which can be used to address various solid tumors); tumors, e.g., associated with colorectal cancer, lung cancer, head and neck cancer), p21 / Ras (e.g., associated with melanoma, pancreatic cancer, and colorectal cancer), CD4 (e.g., associated with melanoma), MUM1 (e.g., associated with melanoma), caspase-8 (e.g., associated with head and neck cancer), CIA0205 (e.g., associated with bladder cancer), HLA-A2-R1701, beta-catenin (e.g., associated with melanoma), TCR (e.g., associated with T-cell non-Hodgkin's lymphoma), BCR-abl (e.g., associated with chronic myeloid leukemia), triosephosphate isomerase, IA 0205, CDC-27, and LDLR-FUT, (c) overexpressed antigens, such as galectin 4 (e.g., associated with colorectal cancer), galectin 9 (e.g., associated with Hodgkin's disease), proteinase 3 (e.g., associated with chronic myeloid leukemia), WT1 (e.g., associated with various leukemias), carbonic anhydrase (e.g., associated with renal cancer), aldolase A (e.g., associated with lung cancer), PRAME (e.g., associated with melanoma), HER-2 / neu (e.g., breast cancer, (e.g., associated with colon, lung, and ovarian cancer), alpha-fetoprotein (e.g., associated with hepatoma), SA (e.g., associated with colorectal cancer), gastrin (e.g., pancreatic and gastric cancer), telomerase catalytic protein, MUC-1 (e.g., associated with breast and ovarian cancer), G-250 (e.g., associated with renal cell carcinoma), and carcinoembryonic antigen (e.g., associated with breast, lung, and gastrointestinal cancers, such as colorectal cancer); (d) shared antigens, e.g., melanoma-melanocyte differentiation antigens, e.g., MART-1 / MelanA, gplOO, MC1R, melanocyte-stimulating hormone receptor, tyrosinase, tyrosinase-related protein-1 / TRP1, and tyrosinase-related protein-2 / TRP2 (e.g., associated with melanoma), (e) prostate-related antigens, e.g., PAP, PSA, PSMA, PSH-P1, PSM-P1, PSM-P2 (e.g., associated with prostate cancer), (f) immunoglobulin idiotypes (e.g., associated with myeloma and B-cell lymphoma), and (g) other tumor antigens, e.g., (i) glycoproteins, e.g., sialyl Tn and sialyl Lex (e.g., associated with breast cancer and ovarian cancer). (ii) lipopolypeptides (e.g., MUC-1 conjugated to a lipid moiety); (iii) polysaccharides (e.g., globo-H synthetic hexasaccharide) that can be conjugated to a carrier protein (e.g., KLH); (iv) polypeptide- and polysaccharide-containing antigens, including gangliosides, e.g., GM2, GM12, GD2, GD3 (e.g., associated with brain cancer, lung cancer, melanoma), that can also be conjugated to a carrier protein (e.g., KLH).
[0370] Other tumor antigens include pi5, Hom / Mel-40, H-Ras, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, Epstein-Barr virus antigens, EBNA, human papillomavirus (HPV) antigens including E6 and E7, hepatitis B and C virus antigens, human T-cell lymphotropic virus antigens, TSP-180, p185erbB2, p180erbB-3, c-met, mn-23H1, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, p16, TAGE, PSCA, CT7, 43-9F, 5T4, 791 Tgp72, beta-HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29\BCAA), CA These include 195, CA 242, CA-50, CAM43, CD68\KP1, CO-029, FGF-5, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV 18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90 (Mac-2 binding protein\cyclophilin C-related protein), TAAL6, TAG72, TLP, and TPS.
[0371] In another embodiment, the antigen is a viral antigen.
[0372] By "viral antigen" herein is meant a protein encoded by the viral genome.
[0373] In certain embodiments, viral antigens preferably comprise epitopes that are exposed on the surface of the virus during at least one stage of its life cycle. Viral antigens are preferably conserved across multiple serotypes or isolates. Viral antigens suitable for use in the context of the present disclosure include, but are not limited to, antigens derived from one or more of the viruses described below, as well as the specific antigen examples identified below.
[0374] Orthomyxovirus: Viral antigens include, but are not limited to, those derived from orthomyxoviruses, such as influenza A, B, and C. In certain embodiments, orthomyxovirus antigens are selected from one or more viral proteins, including one or more of hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix protein (M1), membrane protein (M2), and transcriptase components (PB1, PB2, and PA). In certain embodiments, the viral antigens comprise HA and NA. In certain embodiments, influenza antigens are derived from interpandemic (annual) influenza strains, while in other embodiments, influenza antigens are derived from strains with the potential to cause a pandemic outbreak (i.e., influenza strains with a novel hemagglutinin compared to currently circulating strains, or influenza strains that are pathogenic in avian subjects and have the potential for horizontal transmission to human populations, or influenza strains that are pathogenic for humans).
[0375] Paramyxoviridae: Viral antigens include, but are not limited to, those derived from Paramyxoviridae viruses, such as Pneumovirus (RSV), Paramyxovirus (PIV), Metapneumovirus, and Morbillivirus (measles).
[0376] Pneumovirus: Viral antigens include, but are not limited to, those derived from a pneumovirus, such as, for example, respiratory syncytial virus (RSV), bovine respiratory syncytial virus, pneumonia virus of mice, and turkey rhinotracheitis virus. Preferably, the pneumovirus is RSV. In specific embodiments, pneumovirus antigens are selected from one or more of the following proteins, including surface protein, fusion protein (F), glycoprotein (G), and small hydrophobic protein (SH), matrix proteins M and M2, nucleocapsid proteins N, P, and L, and nonstructural proteins NS1 and NS2. In other embodiments, pneumovirus antigens include F, G, and M.
[0377] Paramyxovirus: Viral antigens include, but are not limited to, those derived from a paramyxovirus, such as parainfluenza types 1-4 viruses (PIV), mumps, Sendai virus, Simian virus 5, bovine parainfluenza virus, Nipah virus, Henipavirus, and Newcastle disease virus. In certain embodiments, the paramyxovirus is PIV or mumps. In certain embodiments, paramyxovirus antigens are selected from one or more of the following proteins: hemagglutinin-neuraminidase (HN), fusion proteins F1 and F2, nucleoprotein (NP), phosphoprotein (P), large protein (L), and matrix protein (M). In other embodiments, the paramyxovirus proteins include HN, F1, and F2. In other embodiments, the paramyxovirus is a Nipah virus or a Henipa virus and the antigen is selected from one or more of the following proteins: fusion (F) protein, glycoprotein (G), matrix (M) protein, nucleocapsid (N) protein, large (L) protein, and phosphoprotein (P).
[0378] Poxviridae: Viral antigens include, but are not limited to, those derived from orthopoxviruses, such as variola, including but not limited to variola major and variola minor.
[0379] Metapneumovirus: Viral antigens include, but are not limited to, metapneumovirus, e.g., human metapneumovirus (hMPV) and avian metapneumovirus (aMPV). In certain embodiments, metapneumovirus antigens are selected from one or more of the following proteins, including surface protein, fusion protein (F), glycoprotein (G), and small hydrophobic protein (SH), matrix proteins M and M2, nucleocapsid proteins N, P, and L. In other embodiments, metapneumovirus antigens include F, G, and M.
[0380] Morbillivirus: Viral antigens include, but are not limited to, those derived from a Morbillivirus, such as measles. In certain embodiments, morbillivirus antigens are selected from one or more of the following proteins: hemagglutinin (H), glycoprotein (G), fusion factor (F), large protein (L), nucleoprotein (NP), polymerase phosphoprotein (P), and matrix (M).
[0381] Picornavirus: Viral antigens include, but are not limited to, those derived from a picornavirus, such as enterovirus, rhinovirus, heparnavirus, cardiovirus, and aphthovirus. In certain embodiments, antigens are derived from an enterovirus, and in other embodiments, the enterovirus is a poliovirus. In yet other embodiments, antigens are derived from a rhinovirus.
[0382] Enterovirus: Viral antigens include, but are not limited to, those derived from an enterovirus, such as poliovirus types 1, 2, or 3, Coxsackie A virus types 1-22 and 24, Coxsackie B virus types 1-6, Echovirus (ECHO virus) types 1-9, 11-27, and 29-34, and enterovirus 68-71. In certain embodiments, antigens are derived from an enterovirus; in other embodiments, the enterovirus is a poliovirus. In certain embodiments, enterovirus antigens are selected from one or more of the following capsid proteins: VP0, VP1, VP2, VP3, and VP4.
[0383] Bunyavirus: Viral antigens include, but are not limited to, those derived from an Orthobunyavirus, such as California encephalitis virus, a Phlebovirus, such as Rift Valley fever virus, or a Nairovirus, such as Crimean-Congo hemorrhagic fever virus. Rhinovirus: Viral antigens include, but are not limited to, those derived from a rhinovirus. In certain embodiments, rhinovirus antigens are selected from one or more of the following capsid proteins: VP0, VP1, VP2, VP2, and VP4.
[0384] Heparnavirus: Viral antigens include, but are not limited to, those derived from a heparnavirus, such as, by way of example only, Hepatitis A virus (HAV).
[0385] Togavirus: Viral antigens include, but are not limited to, those derived from a togavirus, such as a rubivirus, an alphavirus, or an arterivirus. In certain embodiments, the antigen is derived from a rubivirus, such as, by way of example only, a rubella virus. In certain embodiments, the togavirus antigen is selected from E1, E2, E3, C, NSP-1, NSPO-2, NSP-3, or NSP-4. In certain embodiments, the togavirus antigen is selected from E1, E2, or E3.
[0386] Flavivirus: Viral antigens include, but are not limited to, those derived from a flavivirus, such as Tick-borne encephalitis (TBE) virus, Dengue (Type 1, 2, 3, or 4) virus, Yellow Fever virus, Japanese encephalitis virus, Kyasanur Forest disease virus, West Nile encephalitis virus, St. Louis encephalitis virus, Russian Spring / Summer encephalitis virus, Powassan encephalitis virus. In certain embodiments, flavivirus antigens are selected from PrM, M, C, E, NS-1, NS-2a, NS2b, NS3, NS4a, NS4b, and NS5. In certain embodiments, flavivirus antigens are selected from PrM, M, and E.
[0387] Pestivirus: Viral antigens include, but are not limited to, those derived from a Pestivirus, such as Bovine Viral Diarrhea (BVDV), Classical Swine Fever (CSFV), or Border Disease (BDV).
[0388] Hepadnavirus: Viral antigens include, but are not limited to, those derived from a hepadnavirus, such as Hepatitis B. In certain embodiments, the hepadnavirus antigen is selected from surface antigens (L, M, and S), core antigens (HBc, HBe).
[0389] Hepatitis C virus: Viral antigens include, but are not limited to, those derived from hepatitis C virus (HCV). In certain embodiments, the HCV antigen is selected from one or more of peptides derived from the E1, E2, E1 / E2, NS345 polyprotein, NS345 core polyprotein, core, and / or nonstructural regions. In certain embodiments, the hepatitis C virus antigen comprises one or more of the following: HCV E1 and / or E2 proteins, the E1 / E2 heterodimer complex, the core protein, and nonstructural proteins, which may optionally be modified to retain immunogenicity but remove enzymatic activity, or fragments of these antigens.
[0390] Rhabdovirus: Viral antigens include, but are not limited to, those derived from Rhabdovirus, such as Lyssavirus (rabies virus) and Vesiculovirus (VSV). Rhabdovirus antigens can be selected from glycoprotein (G), nucleoprotein (N), large protein (L), and nonstructural protein (NS).
[0391] Caliciviridae: Viral antigens include, but are not limited to, those derived from Caliciviridae, such as Norwalk virus, and Norwalk-like viruses, such as Hawaii virus and Snow Mountain virus.
[0392] Coronavirus: Viral antigens include, but are not limited to, those derived from coronavirus, SARS, human respiratory coronavirus, infectious bronchitis avian (IBV), mouse hepatitis virus (MHV), and transmissible gastroenteritis porcine virus (TGEV). In certain embodiments, the coronavirus antigen is selected from spike (S), envelope (E), matrix (M), nucleocapsid (N), and hemagglutinin-esterase glycoprotein (HE). In certain embodiments, the coronavirus antigen is derived from SARS virus. In certain embodiments, the coronavirus is derived from SARS virus antigens described in WO 04 / 92360.
[0393] Retroviral: Viral antigens include, but are not limited to, those derived from a retrovirus, such as an oncovirus, lentivirus, or spumavirus. In certain embodiments, oncoviral antigens are derived from HTLV-1, HTLV-2, or HTLV-5. In certain embodiments, lentiviral antigens are derived from HIV-1 or HIV-2. In certain embodiments, antigens are derived from an HIV-1 subtype (or clade), including but not limited to HIV-1 subtypes (or clades) A, B, C, D, F, G, H, J, K, and O. In other embodiments, antigens are derived from HIV-1 recombinant pandemic strains (CRFs), including but not limited to A / B, A / E, A / G, A / G / I, and the like. In certain embodiments, retroviral antigens are selected from gag, pol, env, tax, tat, rex, rev, nef, vif, vpu, and vpr. In certain embodiments, HIV antigens are selected from gag (p24gag and p55gag), env (gp160 and gp41), pol, tat, nef, rev vpu, miniprotein (preferably a p55 gag and gp140v deletion). In certain embodiments, HIV viral antigens are derived from one or more of the following strains: HIVIIIb, HIVSF2, HIVLAV, HIVLAI, HIVMN, HIV-1CM235, HIV-1US4, HIV-1 SF162, HIV-1TV1, HIV-1MJ4. In certain embodiments, antigens are derived from endogenous human retroviruses, including, but not limited to, HERV-K ("old" HERV-K and "new" HERV-K).
[0394] Reovirus: Viral antigens include, but are not limited to, those derived from a reovirus, such as an orthoreovirus, a rotavirus, an orbivirus, or a coltivirus. In certain embodiments, reovirus antigens are selected from structural proteins λ1, λ2, λ3, μ1, μ2, σ1, σ2, or σ3, or nonstructural proteins σNS, μNS, or ols. In certain embodiments, reovirus antigens are derived from a rotavirus. In certain embodiments, rotavirus antigens are selected from VP1, VP2, VP3, VP4 (or cleavage products VP5 and VP8), NSP1, VP6, NSP3, NSP2, VP7, NSP4, or NSP5. In certain embodiments, rotavirus antigens include VP4 (or cleavage products VP5 and VP8) and VP7.
[0395] Parvovirus: Viral antigens include, but are not limited to, those derived from a parvovirus, such as parvovirus B19. In certain embodiments, the parvovirus antigen is selected from VP-1, VP-2, VP-3, NS-1, and NS-2. In certain embodiments, the parvovirus antigen is capsid protein VP1 or VP-2.
[0396] Hepatitis Delta Virus (HDV): Viral antigens include, but are not limited to, those derived from HDV, particularly the δ-antigen from HDV.
[0397] Hepatitis E virus (HEV): Viral antigens include, but are not limited to, those derived from HEV.
[0398] Hepatitis G virus (HGV): Viral antigens include, but are not limited to, those derived from HGV.
[0399] Human Herpesvirus: Viral antigens include, but are not limited to, those derived from a human herpesvirus, such as, by way of example only, herpes simplex virus (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), and human herpesvirus 8 (HHV8). In certain embodiments, human herpesvirus antigens are selected from immediate early protein (a), early protein (β), and late protein (γ). In certain embodiments, HSV antigens are derived from HSV-1 or HSV-2 strains. In certain embodiments, HSV antigens are selected from glycoproteins gB, gC, gD, and gH, fusion protein (gB), or immune escape proteins (gC, gE, or gl). In certain embodiments, the VZV antigen is selected from core, nucleocapsid, tegument, or envelope proteins. Live attenuated VZV vaccines are commercially available. In certain embodiments, the EBV antigen is selected from early antigen (EA) proteins, viral capsid antigen (VCA), and membrane antigen (MA) glycoproteins. In certain embodiments, the CMV antigen is selected from capsid proteins, envelope glycoproteins (e.g., gB and gH), and tegument proteins.In other embodiments, the CMV antigen is one of the following proteins: pp65, IE1, gB, gD, gH, gL, gM, gN, gO, UL128, UL129, gUL130, UL150, UL131, UL33, UL78, US27, US28, RL5A, RL6, RL10, RL11, RL12, RL13, UL1, UL2, UL4, UL5, UL6, UL7, UL8, UL9, UL10, UL11, UL14, UL15A, UL16, UL17, UL18, UL22A, UL38, UL40, UL41A, UL42, UL116, UL119, The electrical conductivity may be selected from one or more of UL120, UL121, UL124, UL132, UL147A, UL148, UL142, UL144, UL141, UL140, UL135, UL136, UL138, UL139, UL133, UL135, UL148A, UL148B, UL148C, UL148D, US2, US3, US6, US7, US8, US9, US10, US11, US12, US13, US14, US15, US16, US17, US18, US19, US20, US21, US29, US30, and US34A. A CMV antigen may also be a fusion of one or more CMV proteins, such as, by way of example only, pp65 / IE1 (Reap et al., Vaccine (2007) 25:7441-7449 (Non-Patent Document 10)).
[0400] Papovavirus: Antigens include, but are not limited to, those derived from papovaviruses, such as papillomaviruses and polyomaviruses. In certain embodiments, the papillomavirus comprises HPV serotypes 1, 2, 4, 5, 6, 8, 11, 13, 16, 18, 31, 33, 35, 39, 41, 42, 47, 51, 57, 58, 63, and 65. In certain embodiments, the HPV antigen is derived from serotype 6, 11, 16, or 18. In certain embodiments, the HPV antigen is selected from capsid proteins (L1) and (L2), or E1-E7, or fusions thereof. In certain embodiments, the HPV antigen is formulated into a virus-like particle (VLP). In certain embodiments, the polyomavirus comprises BK virus and JK virus. In certain embodiments, the polyomavirus antigen is selected from VP1, VP2, or VP3.
[0401] Adenovirus: Antigens include those derived from adenovirus. In certain embodiments, adenovirus antigens are derived from adenovirus serotype 36 (Ad-36). In certain embodiments, antigens are derived from protein or peptide sequences encoding the Ad-36 coat protein, or fragments thereof (WO 2007 / 120362).
[0402] In another embodiment, the antigen is a bacterial antigen.
[0403] Examples of bacterial antigens suitable for use in the context of the present invention include, but are not limited to, proteins, polysaccharides, and lipopolysaccharides derived from bacteria. In certain embodiments, the bacterial antigen comprises an epitope that is exposed on the surface of the bacterium during at least one stage of its life cycle. The bacterial antigen is preferably conserved across multiple serotypes. In certain embodiments, the bacterial antigen comprises an antigen derived from one or more of the bacteria described below, as well as examples of specific antigens identified below.
[0404] Neisseria meningitidis: N. meningitidis antigens include, but are not limited to, proteins, saccharides (including polysaccharides or lipooligosaccharides) derived from meningococcal serotypes, e.g., A, C, W135, Y, X, or B. Useful combinations of meningococcal protein antigens include one, two, or three of the following immunogens: NHBA, fHbp, and / or NadA immunogens.
[0405] Streptococcus pneumoniae: Streptococcus pneumoniae antigens include, but are not limited to, saccharides (including polysaccharides or oligosaccharides) and / or proteins from Streptococcus pneumoniae. In certain embodiments, the saccharide antigen is selected from one or more of the following pneumococcal serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and / or 33F. A vaccine or immunogenic composition may comprise multiple serotypes, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or more serotypes. 7-valent, 9-valent, 10-valent, 11-valent, and 13-valent conjugate combinations are already known in the art, as are 23-valent non-conjugated combinations. For example, a 10-valent combination may comprise saccharides from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F. An 11-valent combination may further comprise saccharides from serotype 3. A 12-valent combination may add serotypes 6A and 19A; 6A and 22F; 19A and 22F; 6A and 15B; 19A and 15B; 22F and 15B to a 10-valent mixture; a 13-valent combination may add serotypes 19A and 22F; 8 and 12F; 8 and 15B; 8 and 19A; 8 and 22F; 12F and 15B; 12F and 19A; 12F and 22F; 15B and 19A; 15B and 22F, etc. to an 11-valent mixture.In certain embodiments, the protein antigen is a protein antigen as described in WO 98 / 18931, WO 98 / 18930, U.S. Patent Nos. 6,699,703, 6,800,744, WO 97 / 43303, WO 97 / 37026, WO 02 / 079241, WO 02 / 34773, WO 00 / 06737, WO 00 / 06738, WO 00 / 58475, WO 2003 / 08 No. 2183 (Patent Document 14), No. 00 / 37105 (Patent Document 15), No. 02 / 22167 (Patent Document 16), No. 02 / 22168 No. (Patent Document 17), No. 2003 / 104272 (Patent Document 18), No. 02 / 08426 (Patent Document 19), No. 01 / 12219 ( Patent Document 20), No. 99 / 53940 (Patent Document 21), No. 01 / 81380 (Patent Document 22), No. 2004 / 092209 (Patent Document 23), No. 00 / 76540 (Patent Document 24), No. 2007 / 116322 (Patent Document 25), LeMieux et al., Infect. Imm. (2006) 74:2453-2456 (Non-Patent Document 11), Hoskins et al., J. Bacteriol. (2001) 183:5709-5717 (Non-Patent Document 12), Adamou et al., Infect. Infect. Dis. (2000) 182:1694-1701 (Non-patent document 14), Talkington et al., Microb. Pathog. (1996) 21(1):17-22 (Non-patent document 15), Bethe et al., FEMS Microbiol. Lett. (2001) 205(1): pp. 99-104 (Non-Patent Document 16), Brown et al., Infect. Immun. (2001) 69: 6702-6706 (Non-Patent Document 17), Whalen et al., FEMS Immunol. Med. Microbiol. (2005) 43: 73-80 (Non-Patent Document 18), Jomaa et al., Vaccine (2006) 24(24): 5133-5139 (Non-Patent Document 19).In other embodiments, the Streptococcus pneumoniae protein may be selected from the polyhistidine triad family (PhtX), the choline binding protein family (CbpX), CbpX truncate, LytX family, LytX truncate, CbpX truncate-LytX truncate chimeric protein, pneumolysin (Ply), PspA, PsaA, Spl28, SpIO1, Spl30, Spl25, Spl33, and pneumococcal pilus subunits.
[0406] Streptococcus pyogenes (Group A Streptococcus): Group A Streptococcus antigens include, but are not limited to, proteins identified in WO 02 / 34771 or WO 2005 / 032582 (including GAS40), fusions of fragments of the GAS M protein (including those described in WO 02 / 094851 and Dale, Vaccine (1999) 17:193-200 and Dale, Vaccine 14(10):944-948), fibronectin-binding protein (Sfbl), streptococcal heme-associated protein (Shp), and streptolysin S (SagA).
[0407] Moraxella catarrhalis: Moraxella antigens include, but are not limited to, antigens identified in WO 02 / 18595 and WO 99 / 58562, outer membrane protein antigens (HMW-OMPs), C-antigen, and / or LPS.
[0408] Bordetella pertussis: Pertussis antigens include, but are not limited to, pertussis toxoid (PT) and filamentous hemagglutinin (FHA) from B. pertussis, optionally further combined with pertactin and / or agglutinogens 2 and 3.
[0409] Burkholderia: Burkholderia antigens include, but are not limited to, Burkholderia mallei, Burkholderia pseudomallei, and Burkholderia cepacia.
[0410] Staphylococcus aureus: S. aureus antigens include, but are not limited to, polysaccharides and / or proteins from S. aureus. S. aureus polysaccharides include, but are not limited to, type 5 and type 8 capsular polysaccharides (CP5 and CP8), optionally conjugated to non-toxic recombinant Pseudomonas aeruginosa exotoxin A, e.g., StaphVAX™, type 336 polysaccharide (336PS), and polysaccharide intercellular adhesion (PIA, also known as PNAG). S. aureus proteins include, but are not limited to, antigens derived from surface proteins, invasins (leukocidins, kinases, hyaluronidases), surface factors that inhibit phagocytic engulfment (capsules, protein A), carotenoids, catalase production, protein A, coagulase, clotting factors, and / or membrane-damaging toxins (hemolysins, leukotoxins, leukocidins) that lyse eukaryotic cell membranes (optionally detoxified). In certain embodiments, the Staphylococcus aureus antigen is selected from the group consisting of those disclosed in WO 02 / 094868 (Patent Document 31), WO 2008 / 019162 (Patent Document 32), WO 02 / 059148 (Patent Document 33), WO 02 / 102829 (Patent Document 34), WO 03 / 011899 (Patent Document 35), WO 2005 / 079315 (Patent Document 36), WO 02 / 077183 (Patent Document 37), WO 99 / 27109 (Patent Document 38), WO 01 / 70955 (Patent Document 39), and the like. (Patent Document 39), Patent Document No. 00 / 12689 (Patent Document 40), Patent Document No. 00 / 12131 (Patent Document 41), Patent Document No. 2006 / 032475 (Patent Document 42), Patent Document No. 2006 / 032472 (Patent Document 43), Patent Document No. 2006 / 032500 (Patent Document 44), Patent Document No. 2007 / 113222 (Patent Document 45), Patent Document No. 2007 / 113223 (Patent Document 46), Patent Document No. 2007 / 113224 (Patent Document 47). In other embodiments, the Staphylococcus aureus antigen may be selected from IsdA, IsdB, IsdC, SdrC, SdrD, SdrE, ClfA, ClfB, SasF, SasD, SasH (AdsA), Spa, EsaC, EsxA, EsxB, Emp, HlaH35L, CP5, CP8, PNAG, 336PS.
[0411] Staphylococcus epidermidis: Staphylococcus epidermidis antigens include, but are not limited to, slime-associated antigens (SAA).
[0412] Clostridium tetani (tetanus): Tetanus antigens include, but are not limited to, tetanus toxoid (TT).
[0413] Clostridium perfringens: Antigens include, but are not limited to, epsilon toxin from Clostridium perfringens.
[0414] Clostridium botulinum (botulism): Botulism antigens include, but are not limited to, those derived from C. botulinum.
[0415] Corynebacterium diphtheriae (Diphtheria): Diphtheria antigens preferably include, but are not limited to, detoxified diphtheria toxin, such as CRM 197. In certain embodiments, diphtheria toxoid is used as the carrier protein.
[0416] Haemophilus influenzae B (Hib): Hib antigens include, but are not limited to, Hib saccharide antigens. Hib antigens may be conjugated.
[0417] Pseudomonas aeruginosa: Pseudomonas antigens include, but are not limited to, endotoxin A, Wzz protein, Pseudomonas aeruginosa LPS, LPS isolated from PAO1 (O5 serotype), and / or outer membrane proteins, including outer membrane protein F (OprF).
[0418] Brucella: Bacterial antigens derived from Brucella include, but are not limited to, B. abortus, B. canis, B. melitensis, B. neotomae, B. ovis, B. suis, and B. pinnipediae.
[0419] Francisella: Bacterial antigens derived from Francisella include, but are not limited to, F. novicida, F. philomiragia, and F. tularensis.
[0420] Streptococcus agalactiae (Group B Streptococcus): Group B Streptococcus antigens include, but are not limited to, protein or saccharide antigens identified in WO 02 / 34771, WO 03 / 093306, WO 04 / 041157, and WO 2005 / 002619 (including proteins GBS80, GBS104, GBS276, and GBS322, including saccharide antigens from serotypes Ia, Ib, Ia / c, II, III, IV, V, VI, VII, and VIII).
[0421] Neiserria gonorrhoeae: Gonococcal antigens include Por (or porin) proteins, such as PorB (see Zhu et al., Vaccine (2004) 22:660-669), transferrin-binding proteins, such as TbpA and TbpB (see Price et al., Infection and Immunity (2004) 71(1):277-283), opacity proteins (e.g., Opa), reduction-modifiable proteins (Rmp), and outer membrane vesicle (OMV) preparations (Plante et al., J Infectious Diseases 2004). Disease (2000) 182: 848-855 (Non-Patent Document 24), and also see, for example, International Publication Nos. WO 99 / 24578 (Patent Document 51), WO 99 / 36544 (Patent Document 52), WO 99 / 57280 (Patent Document 53), and WO 02 / 079243 (Patent Document 54).
[0422] Chlamydia trachomatis: Chlamydia trachomatis antigens include, but are not limited to, antigens from serovars A, B, Ba, and C (agent of trachoma, cause of blindness), serovars L1, L2, and L3 (associated with lymphogranuloma venereum), and serovars D through K. In certain embodiments, the Chlamydia trachomatis antigen comprises an antigen identified in WO 00 / 37494 (Patent Document 55), WO 03 / 049762 (Patent Document 56), WO 03 / 068811 (Patent Document 57), or WO 05 / 002619 (Patent Document 58), including, but not limited to, PepA (CT045), LcrE (CT089), ArtJ (CT381), DnaK (CT396), CT398, OmpH-like (CT242), L7 / L12 (CT316), OmcA (CT444), AtosS (CT467), CT547, Eno (CT587), HrtA (CT823), and MurG (CT761).
[0423] Treponema pallidum (syphilis): Syphilis antigens include, but are not limited to, the TmpA antigen.
[0424] Haemophilus ducreyi (cause of chancroid): Ducreyi antigens include, but are not limited to, outer membrane protein (DsrA).
[0425] Enterococcus faecalis or Enterococcus faecium: Antigens include, but are not limited to, trisaccharide repeats or other antigens from enterococci.
[0426] Helicobacter pylori: H. pylori antigens include, but are not limited to, CagA, VacA, NAP, HopX, HopY, and / or urease antigens.
[0427] Staphylococcus saprophyticus: Antigens include, but are not limited to, the saprophytic staphylococcal antigen 160 kDa hemagglutinin.
[0428] Yersinia enterocolitica: Antigens include, but are not limited to, LPS.
[0429] E. coli: E. coli antigens may be derived from enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAggEC), diffusely adhering E. coli (DAEC), enteropathogenic E. coli (EPEC), extraintestinal pathogenic E. coli (ExPEC), and / or enterohemorrhagic E. coli (EHEC). ExPEC antigens include, but are not limited to, accessory colonization factor (orf3526), orf353, bacterial Ig-like domain (group 1) protein (orf405), orffl364, NodT family outer membrane factor lipoprotein efflux transporter (orffl767), gspK (orf3515), gspJ (orf3516), tonB-dependent siderophore receptor (orf3597), fimbrial protein (orf3613), upec-948, upec-1232, type 1 fimbrial protein A chain precursor (upec-1875), yap H homolog (upec-2820), and hemolysin A (recp-3768).
[0430] Bacillus anthracis (anthrax): Anthrax antigens include, but are not limited to, A components (lethal factor (LF) and edema factor (EF)), both of which may share a common B component known as protective antigen (PA). In certain embodiments, B. anthracis antigens are optionally detoxified.
[0431] Yersinia pestis (plague): Plague antigens include, but are not limited to, F1 capsular antigen, LPS, Yersinia pestis V antigen.
[0432] Mycobacterium tuberculosis: Tuberculosis antigens include, but are not limited to, lipoproteins, LPS, BCG antigen, fusion protein of 85B antigen (Ag85B), ESAT-6, Mycobacterium tuberculosis (Mtb) isocitrate dehydrogenase-related antigen, and MPT51 antigen.
[0433] Rickettsia: Antigens include, but are not limited to, outer membrane proteins, including outer membrane protein A and / or B (OmpB), LPS, surface protein antigens (SPA).
[0434] Listeria monocytogenes: Bacterial antigens include, but are not limited to, those derived from Listeria monocytogenes.
[0435] Chlamydia pneumoniae: Antigens include, but are not limited to, those identified in WO 02 / 02606 (Patent Document 59).
[0436] Vibrio cholerae: Antigens include, but are not limited to, proteinase antigens, LPS, particularly V. cholerae II lipopolysaccharide, O1 rice leaf O-specific polysaccharide, Vibrio cholerae O139, antigens from IEM108 vaccine, and zonula occludens toxin (Zot).
[0437] Salmonella typhi (typhoid fever): Antigens include, but are not limited to, capsular polysaccharide, preferably the conjugate (Vi, ie, vax-TyVi).
[0438] Borrelia burgdorferi (Lyme disease): Antigens include, but are not limited to, lipoproteins (e.g., OspA, OspB, OspC, and OspD), other surface proteins such as OspE-related proteins (Erp), decorin-binding proteins (e.g., DbpA), and antigenically variable VI proteins such as P39 and P13 (integral membrane proteins), and VlsE antigenic variant proteins.
[0439] Porphyromonas gingivalis: Antigens include, but are not limited to, Porphyromonas gingivalis outer membrane proteins (OMPs).
[0440] Klebsiella: Antigens include, but are not limited to, OMPs, including OMP A, or polysaccharides optionally conjugated to tetanus toxoid.
[0441] Other bacterial antigens for use in the context of the present invention include, but are not limited to, any of the capsular antigens, polysaccharide antigens, or protein antigens described above. In certain embodiments, bacterial antigens for use in the context of the present invention are derived from Gram-negative bacteria, while in other embodiments, they are derived from Gram-positive bacteria. In certain embodiments, bacterial antigens for use in the context of the present invention are derived from aerobic bacteria, while in other embodiments, they are derived from anaerobic bacteria.
[0442] In another embodiment, the antigen is a fungal antigen.
[0443] Examples of fungal antigens for use in the context of the present invention include, but are not limited to, those derived from one or more of the fungi listed below.
[0444] Fungal antigens may be derived from dermatophytes, such as Epidermophyton floccosum, Microsporum audouini, Microsporum canis, Microsporum distortum, Microsporum equinum, Microsporum gypsum, Microsporum nanum, Trichophyton concentricum, Trichophyton equinum, Trichophyton gallinae ... gallinae, Trichophyton gypseum, Trichophyton megnini, Trichophyton mentagrophytes, Trichophyton quinckeanum, Trichophyton rubrum, Trichophyton schoenleinii, Trichophyton tonsurans, Trichophyton verrucosum, T. verrucosum var. album, T. discoides var., T. ocraciseum var. ochraceum), Trichophyton violaceum, and / or Trichophyton faviforme.
[0445] Fungal antigens may also be selected from the group consisting of Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, Aspergillus terreus, Aspergillus sydowii, Aspergillus flavarus, Aspergillus glaucus, Blastoschizomyces capitatus, Candida albicans, Candida enolase, and Candida tropicalis. tropicalis, Candida glabrata, Candida krusei, Candida parapsilosis, Candida stellatoidea, Candida krusei, Candida parakwsei, Candida lusitaniae, Candida pseudotropicalis, Candida guilliermondii, Cladosporium carrionii, Coccidioides immitis, Blastomyces dermatitidis dermatitidis, Cryptococcus neoformans, Geotrichum clavatum, Histoplasma capsulatum, Klebsiella pneumoniaepneumoniae, Microsporidia, Encephalitozoon spp., Septata intestinalis, and Enterocytozoon bieneusi, and less commonly Brachiola spp., Microsporidium spp., Nosema spp., Pleistophora spp., Trachipleistophora spp., Vittaforma spp., Paracoccidioides brasiliensis, Pneumocystis carinii, Pythium insidiosum, insidiosum, Pityrosporum ovale, Saccharomyces cerevisiae, Saccharomyces boulardii, Saccharomyces pombe, Scedosporium apiospermum, Sporothrix schenckii, Trichosporon beigelii, Toxoplasma gondii, Penicillium marneffeimarneffei, Malassezia spp., Fonsecaea spp., Wangiella spp., Sporothrix spp., Basidiobolus spp., Conidiobolus spp., Rhizopus spp., Mucor spp., Absidia spp., Mortierella spp., Cunninghamella spp., Saxenaea spp. a) species, Alternaria species, Curvularia species, Helminthosporium species, Fusarium species, Aspergillus species, Penicillium species, Monilinia species, Rhizoctonia species, Paecilomyces species, Pithomyces species, and Cladosporium species.
[0446] For example, a fungal antigen may elicit an immune response against Candida, such as C. albicans.
[0447] In another embodiment, the antigen is an autoantigen.
[0448] In the context of the present invention, the term "autoantigen" refers to an immunogenic antigen or epitope that is naturally present in a subject and that may be involved in the pathogenesis of an autoimmune disease.
[0449] In some embodiments, the autoantigen is a central nervous system (CNS) antigen, hi some embodiments, the autoantigen is a multiple sclerosis-associated antigen, a diabetes-associated antigen, a rheumatoid arthritis-associated antigen, a myocarditis-associated autoantigen, or a thyroiditis-associated antigen.
[0450] Exemplary autoantigens are disclosed, for example, in U.S. Patent Application Publication No. 2016 / 0022788 (Patent Document 60), which is incorporated herein by reference in its entirety.
[0451] In some embodiments, the autoantigen is a multiple sclerosis-associated antigen. In some embodiments, the autoantigen is an antigenic peptide of myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), myelin-associated glycoprotein (MAG), alpha B-crystallin, S100 beta, or proteolipid protein (PLP), or is derived from myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), myelin-associated glycoprotein (MAG), alpha B-crystallin, S100 beta, or proteolipid protein (PLP).
[0452] In some embodiments, the autoantigen is a diabetes-associated antigen. In some embodiments, the autoantigen is selected from insulin, chromogranin A, glutamic acid decarboxylase (GAD1; GAD67), glutamic acid decarboxylase 2 (GAD2; GAD65), and pancreatic islet-specific glucose-6-phosphatase catalytic subunit-associated protein, and combinations thereof. Antigenic fragments and derivatives of these antigens are also contemplated. In some embodiments, the antigen may be proinsulin.
[0453] In some embodiments, the autoantigen is a rheumatoid arthritis-associated antigen. In some embodiments, the rheumatoid arthritis-associated autoantigen can be peptide (Q / R)(K / R)RAA. In some embodiments, the arthritis-associated autoantigen can be type II collagen, or a fragment thereof.
[0454] In some embodiments, the autoantigen is a myocarditis-associated autoantigen. In some embodiments, the myocarditis-associated autoantigen is myosin or an antigenic fragment or derivative. In some embodiments, the antigen can be a peptide contained in human myosin. In some embodiments, the antigen can be a peptide contained in α-myosin.
[0455] In some embodiments, the autoantigen is a thyroiditis-associated autoantigen, hi some embodiments, the autoantigen is selected from thyroid peroxidase (TPO), thyroglobulin, or pendrin.
[0456] In another embodiment, the antigen is an allergen.
[0457] An "allergen" is defined as a substance, usually a protein, that induces the production of IgE antibodies in predisposed individuals. Similar definitions are provided in the following references: Clin. Exp. Allergy, Vol. 26, pp. 494-516 (1996) (Non-Patent Document 25); Mol. Biol. of Allergy and Immunology, edited by R. Bush, Immunology and Allergy Clinics of North American Series (August 1996) (Non-Patent Document 26). In a specific embodiment, the antigen is a protein allergen, i.e., any amino acid chain likely to induce an allergic response, including short peptides, polypeptides, or full proteins of about 6 to 20 amino acids.
[0458] Non-limiting examples of allergens include pollen allergens (e.g., tree, herb, grass, and grass pollen allergens), insect allergens (e.g., inhalant allergens, saliva allergens, and venom allergens, e.g., cockroach allergens and midge allergens, bee venom allergens), mite allergens, animal hair allergens, and dung allergens (e.g., from dogs, cats, horses, rats, mice, etc.), and food allergens.
[0459] For example, protein allergens include protein allergens from the genus Dermatophagoides, protein allergens from the genus Felis, protein allergens from the genus Ambrosia, protein allergens from the genus Lolium, protein allergens from the genus Cryptomeria, protein allergens from the genus Alternaria, protein allergens from the genus Alder, protein allergens from the genus Betula, protein allergens from the genus Blomia, and protein allergens from the genus Pseudokirchneriella. Protein allergens;Quercus protein allergens;Olea protein allergens;Artemisia protein allergens;Plantago protein allergens;Parietaria protein allergens;Canine protein allergens;Blattella protein allergens;Apis protein allergens;Cupressus protein allergens; Protein allergens from the Robe (Thuya) genus; Protein allergens from the Cypress (Chamaecyparis) genus; Protein allergens from the American cockroach (Periplaneta) genus; Protein allergens from the Wheatgrass (Agropyron) genus; Protein allergens from the Rye (Secale) genus; Protein allergens from the Wheat (Triticum) genus; Protein allergens from the Rosehip (Cynorhodon) genus; Protein allergens from the Juniperus genus; Protein allergens from the Orchardgrass (Dactylis) genus Protein allergens from the genus Festuca; Protein allergens from the genus Poa; Protein allergens from the genus Avena; Protein allergens from the genus Holcus; Protein allergens from the genus Anthoxanthum; Protein allergens from the genus Arrhenatherum; Protein allergens from the genus Agrostis; Protein allergens from the genus Phleum; Protein allergens from the genus Phalaris;Protein allergens of the genus Paspalum; and protein allergens of the genus Sorghum;
[0460] Examples of various known protein allergens from some of the above genera are: Betula (verrucosa) Bet v I; Bet v II; Bromia Blo t I; Blo t III; Blo t V; Blo t XII; Rosehip Cyn d I; Dermatophagoides (pteronyssinus) or Dermatophagoides (farinae) Der p I; Der p II; Der p III; Der p VII; Der f I; Der f II; Der f III; Der f VII; Felis (domesticus) Fel d I; Ragweed (Ambrosia (artemisfolia)) Amb a I.1; Amb a I.2; Amb a I.3; Amb a I.4; Amb a II; Ryegrass (Lollium (perenne)) Loll p I; Lot p II; Lol p III; Lot p IV; Lol p IX (Lol p V or Lol p Ib); Japanese cedar (Cryptomeria (japonica)) Cry j I; Cry j II; dog (Canis (familiaris)) Can f I; Can f II; Juniperus (sabinoides) or Japanese cedar (Juniperus (virginiana)) Jun s I; Jun v I; cedarwood (Juniperus (ashei)) Jun a I; Jun a II; orchard grass (Dactylis (glomerata)) Dac g I; Dac g V; Kentucky bluegrass (Poa (pretensis)) Poa p I; Phl p I; Phl p V; Phl p VI; and sorghum (Sorghum halepensis) (halepensis))Sor h I included.
[0461] Food allergens can be derived from milk, dairy products, eggs, legumes (peanuts and soybeans), tree nuts, cereals (e.g., wheat), crucifers (e.g., mustard), shellfish, fish, and mollusks. In particular, the food allergen can be ovalbumin or gluten.
[0462] The present invention further comprises a vaccine and / or immunogenic and / or immunotherapeutic composition comprising a DNA vector as defined above which comprises a nucleic acid encoding an antigen as defined above, such as a tumor antigen, a viral antigen, a bacterial antigen, a fungal antigen, an autoantigen, an allergen, or a graft-specific antigen, or an engineered Propionibacterium acnes comprising said DNA vector; and optionally an adjuvant.
[0463] Any conventional or exploratory, synthetic or biological adjuvant for vaccination can be used, including heat-labile toxin (LT), cholera toxin (CT), cholera toxin B subunit (CTB), polymeric liposomes, mutant toxins, probiotic bacteria, oligonucleotides, RNA, siRNA, DNA, and lipids.
[0464] The present invention further includes a method for preventing and / or treating cancer in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically or prophylactically efficient amount of a DNA vector comprising a nucleic acid encoding the tumor antigen defined above, or an engineered Propionibacterium acnes comprising said DNA vector. The present invention further relates to a DNA vector comprising a nucleic acid encoding the tumor antigen defined above, or an engineered Propionibacterium acnes comprising said DNA vector, for use in a method for preventing and / or treating cancer in a subject.
[0465] As used herein, the term "cancer" refers to a type of hyperproliferative disease, including malignant tumors, characterized by deregulated or uncontrolled cell proliferation. Cancers of virtually every tissue are known. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia, or lymphoid tumors. Specific examples of such cancers are described below and include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma), peritoneal cancer, hepatocellular carcinoma, gastric cancer, including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, thyroid cancer, liver cancer, and head and neck cancer. The term "cancer" includes primary malignant cells or tumors (e.g., those whose cells have not migrated to a site in a subject's body different from the site of the primary malignant tumor or tumor), and secondary malignant cells or tumors (e.g., those resulting from metastasis, the migration of malignant or tumor cells to a secondary site different from the site of the primary tumor).
[0466] The term "cancer" is included within the broader term "abnormal cell proliferation," which may also be referred to as "excessive cell proliferation" or "cell proliferative disorders." Examples of disorders associated with abnormal cell proliferation include metastatic tumors, malignant tumors, benign tumors, cancers, precancers, hyperplasias, warts, and polyps, as well as noncancerous conditions such as benign melanoma, benign chondroma, benign prostatic hyperplasia, moles, dysplastic nevi, dysplasias, hyperplasias, and other cell proliferations occurring within the epidermal layer. Classes of precancer include acquired small or microscopic precancers, acquired large lesions with nuclear atypia, precursor lesions occurring with hereditary hyperplastic syndromes that progress to cancer, and acquired diffuse hyperplasia and diffuse metaplasia. Examples of small or microscopic precancers include HGSIL (high-grade squamous intraepithelial lesions of the cervix), AIN (anal intraepithelial neoplasia), vocal cord dysplasia, aberrant crypts (of the colon), and PIN (prostatic intraepithelial neoplasia). Examples of acquired large lesions with nuclear atypia include tubular adenoma, AILD (angioimmunoblastic lymphadenopathy with dysproteinosis), atypical meningioma, gastric polyp, large-scale plaque psoriasis, myelodysplasia, papillary transitional cell carcinoma, refractory anemia with excess blasts, and Schneiderian papilloma.
[0467] The present invention further includes a method for preventing and / or treating cancer in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a DNA vector comprising a nucleic acid encoding the viral antigen defined above, or an engineered Propionibacterium acnes comprising said DNA vector. The present invention further relates to a DNA vector comprising a nucleic acid encoding the viral antigen defined above, or an engineered Propionibacterium acnes comprising said DNA vector, for use in a method for preventing and / or treating a viral infection in a subject.
[0468] In said embodiment, said antigen preferably induces the activation or enhancement of an immune response, in particular an immune response specific to said antigen.
[0469] Specific examples of viral infections include, but are not limited to, cytomegalovirus (CMV) pneumonia, enteritis, and retinitis; Epstein-Barr virus (EBV) lymphoproliferative disease; chickenpox / shingles (caused by varicella-zoster virus, VZV); HSV-1 and -2 mucositis; HSV-6 encephalitis, BK-virus hemorrhagic cystitis; viral influenza; respiratory syncytial virus (RSV) pneumonia; AIDS (caused by HIV); and hepatitis A, B, or C.Further examples of viral infections include Retroviridae; Picornaviridae (e.g., poliovirus, hepatitis A virus; enterovirus, human coxsackievirus, rhinovirus, echovirus); Caliciviridae (e.g., strains causing gastroenteritis); Togaviridae (e.g., equine encephalitis virus, rubella virus); Flaviviridae (e.g., dengue virus, encephalitis virus, yellow fever virus); Coronaviridae (e.g., coronavirus); Rhabdoviridae (e.g., vesicular stomatitis virus, rabies virus); Filoviridae (e.g., Ebola virus); Paramyxoviridae (e.g., parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza virus); Bunyaviridae (e.g., Hantavirus, Bunyaviridae, etc.) These include: Arenaviridae (hemorrhagic fever viruses); Reoviridae (e.g., reoviruses, orbiviruses, and rotaviruses); Bimaviridae; Hepadnaviridae (hepatitis B viruses); Parvoviridae (parvoviruses); Papovaviridae (papillomaviruses, polyomaviruses); Adenoviridae (most adenoviruses); Herpesviridae (herpes simplex viruses (HSV) 1 and HSV-2, varicella-zoster virus, cytomegalovirus (CMV), herpes viruses); Poxviridae (variola virus, vaccinia virus, poxvirus); and Iridoviridae (e.g., African swine fever virus); and unclassified viruses (e.g., etiological agents of spongiform encephalopathies). These include infections caused by the hepatitis delta agent, a hepatitis delta agent (thought to be a defective satellite of hepatitis B virus), non-hepatitis A, non-hepatitis B agents (Class 1 = internally transmitted; Class 2 = parenterally transmitted (i.e., hepatitis C)); Norwalk virus, Norwalk-associated virus, and astrovirus.
[0470] The present invention further includes a method for preventing and / or treating a bacterial infection in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a DNA vector comprising a nucleic acid encoding the bacterial antigen defined above, or an engineered Propionibacterium acnes comprising said DNA vector. The present invention further relates to a DNA vector comprising a nucleic acid encoding the bacterial antigen defined above, or an engineered Propionibacterium acnes comprising said DNA vector, for use in a method for preventing and / or treating a bacterial infection in a subject.
[0471] In said embodiment, said antigen preferably induces the activation or enhancement of an immune response, in particular an immune response specific to said antigen.
[0472] Examples of bacterial infections include Helicobacter pylori, Borrelia burgdorferi, Legionella pneumophila, Mycobacteria species (e.g., M. tuberculosis, M. avium, M. intracellulare, M. kansasii, M. kansasii, M. gordonae, Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (group A streptococci), Streptococcus agalactiae (group B streptococci), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic species), Streptococcus pneumoniae, pathogenic Campylobacter species, Enterococcus species, Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium species, Erysipelothrix rhusiopathiae rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, Bacteroides species, Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, and Actinomyces israelii.
[0473] The present invention further includes a method for preventing and / or treating a fungal infection in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a DNA vector comprising a nucleic acid encoding a fungal antigen as defined above, or an engineered Propionibacterium acnes comprising said DNA vector. The present invention further relates to a DNA vector comprising a nucleic acid encoding a fungal antigen as defined above, or an engineered Propionibacterium acnes comprising said DNA vector, for use in a method for preventing and / or treating a fungal infection in a subject.
[0474] In said embodiment, said antigen preferably induces the activation or enhancement of an immune response, in particular an immune response specific to said antigen.
[0475] Examples of fungal infections include, but are not limited to, aspergillosis, thrush (caused by Candida albicans), cryptococcosis (caused by Cryptococcus), and histoplasmosis. Thus, examples of fungal infections include, but are not limited to, infections caused by Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, or Candida albicans.
[0476] The present invention further includes a method for preventing and / or treating an autoimmune disease in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a DNA vector comprising a nucleic acid encoding the above-defined autoantigen, or an engineered Propionibacterium acnes comprising the DNA vector.The present invention further relates to a DNA vector comprising a nucleic acid encoding the above-defined autoantigen, or an engineered Propionibacterium acnes comprising the DNA vector, for use in a method for preventing and / or treating an autoimmune disease in a subject.
[0477] In said embodiment, said antigen preferably brings about an immune response, in particular a tolerization or suppression of an immune response against said antigen.
[0478] Autoimmune diseases include, but are not limited to, multiple sclerosis, rheumatoid arthritis, myasthenia gravis, psoriasis, systemic lupus erythematosus, autoimmune thyroiditis (Hashimoto's thyroiditis), Graves' disease, inflammatory bowel disease, autoimmune uveoretinitis, myocarditis, polymyositis, and certain types of diabetes, including type 1 diabetes.
[0479] The present invention further includes a method for preventing and / or treating allergies, such as asthma, in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a DNA vector comprising a nucleic acid encoding an allergen as defined above, or an engineered Propionibacterium acnes comprising said DNA vector. The present invention further relates to a DNA vector comprising a nucleic acid encoding an allergen as defined above, or an engineered Propionibacterium acnes comprising said DNA vector, for use in a method for preventing and / or treating allergies, such as asthma, in a subject.
[0480] In said embodiment, said antigen preferably brings about an immune response, in particular a tolerization or suppression of an immune response against said antigen.
[0481] In the context of the present disclosure, allergy relates to asthma or allergies caused by allergens as defined above.
[0482] The present invention further includes a method for preventing and / or treating graft rejection in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a DNA vector comprising a nucleic acid encoding a graft-specific antigen as defined above, or an engineered Propionibacterium acnes comprising said DNA vector. The present invention further relates to a DNA vector comprising a nucleic acid encoding a graft-specific antigen as defined above, or an engineered Propionibacterium acnes comprising said DNA vector, for use in a method for preventing and / or treating graft rejection in a subject.
[0483] In said embodiment, said antigen preferably brings about an immune response, in particular a tolerization or suppression of an immune response against said antigen.
[0484] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0485] All publications mentioned herein are incorporated herein by reference, and it is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a conflict.
[0486] As used in this specification and the appended claims, the singular forms "a," "an," and "the" are intended to include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen" includes a mixture of two or more antigens, and the like.
[0487] definition Delivery Vehicle As used herein, the term "delivery vehicle" refers to any means that allows the transfer of a payload into bacteria.
[0488] There are several types of delivery vehicles encompassed by the present invention, including, but not limited to, bacteriophage scaffolds, viral scaffolds, chemical-based delivery vehicles (e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes), protein- or peptide-based delivery vehicles, lipid-based delivery vehicles, nanoparticle-based delivery vehicles, non-chemical-based delivery vehicles (e.g., transformation, electroporation, sonoporation, optical transfection), particle-based delivery vehicles (e.g., gene gun, magnetofection, impalefection, particle bombardment, cell membrane-penetrating peptides), or donor bacteria (conjugation).
[0489] Any combination of delivery vehicles is also included in the present invention.
[0490] The delivery vehicle may involve a bacteriophage-derived scaffold and may be derived from natural, evolved, or engineered capsids.
[0491] In some embodiments, the delivery vehicle is the payload, since bacteria have the natural ability to take up payloads from the environment on their own.
[0492] 《Conjugate》 Conjugation is the process by which a donor bacterium actively transfers DNA to a recipient bacterium. DNA transfer involves the recognition of the origin of transfer (oriT) by a protein known as relaxase, which nicks and covalently binds to oriT DNA. The relaxase and single-stranded DNA are then injected into the recipient cell, typically via a type IV secretion system. During conjugation of a plasmid or ICE (integrative and conjugative element), the transfer of the relaxase is coupled with rolling-circular replication of the plasmid or ICE. Once inside the recipient, the relaxase recircularizes the transferred strand at oriT. - Smillie et al., Microbiology and Molecular Biology Rev, 2010, pp. 434-452 (Non-Patent Document 27).
[0493] Examples of conjugative plasmids are F, R388, RP4, RK2, R6K. Plasmids of the following groups: IncA, IncB / O (Ind O), IncC, IncD, IncE, IncFI, lncF2, IncG, IncHM, lncHI2, Inch, Incl2, IncJ, IncK, IncL / M, IncN, IncP, IncQI, lncQ2, IncR, IncS, IncT, IncU, IncV, IncW, IncXI, lncX2, IncY, IncZ, ColE1, ColE2, ColE3, p15A, pSC101, lncP-2, lncP-5, lncP-7, lncP-8, lncP-9, Ind, Inc4, Inc7, Inc8, Inc9, Inc11, Inc13, Ind4, or Ind8 are frequently conjugative and carry a type IV secretion system.
[0494] A list of type IV secretion systems can be found in public databases, such as AtlasT4SS.
[0495] Conjugation is not limited to plasmids, but can also occur from bacterial chromosomes if oriT is present. It can occur naturally by recombination of conjugative plasmids in the chromosome, or artificially by introduction of oriT at a desired location in the chromosome. A specific class of conjugative elements is known as integrative and conjugative elements (ICE). Integrative and conjugative elements are not maintained in a circular plasmid form, but are integrated into the host chromosome. Upon transfer, the ICE is excised from the chromosome and then transferred in a manner similar to that of a conjugative plasmid. Upon entry into the recipient cell, the ICE is integrated into the recipient chromosome. A list of ICE elements can be found in public databases, such as ICEberg.
[0496] An ICE or plasmid carrying both the origin of transfer gene and the type IV secretion system genes is commonly called a mobile element, whereas an ICE or plasmid carrying only oriT may be called a mobilizable plasmid. Mobile elements can be transferred from donor cells to recipient cells only if the type IV secretion system is expressed in trans, either by another plasmid or from the host cell chromosome.
[0497] "payload" As used herein, the term "payload" refers to any nucleic acid sequence or amino acid sequence, or a combination of both (e.g., but not limited to, peptide nucleic acid or peptide-oligonucleotide conjugates), that is delivered into the bacterium by a delivery vehicle.
[0498] The term "payload" may also refer to a plasmid, a vector, or a cargo.
[0499] The payload can be a phagemid or phasmid derived from a natural, evolved, or engineered bacteriophage genome. The payload can also consist only in part of a phagemid or phasmid derived from a natural, evolved, or engineered bacteriophage genome.
[0500] In some embodiments, the payload is the delivery vehicle, since bacteria have the natural ability to take up payloads from the environment on their own.
[0501] 《Nucleic acid》 As used herein, the term "nucleic acid" refers to a sequence of at least two covalently linked nucleotides, which may be single-stranded or double-stranded, or contain portions of both single-stranded and double-stranded sequences. Nucleic acids of the present invention may be natural, recombinant, or synthetic. Nucleic acids may be in the form of circular or linear sequences, or a combination of both forms. Nucleic acids may be DNA, both genomic DNA and cDNA, or RNA, or a combination of both. Nucleic acids may contain any combination of deoxyribonucleotides and ribonucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, 5-hydroxymethylcytosine, and isoguanine. Other examples of modified bases that can be used in the present invention are listed in Chemical Reviews 2016, 116(20), pp. 12655-12687 (Non-Patent Document 28). The term "nucleic acid" also includes nucleic acid analogs that may contain other backbones, including, but not limited to, phosphoramide, phosphorothioate, phosphorodithioate, O-methylphosphoroamidite linkages, and / or deoxyribonucleotide nucleic acids and ribonucleotide nucleic acids. Any combination of the above characteristics of nucleic acids is also included in the present invention.
[0502] "vector" As used herein, the term "vector" refers to any construct of sequences capable of expressing a polypeptide in a given host cell. When a vector is used, the choice of vector will depend on the method used to transform the host bacterium, as is well known to those skilled in the art. Vectors include, but are not limited to, plasmid vectors and recombinant phage vectors, or any other vector known in the art suitable for delivering the polypeptide of the present invention to the target bacterium. Those skilled in the art will be familiar with the genetic elements that must be present on the vector to efficiently transform, select, and grow host cells containing any of the isolated nucleotides or nucleic acid sequences of the present invention.
[0503] Phagemid As used herein, the terms "phagemid" or "phasmid" are equivalent and refer to a recombinant DNA vector that includes at least one sequence of a bacteriophage genome. Phagemids of the present disclosure include a phage packaging site and, optionally, an origin of replication (ori), particularly a bacterial and / or phage origin of replication. In one embodiment, phagemids of the present disclosure do not include a bacterial origin of replication and therefore cannot replicate independently when injected into bacteria. Instead, phagemids include a plasmid origin of replication, particularly a bacterial and / or phage origin of replication.
[0504] Packaged phagemid As used herein, the term "packaged phagemid" or "phage-derived particle" refers to a phagemid encapsidated within a bacteriophage scaffold, bacterial virus particle, or capsid. In particular, it refers to a bacteriophage scaffold, bacterial virus particle, or capsid lacking the bacteriophage genome. Packaged phagemids or phage-derived particles can be produced by helper phage strategies well known to those skilled in the art. The helper phage contains all the genes encoding the structural and functional proteins necessary to encapsidate the phagemids of the present invention. Packaged phagemids or phage-derived particles can be produced by satellite virus strategies also well known to those skilled in the art. Satellite viruses are subviral entities, consisting of nucleic acids that depend on the coinfection of host cells by a helper virus for all morphogenetic functions, but are completely autonomous from the helper for all their episomal functions (integration and immunity, multicopy plasmid replication). In one embodiment, the satellite gene may encode a protein that promotes capsid size reduction of the helper phage, as described for the P4 Sid protein that controls P2 capsid size to fit its smaller genome.
[0505] "peptide" As used herein, the term "peptide" refers to both a short chain of at least two amino acids linked together, and to a portion, subset, or fragment of a protein, where that portion, subset, or fragment is not expressed independently of the rest of the protein. In some cases, a peptide is a protein. In other cases, a peptide is not a protein, and the peptide refers to only a portion, subset, or fragment of a protein. Preferably, the peptide is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 amino acids in size, up to 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 100, 200 amino acids in size.
[0506] "Manipulative type"
[01] As used herein, the term "engineered" means that the bacterial cell, phage, phage-derived particle, phagemid, or vector of the invention has been modified by molecular biology techniques. As will be understood by those skilled in the art, engineering of a bacterial cell, phage, phage-derived particle, phagemid, or vector implies deliberate action to introduce or modify a nucleic acid sequence, and does not cover the introduction or modification of a nucleic acid sequence due to the natural evolution of the bacterial cell, phage, phage-derived particle, phagemid, or vector.
[0507] "Percent Identity"
[02] As used herein, percent identity is calculated with respect to aligned polymers (e.g., polynucleotides or polypeptides). The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = number of identical positions / total number of positions × 100), taking into account the number of gaps and the length of each cap that need to be introduced for optimal alignment of the two sequences. Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
[03] The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988) (Non-Patent Document 29)) incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Additionally, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970) (Non-Patent Document 30)) incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a BLOSUM62 matrix, a BLOSUM30 matrix, or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6. In one specific embodiment, the BLOSUM30 matrix is used with a gap open penalty of 12 and a gap extension penalty of 4.
[0508] CRISPR-Cas system The CRISPR-Cas system refers to DNA encoding two distinct elements: i) an endonuclease, in this case a CRISPR-associated nuclease (Cas or "CRISPR-associated protein"), and ii) a guide RNA. Depending on the type of CRISPR system, the guide RNA can be a chimeric RNA consisting of a combination of a CRISPR (crRNA) bacterial RNA and a tracrRNA (trans-activating RNA CRISPR) (Jinek et al., Science 2012). The guide RNA combines the targeting specificity of the crRNA and the conformational properties of the tracrRNA, which represent the "spacing sequence" used as a guide to the Cas protein, in a single transcript. When the guide RNA and Cas protein are co-expressed in a cell, the target genomic sequence can be permanently disrupted (and, depending on its location, cause loss of the targeted and surrounding sequences and / or cell death) or modified. The modification can be guided by a repair matrix.
[0509] CRISPR-Cas systems comprise two main classes depending on the nuclease mechanism of action: - Class 1 consists of multisubunit effector complexes and includes types I, III, and IV - Class 2, like Cas9 nucleases, consists of a single-unit effector module and includes type II (II-A, II-B, II-C, II-C variant), type V (VA, VB, VC, VD, VE, V-U1, V-U2, V-U3, V-U4, V-U5), and type VI (VI-A, VI-B1, VI-B2, VI-C, VI-D).
[0510] Sequences of interest according to the present invention include nucleic acid sequences encoding Cas proteins. A variety of CRISPR enzymes are available for use as sequences of interest on plasmids according to the present invention. In some embodiments, the CRISPR enzyme is a Type II CRISPR enzyme, a Type II-A CRISPR enzyme, or a Type II-B CRISPR enzyme. In other embodiments, the CRISPR enzyme is a Type I CRISPR enzyme or a Type III CRISPR enzyme. In some embodiments, the CRISPR enzyme catalyzes DNA cleavage. In other embodiments, the CRISPR enzyme catalyzes RNA cleavage. In one embodiment, the CRISPR enzyme may be linked to a guide RNA or single guide RNA (sgRNA). In certain embodiments, the guide RNA or sgRNA targets a gene selected from the group consisting of antibiotic resistance genes, genes for pathogenic proteins or virulence factors, genes for toxin proteins or toxic factors, bacterial receptor genes, membrane protein genes, structural protein genes, secreted protein genes, genes expressing resistance to drugs in general, and genes causing adverse effects to the host.
[0511] The sequence of interest may comprise a nucleic acid sequence encoding a guide RNA or sgRNA that guides the Cas protein endogenously to the target bacterium, either alone or in combination with the Cas protein and / or RNA guide encoded by the payload.
[0512] Non-limiting examples of Cas proteins, either as part of a multi-subunit effector or as a single unit effector, include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Cas11(SS), Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), C2c4, C2c8, C2c5, C2c10, C2c9, Cas13a (C2c2), Cas13b (C2c6), Cas13c (C2c7), Cas13d, Csa5, Csc 1, Csc2, Cse1, Cse2, Csy1, Csy2, Csy3, Csf1, Csf2, Csf3, Csf4, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csn2, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10 , Csx16, CsaX, Csx13, Csx1, Csx15, SdCpf1, CmtCpf1, TsCpf1, CmaCpf1, PcCpf1, ErCpf1, FbCpf1, UbcCpf1, AsCpf1, LbCpf1, homologs thereof, orthologs thereof, variants thereof, or modified forms thereof. In some embodiments, the CRISPR enzyme cleaves both strands of the target nucleic acid at a protospacer adjacent motif (PAM) site.
[0513] In one particular embodiment, the CRISPR enzyme is any Cas9 protein, for example, any naturally occurring bacterial Cas9, as well as any variant, homolog, or ortholog thereof.
[0514] "Cas9" refers to the protein Cas9 (also called Csn1 or Csx12), or a protein, peptide, or polypeptide fragment thereof that is functional, i.e., capable of interacting with a guide RNA and exerting enzymatic activity (nuclease) that makes a double-stranded break in DNA of a target genome. Thus, "Cas9" refers to an engineered protein, e.g., an engineered protein that has been truncated to remove domains of the protein that are not essential for the protein's defined function, particularly domains that are not required for interaction with the gRNA.
[0515] Sequences encoding Cas9 (whole protein or fragments thereof) for use in the context of the present invention can be obtained from any known Cas9 protein (Fonfara et al., 2014; Koonin et al., 2017). Examples of Cas9 proteins useful in the present invention include, but are not limited to, the Cas9 proteins of Streptococcus pyogenes (SpCas9), Streptococcus thermophiles (St1Cas9, St3Cas9), Streptococcus mutans, Staphylococcus aureus (SaCas9), Campylobacter jejuni (CjCas9), Francisella novicida (FnCas9), and Neisseria meningitidis (NmCas9).
[0516] Sequences encoding Cpf1 (Cas12a) (whole protein or fragments thereof) for use in the context of the present invention can be obtained from any known Cpf1 (Cas12a) protein (Koonin et al., 2017). Examples of Cpf1 (Cas12a) proteins useful in the present invention include, but are not limited to, Cpf1 (Cas12a) proteins from Acidaminococcus species, Lachnospiraceae bacteria, and Francisella novicida.
[0517] Sequences encoding Cas13a (whole protein or fragments thereof) for use in the context of the present invention can be obtained from any known Cas13a (C2c2) protein (Abudayyeh et al., 2017). Examples of Cas13a (C2c2) proteins useful in the present invention include, but are not limited to, the Cas13a (C2c2) protein of Leptotrichia wadei (LwaCas13a).
[0518] Sequences encoding Cas13d (whole protein or fragments thereof) for use in the context of the present invention can be obtained from any known Cas13d protein (Yan et al., 2018). Examples of Cas13d proteins useful in the present invention include, but are not limited to, the Cas13d proteins of Eubacterium siraeum and Ruminococcus species.
[0519] In certain embodiments, the nucleic acid sequence of interest is a CRISPR / Cas9 system directed to reducing or inactivating gene expression of a gene selected from the group consisting of antibiotic resistance genes, genes for virulence factors or pathogenic proteins, genes for toxin factors or toxin proteins, genes expressing bacterial receptors, membrane proteins, structural proteins, secreted proteins, genes expressing resistance to drugs in general, and genes causing adverse effects to the host.
[0520] In one embodiment, the CRISPR-Cas system is used to target and inactivate virulence factors. A virulence factor can be any substance produced by a pathogen that alters host-pathogen interactions by increasing the degree of damage inflicted on the host. Virulence factors are used by pathogens in many ways, including, for example, in cell adhesion or colonization of a niche within the host, to evade the host's immune response, to facilitate invasion and escape from host cells, to obtain nutrients from the host, or to inhibit other physiological processes in the host. Virulence factors can include enzymes, endotoxins, adhesion factors, motility factors, factors involved in complement evasion, scavenging factors, and factors that promote biofilm formation. For example, such targeted virulence factor genes include, but are not limited to, EHEC-HlyA, Stx1 (VT1), Stx2 (VT2), Stx2a (VT2a), Stx2b (VT2b), Stx2c (VT2c), Stx2d (VT2d), Stx2e (VT2e), and Stx2f (VT2f), Stx2h (VT2h), stx2k, fimA, fimF, fimH, neuC, kpsE, sfa, foc, iroN, aer, iha, papC, papGI, papGII, papGIII, hlyC, cnf1, hra, sat, ireA, usp The target virulence factor gene may be a gene encoding ompT, ibeA, malX, fyuA, irp2, traT, afaD, ipaH, eltB, estA, bfpA, eaeA, espA, aaiC, aatA, TEM, CTX, SHV, csgA, csgB, csgC, csgD, csgE, csgF, csgG, csgH, T1SS, T2SS, T3SS, T4SS, T5SS, or T6SS (secretion system). For example, such a target virulence factor gene may be a Shigella dysenteriae virulence factor gene, such as, but not limited to, stx1 and stx2. For example, such a target virulence factor gene may be a Yersinia pestis virulence factor gene, such as, but not limited to, yscF (plasmid-mediated (pCD1) T3SS outer needle subunit).For example, such a targeted virulence factor gene can be a Francisella tularensis virulence factor gene, such as, but not limited to, fslA. For example, such a targeted virulence factor gene can be a Bacillus anthracis virulence factor gene, such as, but not limited to, pag (anthrax toxin, cell-associated protective antigen). For example, such a targeted virulence factor gene can be a Vibrio cholerae virulence factor gene, such as, but not limited to, ctxA and ctxB (cholera toxin), tcpA (toxin coregulator pilus), and toxT (master virulence regulator). For example, such targeted virulence factor genes can be Pseudomonas aeruginosa virulence factor genes, such as, but not limited to, pyoverdin (e.g., sigma factor pvdS, biosynthetic genes pvdL, pvdI, pvdJ, pvdH, pvdA, pvdF, pvdQ, pvdN, pvdM, pvdO, pvdP, transporter genes pvdE, pvdR, pvdT, opmQ), siderophore pyochelin (e.g., pchD, pchC, pchB, pchA, pchE, pchF, and pchG), and toxins (e.g., exoU, exoS, and exoT). For example, such a targeted virulence factor gene can be a Klebsiella pneumoniae virulence factor gene, such as, but not limited to, fimA (adhesion, type I fimbrial major subunit) and cps (capsular polysaccharide). For example, such a targeted virulence factor gene can be an Acinetobacter baumannii virulence factor gene, such as, but not limited to, ptk (capsule polymerization) and epsA (assembly). For example, such a targeted virulence factor gene can be a Salmonella enterica typhi virulence factor gene, such as, but not limited to, MIA (invasion, SPI-1 regulator), ssrB (SPI-2 regulator), and those associated with bile resistance, including the efflux pump genes acrA, acrB, and tolC. For example, such targeted virulence factor genes can be Fusobacterium nucleatum virulence factor genes, such as, but not limited to, FadA and TIGIT.For example, such a targeted virulence factor gene can be a Bacteroides fragilis virulence factor gene, such as, but not limited to, bft. For example, such targeted virulence factor genes can be Cutibacterium acnes porphyrin genes, CAMP factors (CAMP1, CAMP2, CAMP3, CAMP4), hyaluronate lyases (HYL-IB / II, HYL-IA), lipases (GehA, GehB), hemolysin, sialidase, endoglycoceramidase, endo-β-N-acetylglucosaminidase, dermatan sulfate adhesins (DsA1, DsA2), proline-threonine repeats (PTR), or any virulence factor contained on acne-associated genomic loci 1, 2, 3 (plasmid), and 4 described in Tomida et al., such as the tight adhesion locus (tad), streptolysin S-related gene (sag), and nonribosomal peptide synthetase (NRPS).
[0521] In other embodiments, the CRISPR / Cas9 system is used to target and inactivate antibiotic resistance genes, such as, but not limited to, GyrB, ParE, ParY, AAC(1), AAC(2'), AAC(3), AAC(6'), ANT(2"), ANT(3"), ANT(4'), ANT(6), ANT(9), APH(2"), APH(3"), APH(3'), APH(4), APH(6), APH(7"), APH(9), ArmA, RmtA, RmtB, RmtC, Sgm, AER, BLA1, CTX-M, KPC, SHV, TEM, BlaB, CcrA, IMP, NDM, VIM, ACT, AmpC, CMY, LAT, PDC, OXA β-lactamase, mecA, Omp36, OmpF, PIB, bla (blaI, blaR1), and mec (mecI, mecR1) operons, chloramphenicol acetyltransferase (CAT), chloramphenicol phosphotransferase, ethambutol-resistant arabinosyltransferase (EmbB), MupA, MupB, integral membrane protein MprF, Cfr 23S rRNA methyltransferase, rifampin ADP-ribosyltransferase (Arr), rifampin glycosyltransferase, rifampin monooxygenase, rifampin phosphotransferase, DnaA, RbpA, rifampin-resistant beta subunit of RNA polymerase (RpoB), Erm 23SrRNA methyltransferase, Lsa, MsrA, Vga, VgaB, streptogramin Vgb lyase, Vat acetyltransferase, fluoroquinolone acetyltransferase, fluoroquinolone resistance DNA topoisomerase, fluoroquinolone resistance GyrA, GyrB, ParC, quinolone resistance protein (Qnr), FomA, FomB, FosC, FosA, FosB, FosX, VanA, VanB, VanD, VanR, VanS, lincosamide nucleotidyltransferase (Lin), EreA, EreB, GimA, Mgt, Ole, macrolide phosphotransferase (MPH), Me fA, MefE, Mel, streptothricin acetyltransferase (sat), Sul1, Sul2, Sul3, sulfonamide resistance FolP, tetracycline inactivation enzymes TetX, TetA, TetB, TetC, Tet30, Tet31, TetM, TetO, TetQ, Tet32, Tet36, MacAB-TolC, MsbA, MsrA, VgaB, EmrD, EmrAB-TolC, NorB, GepA, MepA, AdeABC, AcrD, MexAB-OprM, mtrCDE, EmrE, adeR, acrR, baeSR, mexR, phoPQ, mtrR, or any antibiotic resistance gene listed in the Comprehensive Antibiotic Resistance Database (CARD https: / / card.mcmaster.ca / ).
[0522] In other embodiments, the CRISPR-Cas system is used to target and inactivate bacterial toxin genes. Bacterial toxins can be classified as exotoxins or endotoxins. Exotoxins are produced and actively secreted; endotoxins remain part of the bacterium. Responses to bacterial toxins can include severe inflammation and lead to sepsis. Such toxins can be, for example, botulinum neurotoxin, tetanus toxin, staphylococcal toxin, diphtheria toxin, anthrax toxin, alpha toxin, pertussis toxin, Shiga toxin, heat-stable enterotoxin (E. coli ST), colibactin, BFT (B. fragilis toxin), or any of the toxins described by Henkel et al. (Toxins from Bacteria in EXS. 2010;100:1-29 (Non-Patent Document 31)).
[0523] BasesEdit Base editing (BE) refers to the ability to replace specific nucleotide base pairs on DNA or RNA molecules with other base pairs. Until recently, the only way to make specific substitutions on DNA in vivo was to use recombination of template DNA carrying the specific base pair change with the desired locus. Base editing technology relies on a completely different strategy: there is no DNA exchange; instead, enzymatic reactions convert nucleotides into other nucleotides, resulting in mismatches at the level of dsDNA, which are then corrected by the cellular machinery.
[0524] One of the major challenges in base editing is how to restrict the activity of nucleotide-converting enzymes to target nucleotides, such as SNPs involved in pathogenicity. This spatial constraint has recently been achieved by repurposing the CRISPR-Cas system. Indeed, highly efficient base editing can be achieved by fusing catalytically impaired or inactive Cas nucleases with base-modifying enzymes that are active only on single-stranded DNA. This is possible thanks to the ability of CRISPR-Cas to generate a localized ssDNA bubble within an "R-loop" when the complex anneals to its DNA target strand through RNA-DNA base pairing.
[0525] So far, seven DNA base editors have been described: - a cytosine base editor (CBE) that converts C:G to T:A (Komor, A. et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533:420-4 (2016) (Non-Patent Document 32)), - Adenine base editor (ABE) that converts A:T to G:C (Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. Nature 551(7681)pp. 464-471 (2017) (Non-patent document 33)), - Cytosine guanine base editor (CGBE) that converts C:G to G:C, Chen, L et al., Precise and programmable C:G to G:C base editing in genomic DNA. Biorxiv (2020) (Non-patent document 34); Kurt, I et al., CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nature Biotechnology (2020) (Non-patent document 35), - Cytosine adenine base editor (CABE) that converts C:G to A:T, Zhao, D et al., New base editors change C to A in bacteria and C to G in mammalian cells. Nature Biotechnology (2020) (Non-patent document 36), - an adenine cytosine base editor (ACBE) that converts A:T to C:G (Liu, D et al., A:T to C:G base editors and uses thereof. Patent Application WO 2020181180 (2020) (Patent Document 61)), - adenine thymine base editor (ATBE) that converts A:T to T:A (Liu, D et al., A:T to C:G base editors and uses thereof. Patent Application WO 2020181180 (2020) (Patent Document 61)), - Thymine adenine base editors (TABEs) that convert T:A to A:T (Liu, D et al., T:A TO A:T base editing through adenosine methylation. Patent Application WO 2020181193 (2020) (Patent Document 62); Liu, D et al., T:A TO A:T base editing through thymine alkylation. Patent Application WO 2020181178 (2020) (Patent Document 63); Liu, D et al., T:A TO A:T base editing through adenine excision. Patent Application WO 2020181195 (2020) (Patent Document 64)).
[0526] Base editors differ in the base-modifying enzymes. CBEs rely on ssDNA cytidine deaminases: APOBEC1, rAPOBEC1, APOBEC1 variants or evolved forms (evoAPOBEC1), and APOBEC homologs (APOBEC3A (eA3A), Anc689), cytidine deaminase 1 (CDA1), evoCDA1, FERNY, and evoFERNY. ABEs rely on tandemly fused TadA-TadA. * TadA relies on the deoxyadenosine deaminase activity of * is an evolved form of the E. coli tRNA adenosine deaminase enzyme TadA, which can convert adenosine on ssDNA to inosine. * contains TadA-8a-e and TadA-7.10.
[0527] In addition to base-modifying enzymes, further modifications to the base editor were made to improve editing efficiency, precision, and modularity: - Addition of one or two uracil DNA glycosylase inhibitor domains (UGI) to prevent base excision repair mechanisms from reversing the base edition - Addition of Mu-GAM, which reduces insertion-deletion rates by inhibiting non-homologous end joining (NHEJ) in cells - Use of a nickase-active Cas9 (nCas9 D10A) that creates a nick on the non-edited strand, thereby facilitating its repair and thus the fixation of the edited base. - use of different Cas proteins (e.g., Cas12a) from different organisms, variants with different PAM motifs or different fidelity, or from different families
[0528] Non-limiting examples of DNA-based editor proteins include BE1, BE2, BE3, BE4, BE4-GAM, HF-BE3, Sniper-BE3, Target-AID, Target-AID-NG, ABE, EE-BE3, YE1-BE3, YE2-BE3, YEE-BE3, BE-PLUS, SaBE3, SaBE4, SaBE4-GAM, Sa(KKH)-BE3, VQR-BE3, VRER-BE3, EQR-BE3, xBE3, Cas12a-BE, Ea3A-BE3, A3A-BE3, TAM, CRISPR-X, ABE7.9, ABE7.10, ABE7.10 * , xABE, ABESa, VQR-ABE, VRER-ABE, Sa(KKH)-ABE, ABE8e, SpRY-ABE, SpRY-CBE, SpG-CBE4, SpG-ABE, SpRY-CBE4, SpCas9-NG-ABE, SpCas Contains 9-NG-CBE4, enAsBE1.1, enAsBE1.2, enAsBE1.3, enAsBE1.4, AsBE1.1, AsBE1.4, CRISPR-Abest, CRISPR-Cbest, eA3A-BE3, AncBE4.
[0529] Cytosine Guanine Base Editor (CGBE) is: - Cytosine deaminase (rAPOBEC) and base excision repair proteins (e.g., rXRCC1) (Precise and programmable C:G to G:C base editing in genomic DNA. BioRxiv (2020) (Non-Patent Document 34)), - Rat APOBEC1 variant (R33A) protein and Escherichia coli uracil DNA N-glycosylase (eUNG) (Kurt, I et al., CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nature Biotechnology (2020) (Non-Patent Document 35)) It consists of a nickase CRISPR fused to - Cytosine adenine base editors (CABEs) consist of Cas9 nickase, cytidine deaminase (e.g., AID), and uracil DNA glycosylase (Ung). Zhao, D et al., New base editors change C to A in bacteria and C to G in mammalian cells. Nature Biotechnology (2020) (Non-Patent Document 36). ACBEs include nucleic acid-programmed DNA-binding proteins and adenine oxidases. Liu, D. et al., A:T to C:G base editors and uses thereof. Patent application WO 2020181180 (2020) (Patent Document 61). ATBEs consist of a Cas9 nickase and one or more adenosine deaminase or oxidase domains. Liu, D. et al., A:T to T:A base editing through adenine deamination and oxidation. Patent Application WO 2020181202 (2020) (Patent Document 65). TABEs consist of a Cas9 nickase and an adenosine methyltransferase, thymine alkyltransferase, or adenosine deaminase domain (Liu, D. et al., T:A TO A:T base editing through adenosine methylation, Patent Application WO 2020181193 (2020) (Patent Document 62); Liu, D. et al., T:A TO A:T base editing through thymine alkylation, Patent Application WO 2020181178 (2020) (Patent Document 63); Liu, D. et al., T:A TO A:T base editing through adenine excision, Patent Application WO 2020181195 (2020) (Patent Document 64)).
[0530] Base editor molecules can also consist of two or more of the above editor enzymes fused to a Cas protein (e.g., a combination of ABE and CBE). These biomolecules are called dual base editors and allow editing of two different bases (Grunewald, J et al., A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing, Nature Biotechnology (2020) (Non-Patent Document 37); Li, C et al., Targeted, random mutagenesis of plant genes with dual cytosine and adenine base editors, Nature Biotechnology (2020) (Non-Patent Document 38)).
[0531] In one embodiment, a base editor is used to inactivate expression of a gene by editing one or more nucleotides involved in transcription or translation, particularly targeting one or more nucleotides in the promoter, RBS, or start codon.
[0532] In one embodiment, a base editor is used to introduce a premature stop codon.
[0533] In one embodiment, a base editor is used to introduce one or more rare codons.
[0534] In other embodiments, base editors are used to regulate gene expression by editing one or more nucleotides involved in transcription or translation, particularly targeting one or more nucleotides in the promoter, RBS, or start codon, resulting in increased or decreased gene expression.
[0535] In other embodiments, base editors are used to reverse mutations that result in the inactivation, decreased activity, or increased activity of a gene or pathway.
[0536] In other embodiments, base editors are used to reverse mutations that result in increased pathogenicity.
[0537] In one embodiment, a base editor is used to alter the regulation of a gene by editing one or more nucleotides involved in the regulation of that gene, such as nucleotides of an operator sequence, a transcription factor binding site, a riboswitch, an RNAse recognition site, a protease cleavage site, a methylation site, a post-translational modification site (phosphorylation, glycosylation, acetylation, propylation...).
[0538] RNA-based editing RNA base editing is based on the same principle as DNA base editing: an enzyme that catalyzes the conversion of one RNA base to another must be brought close to the target base to perform the conversion locally. To date, the only enzyme used for RNA editing is adenosine deaminase from the ADAR family, which converts adenosine to inosine in dsRNA structures. Some promising studies have exploited this specificity for dsRNA by fusing the ADAR deaminase domain (ADARDD) with antisense oligos to program localized RNA base editing. More recently, the ability of some CRISPR-Cas systems to bind RNA molecules has been repurposed for RNA editing. Using a catalytically dead Cas13b enzyme (dPspCas13b) fused to a hyperactive mutant of the ADAR2 deaminase domain (ADAR2DD-E488Q for REPAIRv1 and ADAR2DD-E488Q-T375G for REPAIRv2), Cox et al. improved specificity and efficiency compared to previous RNA editing strategies.
[0539] Non-limiting examples of RNA-based editors include REPAIRv1 and REPAIRv2.
[0540] In one embodiment, an RNA base editor is used to inactivate expression of a gene by editing one or more nucleotides involved in translation, specifically targeting one or more nucleotides in the 5'UTR, RBS, or start codon.
[0541] In one embodiment, an RNA base editor is used to introduce a premature stop codon.
[0542] In one embodiment, an RNA base editor is used to introduce one or more rare codons.
[0543] In other embodiments, RNA base editors are used to regulate gene expression by editing one or more nucleotides involved in translation, particularly targeting one or more nucleotides in the 5'UTR, RBS, or start codon, resulting in increased or decreased gene expression.
[0544] In other embodiments, RNA base editors are used to reverse mutations that result in the inactivation or reduced activity of genes or pathways.
[0545] In other embodiments, base editors are used to reverse mutations that result in increased pathogenicity.
[0546] Prime Edit The prime editor (PE) described in Anzalone et al. (Anzalone, AV et al., Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, pp. 149-157 (2019) (Non-Patent Document 39)), which is incorporated herein by reference, consists of Cas9 fused to a reverse transcriptase, which is used in combination with a prime editing RNA (pegRNA; a guide RNA containing a template region for reverse transcriptase).
[0547] Prime editing allows for the introduction of insertions, deletions (indels), and 12 base-to-base conversions. Prime editing relies on the ability of a reverse transcriptase (RT) fused to a Cas nickase variant to convert an RNA sequence delivered by a prime-editing guide RNA (pegRNA) into DNA at a nick site generated by the Cas protein. The DNA flap generated by this process is then either included or excluded from the target DNA sequence.
[0548] The Prime Editing System: - a Cas nickase variant, such as Cas9-H840A, fused to a reverse transcriptase domain, such as M-MLV RT, or mutant forms thereof (M-MLV RT(D200N), M-MLV RT(D200N / L603W), M-MLV RT(D200N / L603W / T330P / T306K / W313F)); - Prime editing guide RNA (pegRNA) Includes:
[0549] To facilitate editing, the primed editing system may include expression of an additional sgRNA that directs Cas nuclease activity to the non-edited DNA strand only after resolution of the edited strand flap, ideally by designing it to anneal with the edited strand but not the original strand.
[0550] Non-limiting examples of prime editing systems include PE1, PE1-M1, PE1-M2, PE1-M3, PE1-M6, PE1-M15, PE1-M3inv, PE2, PE3, PE3b, "CRISPEY" (Cas9 Retron precISe Parallel Editing via homologY), a retron RNA fused to an sgRNA and expressed in conjunction with Cas9, and a retron protein comprising at least a reverse transcriptase (Sharon, E. et al., Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing. Cell 175, pp. 544-557. e16 (2018) (Non-Patent Document 40)), and the SCRIBE strategy: a retron system expressed in combination with a recombinase, also known as single-stranded annealing protein (SSAP) 12, that promotes recombination of single-stranded DNA.Such recombinases include phage recombinases such as lambda Red, recET, Sak, Sak4, and the recently described SSAP described by Wannier et al. (Wannier, T. M. et al., Improved bacterial recombineering by parallelized protein discovery. BioRxiv 2020.01.14.906594 (2020) doi:10.1101 / 2020.01.14.906594. (Non-Patent Document 41)), the targetron system based on group II introns described by Karberg et al. (Karberg, M. et al., Group II introns as controllable gene targeting vectors for genetic manipulation of bacteria. Nat Biotechnol 19, 1162-7 (2001) (Non-Patent Document 42)) and adapted to many bacterial species, and the targetron system described by Simon et al. (Simon, A. J., Ellington, A. D. & Finkelstein, I. J., Retrons and their applications in genome engineering. These include, but are not limited to, other retrons based on gene targeting approaches, such as those described in Nucleic Acids Res 47, pp. 11007-11019 (2019) (Non-Patent Document 43).
[0551] In one embodiment, a prime editing system is used to inactivate expression of a gene by substituting, deleting, or inserting one or more nucleotides involved in transcription or translation. In particular, the prime editing system substitutes, deletes, or inserts one or more nucleotides in the promoter, RBS, or coding sequence.
[0552] In one embodiment, a primed editing system is used to introduce one or more premature stop codons.
[0553] In one embodiment, a prime editing system is used to introduce one or more rare codons.
[0554] In one embodiment, a prime editing system is used to introduce or delete nucleotides to induce a frameshift in the reading frame.
[0555] In other embodiments, the prime editing system is used to regulate gene expression by substituting, deleting, or inserting one or more nucleotides involved in transcription or translation. In particular, the prime editing system substitutes, deletes, or inserts one or more nucleotides in the promoter, RBS, or start codon, resulting in increased or decreased gene expression.
[0556] In other embodiments, a prime editing system is used to revert mutations that result in the inactivation or reduced activity of a gene or pathway.
[0557] In other embodiments, a prime editing system is used to revert mutations that result in increased pathogenicity.
[0558] The present invention includes the following embodiments. 1. Recombinant Propionibacterium acnes phage. 2. A recombinant Propionibacterium acnes phage according to embodiment 1, comprising at least one transgene. 3. The recombinant Propionibacterium acnes phage of embodiment 2, wherein the transgene is a CRISPR-Cas system or part of a CRISPR-Cas system. 4. The recombinant Propionibacterium acnes phage of embodiment 1, wherein the host range is different from the host range of the corresponding wild-type Propionibacterium acnes phage. 5. The recombinant Propionibacterium acnes phage of embodiment 1, comprising an engineered capsid. 6. The recombinant Propionibacterium acnes phage of embodiment 5, wherein an antigen is displayed on the surface of the engineered capsid. 7. The following: - DNA template suitable for homologous recombination with the P. acnes phage genome - an origin of replication that allows replication within P. acnes; and - optionally a first selection marker allowing selection of the DNA vector in P. acnes; P. acnes cells carrying a recombinant DNA vector containing 8. The Propionibacterium acnes cell of embodiment 7, wherein a Propionibacterium acnes phage genome is introduced into the cell. 9. The Propionibacterium acnes cell of embodiment 7, wherein the Propionibacterium acnes phage genome recombines with the DNA vector, resulting in the production of a recombinant phage. 10. The following: - an origin of replication that allows replication within P. acnes; - a CRISPR-Cas system that is expressed in said P. acnes but does not target the newly generated recombinant P. acnes phage genome; and - optionally a first selection marker that allows selection of the DNA vector in P. acnes and a P. acnes cell carrying a DNA vector for selective production of a recombinant P. acnes phage, comprising: 11. A method for producing a phage lysate containing wild-type or parental P. acnes phage and recombinant P. acnes phage, comprising introducing a wild-type or parental P. acnes phage genome into a P. acnes cell according to embodiment 7. 12. A method for selecting recombinant P. acnes phage, comprising mixing a phage lysate containing wild-type or parental P. acnes phage and recombinant P. acnes phage with the P. acnes cells of embodiment 10, resulting in the selective production of recombinant P. acnes phage. 13. A method for treating a P. acnes-associated disorder or disease, comprising administering to a subject a recombinant P. acnes phage described in any one of embodiments 1 to 6, or a recombinant P. acnes phage obtainable by the method described in embodiment 11 or 12. 14. - Origin of replication that allows replication within P. acnes; - optionally a selection marker that allows selection of the DNA vector in P. acnes, and - Gene of interest A recombinant DNA vector comprising: 15. The DNA vector of embodiment 14, further comprising oriT, which allows conjugation into P. acnes; an origin of replication, which allows replication in a donor bacterium; and a second selection marker, which allows selection in the donor bacterium. 16. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is R6K (typically the sequence of SEQ ID NO: 42). 17. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is RK2 (typically the sequence of SEQ ID NO: 43). 18. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pBBR1 (typically the sequence of SEQ ID NO: 44). 19. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pRO1600 (typically the sequence of SEQ ID NO: 45). 20. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is RSF1010 (typically the sequence of SEQ ID NO: 46). 21. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pAMβ1 (typically the sequence of SEQ ID NO: 47). 22. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pLME106 (typically the sequence of SEQ ID NO: 48). 23. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pTZC1 (typically the sequence of SEQ ID NO: 49). 24. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pBC1 (typically the sequence of SEQ ID NO: 50). 25. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pEP2 (typically the sequence of SEQ ID NO: 51). 26. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pWVO1 (typically the sequence of SEQ ID NO: 52). 27. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pAP1 (typically the sequence of SEQ ID NO: 53). 28. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pWKS1 (typically the sequence of SEQ ID NO: 54). 29. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pLME108 (typically the sequence of SEQ ID NO: 55). 30. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pLS1 (typically the sequence of SEQ ID NO: 56). 31. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pUB6060 (typically the sequence of SEQ ID NO: 57). 32. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is p545 (typically the sequence of SEQ ID NO: 58). 33. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pJD4 (typically the sequence of SEQ ID NO: 59). 34. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pIJ101 (typically the sequence of SEQ ID NO: 60). 35. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pSN22 (typically the sequence of SEQ ID NO: 61). 36. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pGP01 (typically the sequence of SEQ ID NO: 62). 37. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pIP501 (typically the sequence of SEQ ID NO: 63). 38. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pCU1 (typically the sequence of SEQ ID NO: 64). 39. A DNA vector according to embodiment 14 or 15, wherein the origin of replication enabling replication in Propionibacterium acnes is pBAV1K-T5 (typically the sequence of SEQ ID NO: 65). 40. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pMRC01 (typically the sequence of SEQ ID NO: 1). 41. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_RSF1010 (typically the sequence of SEQ ID NO: 2). 42. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pRS01 (typically the sequence of SEQ ID NO: 3). 43. A DNA vector according to any one of embodiments 15 to 39, wherein oriT is oriT_pMV158 (typically the sequence of SEQ ID NO: 4). 44. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pTF1 (typically the sequence of SEQ ID NO: 5). 45. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pSC101 (typically the sequence of SEQ ID NO: 6). 46. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pBTK445 (typically the sequence of SEQ ID NO: 7). 47. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pBBR1 (typically the sequence of SEQ ID NO: 8). 48. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R721 (typically the sequence of SEQ ID NO: 9). 49. A DNA vector according to any one of embodiments 15 to 39, wherein oriT is oriT_pRmeGR4a (typically the sequence of SEQ ID NO: 10). 50. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_ColE1 (typically the sequence of SEQ ID NO: 11). 51. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pTiC58 (typically the sequence of SEQ ID NO: 12). 52. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pMdT1 (typically the sequence of SEQ ID NO: 13). 53. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R1 (typically the sequence of SEQ ID NO: 14). 54. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_Tn5520 (typically the sequence of SEQ ID NO: 15). 55. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_QKH54 (typically the sequence of SEQ ID NO: 16). 56. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R64 (typically the sequence of SEQ ID NO: 17). 57. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R751 (typically the sequence of SEQ ID NO: 18). 58. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_RP4 (typically the sequence of SEQ ID NO: 19). 59. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pKL1 (typically the sequence of SEQ ID NO: 20). 60. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_RK2 (typically the sequence of SEQ ID NO: 21). 61. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R1162 (typically the sequence of SEQ ID NO: 22). 62. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_Tn4555 (typically the sequence of SEQ ID NO: 23). 63. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pHT (typically the sequence of SEQ ID NO: 24). 64. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_Tn4399 (typically the sequence of SEQ ID NO: 25). 65. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_Tn916 (typically the sequence of SEQ ID NO: 26). 66. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pST12 (typically the sequence of SEQ ID NO: 27). 67. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pCU1 (typically the sequence of SEQ ID NO: 28). 68. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pSU233 (typically the sequence of SEQ ID NO: 29). 69. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_F (typically the sequence of SEQ ID NO: 30). 70. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pMAB01 (typically the sequence of SEQ ID NO: 31). 71. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R388 (typically the sequence of SEQ ID NO: 32). 72. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pS7a (typically the sequence of SEQ ID NO: 33). 73. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pS7b (typically the sequence of SEQ ID NO: 34). 74. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R702 (typically the sequence of SEQ ID NO: 35). 75. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pMUR274 (typically the sequence of SEQ ID NO: 36). 76. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R100 (typically the sequence of SEQ ID NO: 37). 77. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pVCR94deltaX (typically the sequence of SEQ ID NO: 38). 78. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_R46 (typically the sequence of SEQ ID NO: 39). 79. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pGO1 (typically the sequence of SEQ ID NO: 40). 80. A DNA vector described in any one of embodiments 15 to 39, wherein oriT is oriT_pIP501 (typically the sequence of SEQ ID NO: 41). 81. Further- relaxase gene; - a selection marker that allows selection in exconjugants P. acnes, and - a selection marker that allows selection in the donor bacteria, which may be a conjugative plasmid, a conjugative transposon, or an E. coli strain expressing the conjugation machinery, carrying an integrative and conjugative element (ICE) 81. The DNA vector of any one of embodiments 14 to 80, comprising: 82. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pMRCO1. 83. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE RSF1010. 84. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pRS01. 85. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pMV158. 86. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pTF1. 87. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pSC101. 88. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pBTK445. 89. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pBBR1. 90. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R721. 91. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or the ICE pRmeGR4a. 92. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE ColE1. 93. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or the ICE pTiC58. 94. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or the ICE pMdT1. 95. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R1. 96. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE Tn5520. 97. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE QKH54. 98. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R64. 99. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R751. 100. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE RP4. 101. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pKL1. 102. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE RK2. 103. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R1162. 104. The DNA vector of embodiment 81, wherein the donor bacterium is an E. coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE Tn4555. 105. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pHT. 106. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE Tn4399. 107. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE Tn916. 108. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pST12. 109. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pCU1. 110. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pSU233. 111. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE F. 112. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pMAB01. 113. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R388. 114. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pS7a. 115. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pS7b. 116. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R702. 117. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or the ICE pMUR274. 118. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R100. 119. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pVCR94deltaX. 120. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE R46. 121. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pGO1. 122. The DNA vector of embodiment 81, wherein the donor bacterium is an Escherichia coli strain carrying a conjugative plasmid, a conjugative transposon, or ICE pIP501. 123. An engineered Propionibacterium acnes comprising any of the DNA vectors described in any one of embodiments 14 to 122. 124. An engineered Propionibacterium acnes produced by contacting Propionibacterium acnes with any of the vectors of any one of embodiments 14 to 122. 125. A method for manipulating Propionibacterium acnes, comprising introducing into Propionibacterium acnes a DNA vector described in any one of embodiments 14 to 122. [Example]
[0559] Example 1 Phage-derived particles for delivery of DNA payloads into Propionibacterium acnes We developed Propionibacterium acnes phage-derived particles that contain a synthetic DNA payload and can be injected into Propionibacterium acnes. This represents the first demonstration of stable, autonomous replication of a recombinant DNA vector enabling transgene expression. The phage-derived particles are produced immediately within Propionibacterium acnes-producing cells upon coexistence of the Propionibacterium acnes phage genome and the DNA payload. The DNA payload is introduced into Propionibacterium acnes-producing cells by different methods, including electroporation into the cells, electroporation of protoplasts, conjugation, chemical transformation, and transduction. These phage-derived particles open the possibility of delivering DNA encoding therapeutic molecules to all strains of Propionibacterium acnes in situ with high efficiency and specificity, enabling, for example, sequence-specific killing via CRISPR-Cas expression or modulation of the immune system via secretion of immunomodulators.
[0560] Editing the Cutibacterium acnes population by eliminating specific proinflammatory strains to prevent or treat diseases such as acne vulgaris, or exploiting its privileged location in the pilosebaceous subunit to modulate the host immune response or improve wound healing, are intriguing therapeutic approaches. To implement such approaches, P. acnes strains can be either genetically mo...
Claims
1. Recombinant P. acnes phages.
2. The recombinant Propionibacterium acnes phage of claim 1 , comprising at least one transgene.
3. The recombinant Propionibacterium acnes phage of claim 2 , wherein the transgene is a CRISPR-Cas system or part of a CRISPR-Cas system.
4. The recombinant Propionibacterium acnes phage of claim 2 , wherein the transgene is a DNA encoding an antigen.
5. 5. The recombinant Propionibacterium acnes phage of claim 1, wherein the host range of the recombinant phage is different from the host range of the corresponding wild-type Propionibacterium acnes phage.
6. 6. The recombinant Propionibacterium acnes phage of claim 1, comprising an engineered capsid.
7. The recombinant Propionibacterium acnes phage of claim 6, wherein an antigen is displayed on the surface of the engineered capsid.
8. below: - a DNA template suitable for homologous recombination with the P. acnes phage genome, - an origin of replication that allows replication in P. acnes, and - optionally a first selection marker allowing selection of the DNA vector in P. acnes P. acnes cells carrying a recombinant DNA vector containing
9. The P. acnes cell of claim 8 , wherein a P. acnes phage genome is introduced into the cell.
10. The P. acnes cell of claim 8, wherein the P. acnes phage genome recombines with the DNA vector, resulting in the production of a recombinant phage.
11. Propionibacterium acnes cells containing a recombinant DNA vector containing DNA encoding an antigen.
12. below: - an origin of replication that allows replication within P. acnes, - a CRISPR-Cas system that is expressed in said P. acnes but does not target the newly generated recombinant P. acnes phage genome; and - optionally a first selection marker allowing selection of the DNA vector in P. acnes and a P. acnes cell carrying a DNA vector for selective production of a recombinant P. acnes phage comprising:
13. A method for producing a phage lysate containing a wild-type or parent P. acnes phage and a recombinant P. acnes phage, comprising introducing a wild-type or parent P. acnes phage genome into a P. acnes cell according to claim 8.
14. A method for selecting recombinant P. acnes phage comprising mixing a phage lysate containing a wild-type or parent P. acnes phage and a recombinant P. acnes phage with the P. acnes cells of claim 12, resulting in selective production of the recombinant P. acnes phage.
15. A composition for treating a P. acnes-associated disorder or disease, comprising a recombinant P. acnes phage according to any one of claims 1 to 6, or a recombinant P. acnes phage obtainable by the method according to claim 13 or 14.
16. A vaccine and / or immunogenic composition comprising the Propionibacterium acnes cell of claim 11, comprising a DNA vector comprising a nucleic acid encoding an antigen.
17. A composition for preventing and / or treating cancer in a subject in need thereof, comprising the Propionibacterium acnes cell of claim 11, wherein the Propionibacterium acnes cell comprises a DNA vector comprising a nucleic acid encoding a tumor antigen.
18. A composition for preventing and / or treating a viral infection in a subject in need thereof, comprising the Propionibacterium acnes cell of claim 11, wherein the Propionibacterium acnes cell comprises a DNA vector comprising a nucleic acid encoding a viral antigen.
19. A composition for preventing and / or treating a bacterial infection in a subject in need thereof, comprising the Propionibacterium acnes cell of claim 11, wherein the Propionibacterium acnes cell comprises a DNA vector comprising a nucleic acid encoding a bacterial antigen.
20. A composition for preventing and / or treating a fungal infection in a subject in need thereof, comprising the Propionibacterium acnes cell of claim 11, wherein the Propionibacterium acnes cell comprises a DNA vector comprising a nucleic acid encoding a fungal antigen.
21. A composition for preventing and / or treating an autoimmune disease in a subject in need thereof, comprising the Propionibacterium acnes cell of claim 11, wherein the Propionibacterium acnes cell comprises a DNA vector comprising a nucleic acid encoding an autoantigen.
22. A composition for preventing and / or treating allergies in a subject in need thereof, comprising the Propionibacterium acnes cell of claim 11, wherein the Propionibacterium acnes cell comprises a DNA vector comprising a nucleic acid encoding an allergen.
23. A composition for preventing and / or treating graft rejection in a subject in need thereof, comprising the Propionibacterium acnes cells of claim 11, wherein the Propionibacterium acnes cells comprise a DNA vector comprising a nucleic acid encoding a graft-specific antigen.
